 
Clinical Investigational Plan Cover Page  
 
 
 
CIP Cover page  Adaptive  DBS Algorithm for  Personalized Therapy in P arkinson’s  Disease 
(ADAPT -PD) Trial  
Clinicaltrials.gov ID:  NCT 04547712 
Document Date: 11 September 2023 
  
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 1 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
   
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  Adaptive DBS Algorithm for Personalized Therapy 
in Parkinson’s Disease (ADAPT -PD) Trial  
Clinical Investigation Plan Identifier  MDT19001  
CA - CIV-20-07-[ADDRESS_302658] Name  [CONTACT_249032]™ PC with Adaptive DBS (aDBS™)  
Sponsor/Local Sponsor  Medtronic  
Medtronic Neuromodulation  
[ADDRESS_302659]  
Brampton, Ontario L6Y 0R3  Canada 
+[PHONE_2906]  
Document Version   5.[ADDRESS_302660] Movement Disorders Center (SMDC)  
Director, Human Motor Control and Neuromodulation Lab (HCMNL)  
Department of Neurology and Neurological Sciences,  
Stanford University School of Medicine  
Center for Academic Medicine  

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302661] Accountability  ................................................................................................... 45 
7. Study Site Requirements  ...............................................................................................  46 
7.1. Investigator/Investigation Site Selection  .................................................................................. [ADDRESS_302662] Enrollment  .................................................................................................................  48 
8.3. Inclusion Criteria  ....................................................................................................................  49 
General (Primary Cohort):  ................................................................................................................... 49 
General (Directional Stimulation Cohort):  .......................................................................................... 49 
LFP Screening:  ..................................................................................................................................... 49 
8.4. Exclusion Criteria  ...................................................................................................................  50 
General (Primary Cohort):  ................................................................................................................... 50 
General (Directional Stimulation Cohort):  .......................................................................................... [ADDRESS_302663] Consent  .....................................................................................................................  57 
9.7. Enrollment and Screening Phase  .............................................................................................  60 
9.7.1.  Enrollment  ............................................................................................................................. 60 
9.8. cDBS Baseline Phase  ..............................................................................................................  61 
9.8.1.  LFP Screening Visit  ................................................................................................................ 61 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 5 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  9.8.2.  cDBS Baseline Period  ............................................................................................................. 63 
9.8.3.  cDBS Baseline Visit  ................................................................................................................ 63 
9.9. aDBS Setup and Adjustment Phase  .........................................................................................  64 
9.9.1.  aDBS Set up Visit  .................................................................................................................... 64 
9.9.2.  aDBS Adjustment Period (optional)  ...................................................................................... 66 
9.9.3.  Randomization  ...................................................................................................................... 67 
9.10.  aDBS Evaluation Phase  ..................................................................................................  68 
9.10.1.  Evaluation Visit 1  ............................................................................................................... 68 
9.10.2.  Evaluation Visit 2  ............................................................................................................... 69 
9.11.  Long-term Follow -up Phase  ........................................................................................... 70 
9.11.1.  Visit 3  ................................................................................................................................. 71 
9.11.2.  Visit 4  ................................................................................................................................. 72 
9.11.3.  Visit 5  ................................................................................................................................. 72 
9.11.4.  Visit 6  ................................................................................................................................. 72 
9.12.  Extended Access Phase  ................................................................................................. 73 
9.12.1.  Extended Access Visits  ....................................................................................................... 73 
9.13.  Unscheduled Visi t ..........................................................................................................  73 
9.14.  System Modification  ......................................................................................................  74 
9.15.  Assessment of Efficacy and Device Performance  .............................................................  74 
9.15.1.  Parkinson’s Disease (PD) Home Diary  ............................................................................... 74 
9.15.2.  Total Electrical Energy Delivered (TEED)  ........................................................................... 75 
9.15.3.  Wearable Data  ................................................................................................................... 75 
9.15.4.  European Quality of Life – 5 Dimensions (EQ -5D-5L) ........................................................ 75 
9.15.5.  Parkinson’s Disease Questionnaire (PDQ -39) .................................................................... 76 
9.15.6.  Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS -UPDRS)  ... 76 
9.15.7.  Parkinson’s Disease Sleep Scale 2 (PDSS -2) ....................................................................... 77 
9.15.8.  Voice Handicap Index (VHI)  ...............................................................................................  [ADDRESS_302664] Chooses to  Exit (i.e. Revokes Consent)  ................................................................. [ADDRESS_302665]  ........................................................................................ 83 
9.19.6.  Conditional Disengagement  .............................................................................................. 83 
10. Risks and Benefits  .........................................................................................................  83 
10.1.  Potential Risks  ..............................................................................................................  83 
10.1.1.  Pregnancy  .......................................................................................................................... 84 
10.1.2.  Potential aDBS risks  ........................................................................................................... 84 
10.1.3.  Potential Study Procedures Risks  ...................................................................................... 84 
10.1.4.  Potential Study Procedure Inconveniences  ....................................................................... 84 
10.2. Risk Minimization  ..........................................................................................................  85 
10.3.  Potential Benefits  ..........................................................................................................  86 
10.4.  Risk-Benefit Rationale  ................................................................................................... 86 
10.5.  Risk Determination  ........................................................................................................  86 
11. Adverse Events and Device Deficiencies  .......................................................................  87 
11.1.  Adverse Events  ............................................................................................................. 87 
11.2.  Device Deficiency  ..........................................................................................................  87 
11.3.  Processing Updates and Resolution  ................................................................................  87 
11.4.  Definit ions/Classifications ..............................................................................................  [ADDRESS_302666] Complaint Reporting .........................................................................................  98 
12. Data Review Committees  .............................................................................................. 99 
12.1.  Data Monitoring Committee  ........................................................................................... 99 
12.2.  Clinical Events Committee  ............................................................................................  100 
13. Statistical Design and Methods  ...................................................................................  100  
13.1.  General Aspects of Analysis  .........................................................................................  100 
13.2.  General Statistical Considerations  .................................................................................  101 
13.2.1.  Analysis sets  ..................................................................................................................... 101 
13.2.2.  Factors That May Compromise the Outcome or Interpretation of the Results  .............. 102 
13.2.3.  Familywise error rate and hypothesis testing  ................................................................. 102 
13.2.4.  Sample size rationale  ....................................................................................................... 102 
13.2.5.  Handling of missing data  ................................................................................................. 103 
13.2.6.  Interim sample size adjustment  ...................................................................................... 104 
13.2.7.  Reports  ............................................................................................................................ 104 
13.2.8.  Demographics and baseline variables  ............................................................................. 104 
13.2.9.  Pooling of aDBS mode  ..................................................................................................... 104 
13.2.10.  Center pooling  ................................................................................................................. 105 
13.3.  Analysis Execution  ......................................................................................................  105 
13.4.  Primary Objective  ........................................................................................................  106 
13.4.1.  Hypothesis  ....................................................................................................................... 106 
13.4.2.  Endpoint definition  .......................................................................................................... 1 06 
13.4.3.  Sample size justification  .................................................................................................. 107 
13.4.4.  Analysis methods  ............................................................................................................. 107 
13.4.5.  Handling of missing data  ................................................................................................. 108 
13.4.6.  Supporting analyses  ......................................................................................................... 109 
13.5.  Secondary Objective  ................................................................................................... 110 
13.5.1.  Secondary Objective  ........................................................................................................ 110 
13.5.2.  Hypothesis  ....................................................................................................................... 110 
13.5. 3. E
ndpoint definition  .......................................................................................................... 110 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 8 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  13.5.4.  Sample Size justification  .................................................................................................. 111 
13.5.5.  Analysis methods  ............................................................................................................. 111 
13.5.6.  Handling of missing data  ................................................................................................. 111 
13.5.7.  Supporting analyses  ......................................................................................................... 112 
13.6.  Safety Assessment  ......................................................................................................  112 
13.7.  Additional Objectives  ................................................................................................... 113 
13.8.  Minimization of Bia s ....................................................................................................  113 
14. Ethics  ...........................................................................................................................  113  
14.1.  Statement(s) of Compliance .........................................................................................  [ADDRESS_302667] Access to Source Data/Documents  .....................................................................  117 
15.4.  Confidentiality ............................................................................................................. 117 
15.5.  Liability/Insurance Information  ....................................................................................  118 
15.5.1.  Insurance (Canada)  .......................................................................................................... 118 
15.5.2.  Insurance (Europe)  .......................................................................................................... [ADDRESS_302668] Retention  ........................................................................................................  119 
15.7.1.  Investigator Records  ........................................................................................................ 119 
15.7.2.  Sponsor Records  .............................................................................................................. 120 
15.8.  Reporting Requirements  ..............................................................................................  121 
15.8.1.  Investigator Re ports  ........................................................................................................ 121 
15.8.2.  Sponsor Reports  .............................................................................................................. 124 
15.9.  Publication and Use of Information  ..............................................................................  128 
15.9.1.  Publication Committee  .................................................................................................... 128 
15.9.2.  Man ag ement of Primary, Secondary, and Ancillary Publications  ................................... 128 
15.9.3.  Criteria for Determining Authorship ................................................................................ 129 
15.9.4.  Transparency  ................................................................................................................... 129 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 9 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  15.10.  Suspension or Early Termination  .................................................................................. 130 
15.10.1.  Plan ned Study Closure  ..................................................................................................... 130 
15.10.2.  Early Termination or Suspension ..................................................................................... 130 
[IP_ADDRESS].  Study -wide termination or suspension  ........................................................................ 130 
[IP_ADDRESS].  Investigator/study site termination or suspension  ..................................................... 130 
15.10.3.  Procedures for Termination or Suspension  ..................................................................... 131 
[IP_ADDRESS].  Medtronic -initiated and regulatory authority initiated  ............................................... 131 
[IP_ADDRESS].  Investigator- initiated  ................................................................................................... 131 
[IP_ADDRESS].  Ethics Committee- initiated  .......................................................................................... 132 
16. References  ...................................................................................................................  133  
17. Version History  ............................................................................................................  138  
Appendix A - aDBS Global Impression of Change Score (GIC)  .............................................  152  
 
  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 10 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  1. Glossary  
Term /Acronym  Definition  
µV/√Hz  Micro -volts per root -hertz (amplitude spectral 
density)  
Acute stimulation -induced effects  Transient effects that occur during implantable 
neurostimulator programming sessions or while 
running adaptive Deep Brain Stimulation that resolve with, or without, stimulation adjustments 
prior to the subject leaving a clinic visit and do 
not require further follow -up or medical care 
outsid e of the visit.  
aDBS  Adaptive Deep Brain Stimulation (aDBS). This is 
the general concept under study whereby [CONTACT_248941] -time in response to LFP signal of interest  
aDBS Mode  An aDBS Mode is an amplitude increment / 
decrement stimulation algorithm . 
The two aDBS modes being evaluated in this 
study  are Dual and Single Threshold Modes  
aDBS Se tup The initial process of setting up a subject to an 
aDBS mode.  
ADE Adverse Device Effect  
AE Adverse Event  
ASADE  Anticipated Serious Adverse Device Effect  
Algorithm  A defined process or set of rules to be followed 
for decision -making, (i.e., to increase or decrease 
stimulation amplitude).  
Alpha  - Beta  Synchronized local field potential neural 
oscillatory activity within the [ADDRESS_302669] for 
this study.  
App Application  
BDI- II Beck Depression Inventory ©- II 
Best condition  The time period when PD subjects are receiving 
relief from their Parkinson’s disease symptoms, 
also known as “on” time or “on” period  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 11 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Term /Acronym  Definition  
BKS Bradykinesia Score  (from wearable)  
BrainSense ™ Technology  The family of features in the Percept PC system 
that make use of the system capabi lity to capture 
and display local field potential (LFP) signals.  
CA Competent Authority  
cDBS  Continuous Deep Brain Stimulation (cDBS) is the 
commercially available Deep Brain Stimulation 
Therapy.  
CDU Application  Clinical Data Upload web -based application  
CEC Clinical Events Committee  
CE Mark  A certification mark that indicates conformity 
with health, safety, and environmental protection 
standards for products sold within the European 
Economic Area (EEA) . 
CFR Code of Federal Regulations (US)  
CIP Clinical Investigation Plan  
clDBS    Closed Loop Deep Brain Stimulation  
CPA Clinician Programmer Application  
CRF Case Report Form  
C-SSRS Columbia Suicide Severity Rating Scale  
CSV Comma Separated Values, a data file format  
CTA Clinical Trial Agreement  
CTM Clinician  Telemetry Module  
CV Curriculum Vitae  
DBS Deep Brain Stimulation  
DD Device Deficiency  
Directional Stimulation  3387 and 3389 leads are not capable of delivering 
directional stimulation  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 12 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Term /Acronym  Definition  
For SenSight  leads , the same amplitude is not 
used on all three electrodes at the same 
electrode level (e.g. 1a -1c, 2a -2c) 
Directional Stimulation Cohort  Cohort comprised of study subjects with the 
SenSight ™ system programed to directional 
stimulation  
DKS Dyskinesia Score  (from wearable)  
DMC Data Monitoring Committee  
DoH  Declaration of Helsinki  
DTL Delegated Task List  
Dual Monopolar  A Deep Brain Stimulation configuration where 
two contacts of one (or more) electrodes are 
programmed as a cathode ( -) and the implantable 
neurostimulator  (case) is programmed as the 
anode (+).  
eCRF  Electronic Case Report Form  
EC Ethics Committee  
ECT Electroconvulsive Therapy  
EEA European Economic Area  
EQ-5D-5L Five-dimensional five-level generic measure 
designed to measure, compare and value health status across disease areas; developed by [CONTACT_185266].  
Event markers  Used to capture and record patient triggered 
events and provide additional information for 
analysis around patients outside the clinic.  
EU European Union  
EU MDR  European Union Medical Device Regulation  
FAL Foreseeable Adverse Events Listing  
FD Financial Disclosure  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 13 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Term /Acronym  Definition  
FDA US Food and Drug Administration  
FDAAA Food and Drug Administration Amendments Act  
FDS Fluctuation and Dyskinesia Score (from wearable)  
FW Firmware  
GCP Good Clinical Practice  
GIC Global Impression of Change  
GKC Global Kinetics Corporation  
GPi [INVESTIGATOR_248915]'s Brochure  
IC Informed Consent  
IDE Investigational Device Exemption 
INS Implantable Neurostimulator  
IRB Institutional Review Board  
ISO International Organization for Standardization  
ITA Investigational Testing Authorization  
JSON JavaScript Object Notation, a data file format  
LFP Local Field Potential  
MAR  Missing at Random  
MCIC  Minimal Clinically Important Change  
MDS -UPDRS  Movement Disorder Society -Sponsored Revision 
of the Unified Parkinson’s Disease Rating Scale – 
The assessment has 4 parts, I -IV 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 14 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Term /Acronym  Definition  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Multiple Imputation  
Monopolar  A Deep Brain Stimulation configuration where 
one contact [CONTACT_248942] s is 
programmed as a cathode ( -) and the implantable 
neurostimulator (case) is programmed as the 
anode (+).  
NPU Neuro Programmer Upload. The NPU databas e 
will store clinician programmer JSON session 
reports from the neurostimulator interrogations.  
OC Oracle Clinical  
PHI Protected Health Information  
PD Parkinson’s Disease  
PDQ -39 The 39 -item Parkinson ’s Disease Questionnaire  
PDQ -39 SI  PDQ -39 summary index  
PDSS-2 Parkinson’s Disease Sleep Scale 2  
PKG® Personal KinetiGraph® (US), Parkinson’s 
Kinetigraph (EU)  
PMA  Premarket Approval  
PPA Patient Programmer Application  
Primary Cohort  Cohort comprised of study subjects implanted 
with legacy lead models 3387 or 3389, or with 
the SenSight™ Directional Lead program med to 
ring mode stimulation  
PRO  Patient Reported Outcome  
PTM  Patient Telemetry Module  
PW Pulse Width  
RA Regulatory Authority  
RDC Remote Data Capture  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 15 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Term /Acronym  Definition  
RF Radio Frequency  
Ring Mode  For 3387 and 3389 leads , stimulation  is always 
delivered  in Ring Mode  
For SenSight  leads , all segmented electrodes at 
the same electrode level (e.g. 1a -1c, 2a -2c) are 
activated at the same amplitude   
SADE  Serious Adverse Device Effect  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SOI Signal of interest, also referred to as a b iomarker 
in literature. The signal of interest for this study is 
Alpha - Beta  local field potential.  
Stable (cDBS Programming)  The current cDBS settings are deemed by [CONTACT_248943].  
STN Subthalamic Nucleus  
SW Software  
TEED  Total Electrical Energy Delivered  
TMS  Transcranial Magnetic Stimulation  
Troublesome dyskinesia  Dyskinesia which interferes with function or 
causes meaningful discomfort.  
TÜV TÜV SÜD is the EU Notified Body  
UADE  Unanticipated Adverse Device Effect  
UAE  Unavoidable Adverse Event  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
VHI Voice Handicap Index  
WHODrug  World Health Organization Drug  
Worst condition  The time period when PD subjects are not 
receiving relief from their Parkinson’s disease 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 16 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Term /Acronym  Definition  
symptoms, also known as “off” time or “off” 
period.  
Percept™ PC Neurostimul ator, BrainSense™ T echnology , SenSight™  and aDBS™ Therapy are registered  
trademarks of Medtronic.   
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 17 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  2. Synopsis  
Title  Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s  
Disease (ADAPT -PD) Trial  
Clinical Study Type  Pi[INVESTIGATOR_248916]™ PC Neurostimulator  and aDBS ™ Therapy  
Sponsor  Medtronic  
Local Sponsor  Medtronic Neuromodulation , [LOCATION_003] 
Medtronic International Trading Sàrl, Switzerland  
EU Legal Representative: Medtronic Bakken Research Center B.V ., The 
Netherlands   
Medtronic Canada ULC, Canada  
Indication under 
investigation  Parkinson’s disease (PD) – Deep Brain Stimulation (DBS) implant to 
subthalamic nucleus ( STN) or Globus Pallidus  (GPi) target sites  
Investigation Purpose  The purpose of the study is to demonstrate  the safety and 
effectiveness  of adaptive DBS (aDBS) for Parkinson’s disease.  
Product Status  Investigational aDBS firmware will be enabled on an already 
implanted, commercially available Model B35200 Percept PC 
implantable neurostimulator (INS). An investigational version of the 
DBS Clinician Programmer will enable  the aDBS functionality on the 
INS. An investigational version of the DBS Patient Programmer will be 
available to study subjects.   
Primary Objective(s)  To demonstrate that the proportion of aDBS subjects with “On” time 
without troublesome dyskinesia during the Evaluation Phase exceeds 
a performance goal of 50%.  
Secondary Objective  To demonstrate decreased stimulation energy use during the  aDBS 
Evaluation Phase as compared with  continuous DBS  (cDBS ). 
Safety Assessments  To characterize:  
• Stimulation -related adverse events during the aDBS 
Evaluation and the cDBS Baseline Phases. 
• Serious adverse events, adverse events  and device 
deficiencies throughout the study.  
Additional Objectives  To characterize aDBS  during the Evaluation Phase  as compared to 
cDBS (Primary Cohort) : 
• Voice Handicap Index (VHI): “best” and “worst” conditions  
• Movement Disorder Society Unified Parkinson’s Disease Rating Scale ( MDS -UPDRS ) Part  III subscore (On stim/O n med) 
of tremor, rigidity, and bradykinesia questions where a side can be determined: 3.3 b, c, d, e (rigidity), 3.4 a, b (finger taps/bradykinesia) , 3.15 a, b (postural tremor of hands), 3.16 
a, b (kinetic tremor of hands), and 3.17 a, b, c, d (rest tremor 
amplitude)  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 18 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • MDS -UPDRS III (On stim/On med)  
• MDS -UPDRS II : “best” and “worst” conditions  
• MDS -UPDRS III speech question (On stim/On med) q 3.1  
• MDS -UPDRS IV  
• EQ-5D-5L 
• PDSS-2 
• Data collected from wearable  (for example: % of wear time 
tremor was detected, Dyskinesia Score [DKS], Bradykinesia 
Score [BKS], Fluctuation and Dyskinesia Score [FDS])  
• Parkinson’s Disease Questionnaire ( PDQ )-39 Summary Index 
(SI) an d subscores: mobility, activities of daily living, 
emotional well-being, stigma, social support, cognition, 
communication, bodily discomfort  
• PDQ -39 speech questions 34 and 35  
• % of subjects with at least 25% increase in projected battery longevity as compared with cDBS  
• Parkinson’s Disease Home  Diary: “On” time without 
troublesome dyskinesia,  “On” time without dyskinesia, “On ” 
time with non -troublesome dyskinesia,  “On” time with 
troublesome dyskinesia, “ Off” time, and A sleep time.  
• Patient preference of aDBS vs cDBS (as assessed by a Medtronic -developed patient preference questionnaire)  
• Patient satisfaction with aDBS (as assessed by a Medtronic -
developed patient satisfaction questionnaire)  
• Device data from JSON file , including BrainSense data  
Subgroup analyses  (from the entire study population) :  
• For those with dyskinesia at least 25% of time: Wearable data  
• For those with speech side effects: VHI 
• For those with mixed programming (aDBS and cDBS): MDS -
UPDRS III by [CONTACT_10167]  
• For those who use event markers in long -term follow -up: 
characterize subject population and satisfaction with use of event markers  
• For those who finished the aDBS Evaluation Phase: one aDBS 
mode will be selected per subject based on subject 
preference or programming availability at the end of the aDBS Evaluation Phase. The aDBS Evaluation Phase results may be 
characterized based on the selected mode.  
Primary Endpoint  Proportion of aDBS subjects with “On” time witho ut troublesome 
dyskinesia exceeding the threshold.  The threshold will be determined 
using the following: o n a per -patient basis, the hours of “On” time 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302670] deviation is calculated from 
the difference between aDBS and cDBS in the Full Analysis Set (FAS).  
Secondary Endpoint  Decreased total electrical energy delivered (TEED)  during the 
respective aDBS Evaluation Period as compared with cDBS during the 
cDBS Baseline Phase . 
Safety Analyses  • Stimulation -related adverse events during the cDBS baseline 
and aDBS evaluation phases for all subjects, with tabulations individualized by [CONTACT_248944] . 
• Serious adverse events , adverse events  and device 
deficiencies throughout the study for all subjects.  
Study Design  Prospective , single -blind , randomized crossover , multi -center study of 
aDBS in subjects with Parkinson’s disease. 
The study is expected to be conducted at approximately [ADDRESS_302671] 1 aDBS mode is acceptable 
and who enter the aDBS evaluation phase. Accounting for a 10% dropout during the aDBS Evaluation  Phase , a minimum of 36 subjects 
(at least 8 per brain target) will complete the aDBS Ev aluation phase .  
In addition, approximately [ADDRESS_302672] 1 aDBS mode is acceptable and who 
enter the aDBS Evaluation Phase. Accounting for dropout during the 
aDBS Evaluation Phase, a minimum of 8 subjects will  complete the 
aDBS Evaluation Phase.    
Study  visits and/or phases  include :  
• Enrollment  Visit : Consent, Screening  
• cDBS Baseline Phase: Local Field Potential (LFP) Screening  and 
Baseline cDBS visits   
• aDBS Setup and Adjustment Phase: aDBS Setup visit and additional optional visits during an aDBS Adjustment period  
• aDBS Evaluation Phase: One -month  treatment period s in each 
acceptable aDBS mode with aDBS evaluation visits at the end of each period .  Randomized crossover to the  two investigational 
treatments in subjects for whom both aDBS modes were 
acceptable and a single treatment period in those subjec ts for 
whom only one aDBS mode was acceptable.   
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 20 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • Long -Term Follow Up Phase: Four visits in preferred aDBS mode 
for approximately 10 months  
• Extended  Access Phase: Additional  visits in the preferred aDBS 
mode every [ADDRESS_302673] 1 
aDBS mode is acceptable and who enter the aDBS evaluation phase . It 
is expected that approximately 50% of enrolled subjects will be exited from the study at LFP Screening due to insufficient Alpha - Beta  band 
amplitude and/or artifact.  Accounting for a 10% dropout during the 
aDBS Evaluation  Phase , a minimum of 36 subjects (at least 8 per brain 
target) are expected to  complete the aDBS Evaluation phase.  
Because the device implant will occur outside of the study and the 
study require s participants to be stable on cDBS, the standard 
deviation of the change from cDBS to aDBS in  “On” time without 
troublesome dyskinesia  will be used  to establish a threshold  for 
assessing the performance goal. The thres hold will be set  as [ADDRESS_302674] deviation. If the difference between aDBS and cDBS (aDBS -
cDBS) for a subject is at least  -[ADDRESS_302675] for a proportion t o compare to a performance goal of 50%. 
Assuming the alternative hypothesis of 85% of subj ects exceeding the 
threshold  described above , a minimum of [ADDRESS_302676] 90% power to reject a performance goal of 50%.  Sample size was 
computed in PASS 11.  
For the safety analysis, a minimum of 30 subjects followed for 
approximately 30 days with aDBS out -of-clinic in the subjects’ real -
world environments provides  greater than  95% probability  that all 
stimulation -related a dverse events with a true adverse event rate of 
at least 10% would be reported at least once.  
Directional Stimulation  Cohort  
In addition, approximately [ADDRESS_302677] 1 aDBS mode is acceptable and who 
enter the aDBS Evaluation Phase. Accounting for dropout during the aDBS Evaluation Phase, a minimum of 8 subjects will complete the 
aDBS Evaluation Phase.  
Inclusion/Exclusion Criteria  There are two sets of criteria for study participation pri or to the 
investigational use of aDBS.  
1. Subjects must meet all general inclusion/exclusion criteria (as 
assessed at the Enrollment Visit)  
2. Subjects must meet the  LFP screening inclusion criterion  (as 
assessed at the LFP Screening  Visit)  
General  
Inclusion Criteria  
Primary Cohort:  
1. Subject has idiopathic Parkinson’s disease 
2. Subject is implanted with Percept PC (Model B35200) and 
Medtronic DBS leads (Model 3387 , 3389, B33005 or B33015 ) 
and extensions (Model [ZIP_CODE] , [ZIP_CODE]  or B34000 ) bilaterally in 
the same target (physician confirmed), STN or GPi  
3. In the opi[INVESTIGATOR_871], the subject responds to DBS Therapy.  
4. Based on the opi[INVESTIGATOR_871], the subject’s cDBS parameters and PD medications are stable and expected to 
remain stable from enrollment through the end of the aDBS 
Evaluation  phase  
5. Subject is configured to ring mode monopolar or dual monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side.  
6. Subject is willing and able to attend all study -required visits 
and complete the study procedures (e.g. 1 -month recall 
questionnaires, MDS -UPDRS III)  
7. Subject has the ability to understand and provide written informed consent for participation in the study prior to the study -related procedures being conducted  
8. Subject is a male or non -pregnant female. If female of child -
bearing potential, and if sexually active, must be using, or agree to use, a medically -acceptable method of birth control 
as confirmed by [CONTACT_093]  
9. For subjects with the SenSight system:  Subject is configured 
to the following stimulation rates: 55, 85, 110, 125, 145, 164 or 180 Hz (as required for sensin g/aDBS)  
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 22 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Directional Stimulation  Cohort:  
Subjects must meet the s ame inclusion criteria as the primary cohort  
except for revised #2 and  #5. 
 
Revised Inclusion Criteria:  
2. Subject is implanted with Percept PC (Model B35200) and 
Medtronic DBS leads (Model B33005 or B33015 ) and 
extensions (Model B34000 ) bilaterally in the same target 
(physician confirmed), STN or GPi  
5. Subject is configured to directional monopolar or dual 
monopolar stimulation using contacts 1 and/or 2 (9 and/or 10)  
Exclusion Criteria  (All Cohorts)  
1. Subject and/or caregiver is unable to utilize the patient programmer  
2. Subject has more than one lead in each hemisphere of the 
brain  
3. Subject h as cortical leads or additional unapproved hardware 
implanted in the brain  
4. Subject has more than one INS  
5. At enrollment, the subject’s INS has a predicted battery life of 
<[ADDRESS_302678] has Beck Depression Inventory II (BDI -II) > [ADDRESS_302679] requires diathe rmy, transcranial magnetic stimulation 
(TMS), or electroconvulsive therapy (ECT)  
8. Subject has a metallic implant in the head, (eg, aneurysm clip, 
cochlear implant)  
9. Subject has, or plans to obtain, an implanted electrical 
stimulation medical device anywhere  in the body (eg, cardiac 
pacemaker, defibrillator, spi[INVESTIGATOR_55441])  
10. Subject has, or plans to obtain, an implanted medication pump  for the treatment of Parkinson’s disease (eg, DUOPA
TM 
infusion pump) and/or portable infusion pump  
11. Based on the opi[INVESTIGATOR_871], the subject has an abnormal neurological examination that would preclude them from study participation  
12. Subject is breast feeding  
13. Subject is under the age of [ADDRESS_302680] is currently enrolled in or plans to enroll in any 
concurrent drug and/or device study that may confound the 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302681] on all 6 aDBS sense pathways  (3 
each on both DBS leads ) which preclude the clinician from 
setting thresholds  
LFP Screening  
Inclusion Criteria (All Cohorts)  
1. Subject has Alpha - Beta  band ( 8-30 Hz) amplitude ≥ 1.2 µVp 
detected on  either  left and/or  right DBS leads on sensing 
channels 0 -2, 0-3, or 1 -3; 8-10, 8 -11, or 9 -11 
Study Procedures and 
Assessments  Subjects will be considered enrolled at the time they sign the 
informed consent form.  
Scheduled visits will include the following:  
Enrollment, LFP Screening, cDBS Baseline, aDBS Setup, 
Randomization, aDBS Evaluation Visit 1, aDBS Evaluation Visit 2, Long -
term follow -up Visit 3, Long-term follow -up Visit 4, Long-term follow -
up Visit 5, and Long- term follow -up Visit 6.  
Subjects participating in the extended  access phase prior to 
commercial approval of aDBS, will have visits every 6 months.  
The following assessments / data will be collected during the study:  
• Concomitant m edications  
• PDQ -39 
• EQ-5D-5L 
• MDS -UPRDS Parts I- IV 
• Parkinson’s Disease Home Diary  
• VHI 
• PDSS-2 
• aDBS Global Impression of Change score  
• Patient preference questionnaire  
• Patient satisfaction questionnaire  
• Wearable  data  
• Programming session  data , including BrainSense data  
• Event markers (optional)  
• Adverse Events  and Device Deficiencies  
 Statistics  Primary  and secondary  objectives will be analyzed using the FAS . The 
FAS includes all Primary Cohort subjects , using the intention -to-treat 
(ITT) principle, who initiate the aDBS Evaluation Phase  using the 
randomized treatment assignment for each subject  that was 
randomized and the programmable treatment assignment for those 
subjects that may only be configured to one aDBS mode (dual or 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 24 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  single threshold) . Safety analyses will be evaluated using the As -
Treated (AT) Analysis Set.  AT includes all Primary Cohort subjects who 
are treated with continuous Deep Brain Stimulation (cDBS) and/or 
adaptive Deep Brain Stimulation (aDBS) during the cDBS Baseline Evaluation Phase and/or the aDBS Evaluation Phase, and Lo ng-term 
Follow -up Phase and uses the observed treatment used for each 
subject  in each phase . 
The Parkinson’s Disease Home  Diary from the two weeks prior to the 
Baseline visit (cDBS) and the aDBS Evaluation visits (aDBS)  will be used 
to evaluate the primary  objective. The observed proportion will b e 
computed for each aDBS mode separately and compared to the performance goal using a binomial exact test.    
The secondary objective will evaluate the decrease in Total Electrical Energy Delivered (TEED) for each aDBS  mode  compared to cDBS  using 
data from the 14 -days prior to the Baseline visit (cDBS) or the 
respective aDBS Evaluation Visit (aDBS).  
Supporting an alyses  for the objectives in the Primary Cohort include: 
verifying the lack of a period or carryover effect , verifying  poolability 
by [CONTACT_248945] (STN/GPi) and center effects. In 
addition , summarized results from the Directional Stimulati on Cohort 
will be provided as supporting analyses to the primary, secondary, and safety Primary Cohort results. Sensitivity analyses will be 
performed.   
The additional objectives will be evaluated from the Primary Cohort to compare each outcome for each aDBS  mode  during the aDBS 
Evaluation Phase compared to cDBS during the cDBS Baseline Phase.  
The familywise error rate will be controlled using one -sided tests with 
an overall alpha- level of 0.025  approach to multiple testing. Each 
primary hypothesis (one for each aDBS mode) will be assigned a 
Bonferroni corrected alpha (0.0125) for the respective  primary 
hypothesis (see Section  13.4.1). The primary hy pothesis will serve as a 
gate keeper for the secondary hypothes is within each mode . 
Sample size  in the Primary Cohort  may be increased to a maximum of 
[ADDRESS_302682] 8 subjects per 
aDBS mode and 8 subjects per target site (STN/GPi ). 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 25 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  All attempts will be made to minimize missing data. If 5% of the data 
or fewer are missing  for the analysis, no imputation will be used. 
Otherwise, if missing data are  observed, multiple imputation will be 
used with the primary  and secondary  objective s. If an aDBS mode is 
not programmable to a patient, summary statistics will be computed 
to summarize the percent who were not programmed to a mode and no imputation will occur for that outcome for that aDBS mode.  The 
Complete Case Analysis Set and the As -Treated Analysis Set will be 
used for sensitivity analysis to the primary  and secondary  objective  
analyses.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 26 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  3. Introduction  
3.1. Background  
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease associated with both motor 
and non -motor symptoms.  It affects [ADDRESS_302683] or fourth decade.1  PD is caused by a loss of dopamine -producing cells in the substantia nigra and is 
associated with pathological beta ( approximately 13-35 Hz) bursts and excessive synchronization within 
the cortico -basal ganglia network of the brain .1,2,3  This disrupti on in brain activity is associated with the 
characteristic motor symptoms of the disease:  resting tremor, rigidity, bradykinesia, and postural 
instability.4-5, 6,7 
In the initial stages of PD, motor symptoms are often well controlled using dopaminergic drugs.  However, chronic use of these levodopa medications  over a 5 -10 year period is associated with 
symptom fluctuations, dyskinesia and other motor complications in  up to 80% of PD patients.
4  These 
complications may be equal to or worse in severity than the motor impairment caused by  [CONTACT_248946].8  Deep Brain Stimulation (DBS) Therapy may be used to treat some of the motor complications of 
PD that are not adequately controlled with medication. DBS is a surgical intervention that involves the placement of electrodes in targeted areas of the brain. These electrodes are arranged on a lead and are 
connected to an implanted neurostimulator  that delivers mild electrical pulses to targeted brain areas. 
Once patients are implanted with the DBS device, clinicians may adjust the electrical stimulation parameters t o obtain maximal symptom relief and minimize stimulation -induced adverse effects.  
The use of DBS in the subthalamic nucleus (STN) and globus pallidus interna (GPi) has been shown to improve symptoms of PD.
4,9,10,11,12,13,14,15,16,17 Several multicenter, randomized controlled trials 
conducted in the [LOCATION_002], Europe, and in several other geographies worldwide provide evidence of 
its effectiveness.18,19,20,21,22,23,24 Deep Brain Stimulation Therapy is currently delivered in a cont inuous 
fashion (cDBS) where stimulation settings are constant  over time and do not adjust to fluctuations in 
symptoms typi[INVESTIGATOR_248917]’s disease patients  during medication On and Off states .  
During On -medication states the addition of stimulation is thought to contribute to dyskinesias and 
other side effects experienced by [CONTACT_102].25 To make DBS more responsive to an individual patient’s 
clinical state, investigators have explored the use of adaptive DBS (aDBS) therapy .   
aDBS  Therapy, also known as closed- loop DBS (clDBS ), adjusts stimulation in a variable fashion. It  relies 
on a  biomarker, or signal of interest  (SOI) , to adjust  stimulation .  The SOI  must correlate to a patient’s 
clinical state (i.e. severity of disease symptoms), dynamically reflect changes in disease symptoms, be 
persistent  over time, be discernible from background artifacts and be measurable with minimal 
additional intervention.26,27,28,[ADDRESS_302684] studied SOIs  within this context are local field 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 27 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  potentials (LFPs ), which represent the transient oscillatory activity of various neuronal populations in 
the brain.  
During the last decade, researchers have worked to characterize LFP signals in the brain.  LFPs represent 
the summed pre - and post -synaptic neuronal activity in the area of the brain where the LFPs are being 
recorded.  Researchers have shown the presence of excessive LFP beta oscillations in the range of 
approximately 13-35 Hz and over -synchronization in the cortico -basal ganglia network in the brains of 
PD patients.4,30,31,32,33  In a review of 20 publications between 2001 and 2011, r esearchers reported 
measurable beta peaks in the Off -medication state in  a mean of 95% of PD patients/nuclei.29 These beta 
LFP signals are persistent over time ,34,35,36,37,38,39 can be measured using the currently approved 
Medtronic DBS l eads ,34,35,36,38,40 can correlate with severity of bradykinesia and rigidity in PD patients and 
are attenuated by [CONTACT_248947] (i .e., in the ON -medication state) and DBS stimulation.7,28,31,32,41,42,[ADDRESS_302685] is a scalar approach (i.e. , dual threshol d aDBS mode) whereby 
[CONTACT_248948], clinician- defined therapeutic 
limits  to maintain beta LFP within a defined range .45,46,47 The second is a binary approach (i.e., single 
threshold aDBS mode), whereby  [CONTACT_248949] a preset threshold 
and switches off when the LFP falls below the preset threshold. 25,48,49,[ADDRESS_302686] as efficacious as 
cDBS based on UPDRS III motor scores and could potentially be up to 27% more effective .47,48,[ADDRESS_302687] of stimulation and medica tion.25,52,54 Regarding speech, one study 
of 10 subjects showed a clinically meaningful improvement in speech intelligibility with aDBS over 
cDBS.50  Overall aDBS was well tolerated in freely moving PD subjects both On and Off medications for 
up to 8 hours .47,49,52,53, 55  In addition, multiple studies showed a significant reduction in the power usage  
with aDBS compared to cDBS, averaging about 50% of the power demand of standard cDBS Therapy.45-
49,52,[ADDRESS_302688] 
consistently shown the f easibility of using aDBS controlled by [CONTACT_248950] . 
3.2. Purpose  
The purpose of the study is to demonstrate  the safety and effectiveness  of adaptive DBS (aDBS) for 
Parkinson’s disease.  
4. Objectives  and Endpoints  
4.1. Objectives  
4.1.1.  Primary Objective  
To demonstrate that the proportion of aDBS subjects with “ On” time without troublesome dyskinesia  
during the Evaluation Phase exceeds a performance goal of 50%.  
4.1.2.  Secondary Objective  
To demonstrate decreased stimulation energy use during the  aDBS Evaluation Phase  as compared with 
cDBS. 
4.1.3.  Safety Assessments  
To characterize:  
• Stimulation -related adverse events (AEs) during the aDBS evaluation and the cDBS baseline 
phases.  
• Serious adverse events  (SAEs), adverse events  and device deficiencies throughout the study.  
4.1.4.  Additional Objectives  
To characterize aDBS as compared to cDBS  (Primary Cohort) : 
• Voice Handicap Index ( VHI): “best” and “worst” conditions  
• MDS -UPDRS III subscore (On stim/O n med) of tremor, rigidity, and bradykinesia questions where 
a side can be determined: 3.3 b, c, d, e (rigidity), 3.4 a, b (finger taps/bradykinesia), 3.15 a, b (postural tremor of hands), 3.16 a, b (kinetic tremor of hands), and 3.17 a, b, c, d (rest tremor 
amplitude)  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 29 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • MDS -UPDRS III (On stim/On med)  
• MDS -UPDRS II : “best” and “worst” conditions  
• MDS -UPDRS III speech question (On stim/On med) q 3.1  
• MDS -UPDRS IV  
• EQ-5D-5L 
• PDSS -2 
• Data collected from wearable  (for example: % of wear time tremor was detected, Dyskinesia 
Score [DKS], Bradykinesia Score [BKS], Fluctuation and Dyskinesia Score [FDS])  
• PDQ -39 Summary Index (SI) and subscores: mobility, activities of daily living, emotional well-
being, stigma, social support, cognition, communication, bodily discomfort  
• PDQ -39 speech questions 34 and 35  
• % of subjects with at least 25% increase in  projected  battery longevity as compared with cDBS  
• Parkinson’s Disease Home  Diary: “On” time without troublesome dyskinesia,  “On” time without 
dyskinesia, “On” time with non -troublesome dyskinesia,  “On” time with troublesome dyskinesia, 
“Off” time, and A sleep time.  
• Patient preference of aDBS vs cDBS (as as sessed by a Medtronic -developed patient preference 
questionnaire)  
• Patient satisfaction with aDBS (as assessed by a Medtronic -developed patient satisfaction 
questionnaire)  
• Device data from JSON file including BrainSense data  
Subgroup analyses  (from the entire study population) :  
• For those with dyskinesias: at least 25% of time: Wearable data  
• For those with speech side effects: VHI 
• For those with mixed programming ( one hemis phere with aDBS and one with cDBS): MDS -
UPDRS III by [CONTACT_10167]  
• For those who use event markers in long -term follow -up: characterize subject population and 
satisfaction with use of event markers   
• For those who finished the aDBS Evaluation Phase: one aDBS mode will be selected per subject 
based on subject preference or programming availability at the end of the aDBS Evaluation 
Phase. The aDBS Evaluation Phase results may be characterized based on the selected mode.  
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 30 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  4.2. Endpoints  
4.2.1.  Primary Endpoint  
Proportion of aDBS subjects with “On” time without troublesome dyskinesia exceeding the threshold.  
The threshold will be determined using the following: on a per -patient basis, the hours of “ On” time 
without troublesome dyskinesia for aDBS is no worse than [ADDRESS_302689] deviation is calculated from the difference between aDBS and cDBS in the Full Analysis Set 
(FAS).  
A performance goal of 50% was chosen for this  study in order to demonstrate that at least 50% of the 
subjects are able to achieve the threshold  with 95% confidence , demonstrating some level of efficacy . 
The endpoint of the Parkinson’s Disease (PD) Home D iary was chosen to determine the threshold of 
success as it is a measure of the subject response to DBS therapy over time, because the aDBS algorithm 
will adapt the therapy over time, and because the PD Home Diary has been used as an endpoint in 
previous DBS trials.  A unit of one standard deviation wa s chosen as it is an acceptable amount of 
statistical variability in the PD Home D iary endpoint given the fluctuating nature of Parkinson’s disease 
and the percentiles of a normal distribution.  
4.2.2.  Secondary Endpoint  
Decreased total electrical energy delivered  (TEED) for each  aDBS  mode during the respective aDBS 
Evaluation Period  as compared with cDBS  during the cDBS Baseline Phase . 
5. Study Design  
The ADAPT- PD trial is a prospective, multicenter, single -blind , randomized crossover clinical 
investigation and is designed to demonstrate the safety and effectiveness  of adaptive DBS for 
Parkinson’s disease . It is composed of a primary trial cohort (Primary cohort) with subjects programmed 
in ring mode and a cohort of subjects implanted with the SenSight system  and programmed to 
directional stimulation ( Directional Stimulation  Cohort).  For subjects with the 3387 and 3389 DBS leads, 
stimulation is always delivered in Ring mode . In subjects with the  SenSight lead, ring mode  is when all 
segmented electrodes at the same electrode level (e.g. 1a -1c, 2a -2c) are activated at the same 
amplitude . Directional stimulation, which can only be programmed  in subjects  with SenSight leads, is 
when the same amplitude is not  used on all three electrodes at the same electrode level (e.g. 1a -1c, 2a -
2c). 
The study is expected to be conducted at approximately [ADDRESS_302690] 1 aDBS mode is acceptable and who enter the aDBS E valuation Phase . Accounting for 
a 10% dropout during the aDBS Evalua tion Phase , a minimum of 36 subjects (at least 8 per brain target) 
will complete the aDBS Evaluation Phase . In addition, approximately [ADDRESS_302691] 1 aDBS mode is acceptable and who enter the aDBS Evaluation Phase  (~25% of the  total planned 
number of subjects). For the  Directional Stimulation  Cohort,  each study center will stop enrollment after 
they have identified a maximum of [ADDRESS_302692] 1 aDBS mode is acceptable  and who 
enter the aDBS Evaluation Phase. The a ctual number of subjects at a study center may be slightly larger 
due to the number of subjects that are enrolled prior to cessation of enrollment. This restriction is 
intended to reduce the possibility that the results from one study center will be overly  influential in the 
overall study results.  
The study consists of four phases following enrollment:  
• cDBS Baseline Phase  (approximately 1 month): LFP Screening, Baseline cDBS and Off stimulation 
Assessments  
• aDBS Setup and Adjustment Phase  (up to 2 months) : aDBS Setup visit and additional optional 
visits during an aDBS Adjustment period  
• aDBS Evaluation Phase  (approximately 2 months): One-month  treatment period s in each 
acceptable aDBS mode with aDBS evaluation visits at the end of each period .  Randomized 
crossover to the  two investigational treatments in subjects for whom both aDBS modes were 
acceptable and a single treatment period in those subjects for whom only one aDBS mode was acceptable.   
• Long- Term Follow Up Phase  (approximately 10 months) : Four sched uled visits  in the preferred 
aDBS mode  
Subject participation in an Extended  Access Phase  is optional and includes a dditional  visits in the 
preferred aDBS mode every [ADDRESS_302693] will continue the study in their preferred aDBS 
mode until aD BS is commercially approved  or closure of the study, whichever comes sooner.  
The study may also be stopped on recommendation of the DMC . See Section  12.1. 
5.2. Rationale  
The ADAPT- PD study will utilize the commercially approved Model B35200 Percept PC INS that has 
investigational aDBS functionality enabled.  This  aDBS  functionality was developed using the clinical 
knowledge gained in numerous investigator -sponsored, single -center, feasibility studies and investigator 
experience with the Medtronic Activa PC+S INS, a first generation aDBS device.  The aDBS control algorithm will rely on STN and GPi [INVESTIGATOR_248918] - - Beta band (approximately 8-30 Hz) activity as the signal of 
interest.  The feasibility of using Alpha - Beta  LFP has been demonstrated by [CONTACT_248951].
25,45,46,47,48,49,50,51,52,53,54,55 The ADAP T-PD Study will assess both dual and  single  
threshold aDBS modes  (algorithms) .  Evidence generated by [CONTACT_248952]-Stewart/Stanford group using a 
dual threshold algorithm and the Brown/Oxford group using a single threshold algorithm has demonstrated that aDBS is feasible. In addition, both dual and single threshold aDBS were  well 
tolerated, were  as effective or more effective than cDBS, may reduce DBS induced side effects and were  
associated with a significant reduction in DBS power usage compared to cDBS.
25,45,46,47,48,49,[ADDRESS_302694] Description  
6.1. General  
Medtronic DBS Therapy uses implantable, programmable neurostimulators, leads and extensions to 
deliver electrical stimulation to the STN or GPi [INVESTIGATOR_248919].  
The Percept PC system includes the Percept PC INS and external components  that use telemetry to 
communicate with the INS for programming stimulation parameters. Table 1 provides a listing of the 
Percept PC system components which will be used in the ADAPT -PD Trial. Figure 1 illustrates the full 
Percept PC system. The commercially available components are described below in Section 6.1.1 .  
The devices  that are considered investigational for the ADAPT -PD system include the Model B35200 
Percept PC INS when aDBS firmware  is enabled, the Model A610 Clinician Programmer Application 
Version 3.0 with aDBS software enabled and the Model A620  Version 2.0 Patient Programmer 
Application  (PPA) with aDBS functionality. These components are described in  Section  6.1.2. The devices 
will become investigational in the ADAPT -PD Trial when the aDBS firmware or software feature flags are 
enabled or when aDBS screens are displayed on the programmers. There is no physical difference between the commercially available components of the Percept PC system and the investigational components. Parts of the clinician programmer system and patient programmer system to be used in 
the ADAPT- PD Trial are completely unchanged from the commercially available versions but are 
packaged and used with devices that will be considered investigational once aDBS is enabled and will therefore also be considered investigational.  
The combination of approved labeling, investigational labeling and the Clinical Investigation Plan contains adequate information for the purposes of the investigation.  The investigational labeling will be 
provided to investigational sites, IRBs/ECs and Regulatory Authorities (as applicable) in the Inve stigator’s 
Brochure  (IB). Investigational labeling for the Patient Programmer System will be provided  to patients  
after aDBS is set up.    
  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 34 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
   
Table 1: Medtronic DBS System Components  
 Component  Model  
Implantable  Neurostimulator  Mode l B35200  Percept PC INS with aDBS firmware (FW) 
enabled * 
• Product Firmware Version 7.5 
• Device Firmware Version 7.5  
• Core Firmware Version 7.5 
External  Clinician Programmer 
System Components  • Model 8880T2 Version 1.107 Clinician Telemetry 
Module**  
• Model CT900 Clinician Programmer Tablet ** 
o Model A610 Clinician Programmer Application  
Version 3.0 with aDBS software enabled* * 
o Model A901 Version 1.0 Communication 
Manager**  
o Model A902 Version 1.0 Patient Data 
Services**  
Patient Programmer 
System Components  TH91 Package Kit  
1. Model TM91 Version 2.1 Patient Telemetry Module**   
2. Model HH90 Patient Programmer Phone**  
3. Model A620 Version 2.0 Patient Programmer 
Application  (PPA) with aDBS functionality*  
*Components are physically the same as the commercially available product with investigational firmware or 
software feature flags enabled or investigational screens displayed.  The software/firmware versions are the same 
as the commercially available product.  
**Components are not modified from the c ommercially available version but will be considered investigational as 
they are packaged together with the Patient and Clinician Programmer Applications as a system.   
 
The commercially approved (FDA approved, CE marked , and Health Canada licensed)  devices will be 
used within the scope of their approved labeling for which FDA approval, CE mark , or Health Canada 
approval has been obtained.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 35 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Figure 1 : Percept PC System  

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 36 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  6.1.1.  Medtronic Commerci ally Available DBS System Components  
Model B35200 Percept PC INS  
The model B35200 Percept PC Neurostimulator with BrainSense™ (Product Firmware Version 7.5, Device 
Firmware Version 7.5, Core Firmware Version 7.5) is commercially available for DBS Therapy and is part 
of an active implantable device system for deep brain stimulation and sensing. The DBS system delivers 
electrical stimulation to targeted regions of the brain, defined by [CONTACT_248953]/ or physiology, to 
suppress the symptoms associated with a neurologic disorder treatable by [CONTACT_248954]. The 
neurostimulator is a multiprogrammable device that delivers stimulation thr ough [ADDRESS_302695] 
bioelectric data through the DBS leads implanted in the brain . 
Percept PC has embedded firmware  which adjusts the stimulation output of the device to conform to 
clinician programmed parameters. The firmware stores data pertinent to device operation and sends 
the data via radio frequenc y (RF) telemetry when requested by [CONTACT_248955] (clinician 
programmer or patient programmer). The firmware  limits stimulation outputs to within clinician -defined  
ranges and modes.  
The commercially available Model B35200 Percept PC INS will be implanted prior to subject enrollment in the study. The commercially available Model B35200 Percept PC INS contains  the aDBS FW , but the 
FW is not active.  
DBS Lead s (Includes m odel s 3387 , 3389 , B33005 and B33015)  
The Models 3387 and 3389 DBS Leads are  composed of a polyurethane protective sheath with four 
platinum/iridium electrodes located at the distal end, which are used to deliver the electrical stimulation to the target site.   
The Model 3387 DBS Lead features wide (1.5 mm) spacing between each of the four electrodes at the 
distal end. The Model 3389 DBS Lead features narrow (0.5 mm) spacing between each of the four 
electrodes at the distal end .  
The Models B33005 and B33015 SenSight  Leads  are composed of a poly urethane protective sheath with 
eight platinum/iridium electrodes located at the distal end (in a [ADDRESS_302696] electrodes separated into three separate electrodes spaced 120° from the center of each 
segment) , which are used to deliver the electrical stimulation to the target site.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 37 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  The Model B33015 SenSight Lead features wide (1.5 mm) spacing between each of the four electrode 
levels at the distal end. The Model B33005 SenSight Lead features narrow (0.5 mm) spacing between 
each of the four electrode levels at the distal end.   
DBS Extension Kits (Includes models [ZIP_CODE] , [ZIP_CODE] , or B34000  in 40, 60, 95 cm lengths)  
The Model [ADDRESS_302697] the neurostimulator to the lead, providing an electrical 
path that allows stimulation to be delivered to the target site.  The  Model [ZIP_CODE] and [ZIP_CODE] DBS 
Extension s are identical.  The only difference is the  Model  [ZIP_CODE]  DBS Extension Kit contains a tunneling 
tool and the Model [ZIP_CODE] DBS Extension Kit does not.  
The Model B34000 SenSight  Extension  connects the neurostimulator to the lead, providing an electrical 
path that allows stimulation to be delivered to the target site.  
Clinician Progr ammer System Components ( Model A610 Clinician Programmer Application , Model 
CT900 Clinician Programmer Tablet , Model 8880T2 Clinician Telemetry Module , Model A901 
Communication Manager  and Model A902 Patient Data Services ) 
The Medtronic Model A610 DBS Version  3.0 () Clinician Programmer Application  (CPA) is intended for 
use by [CONTACT_248956] (external and implantable) for deep 
brain  stimulation (DBS).   
The Model CT900 clinician programmer tablet, with Android® -based operating system, is  intended for 
use by [CONTACT_248957].  
The Model 8880T2 Communicator is intended for use by [CONTACT_248958] t he 
clinician tablet and CPA for communication with Medtronic Neuromodulation therapy  devices.  
The Model A901 Version 1.[ADDRESS_302698] (or disable) the  auto -delete feature, which 
automatically deletes patient data (after it  has been compi[INVESTIGATOR_248920]) after a designated amount of 
time.  
Patient Programmer System Components ( TH91 package kit i ncludes: Model A620 Patient 
Programmer Application, Model HH90 Patient Programmer Phone, Model TM9 1 PTM ) 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302699]’s neurostimulator.  
6.1.2.  Medtronic Investigational  DBS System Components  
aDBS Feature  
The intended purpose of the aDBS feature is to automatically adjust stimulation  amplitude, within 
clinician- defined limits, based on changes in a patient’s brain state measured using Alpha - Beta  LFPs as 
a signal of interest.   Under the assumption that cor relations exist between brain state and clinical 
symptoms and side effects, the goal is to maintain the brain state such that certain clinical symptoms 
and side effects can be managed. The aDBS feature is investigational for this study and is enabled using  
a Clinician Programmer System with investigational aDBS software  enabled . The ADAPT- PD Trial will 
study two aDBS modes , Dual and Single Threshold modes. Additional modes will be available on the 
clinician programmer as part of the aDBS feature but will no t be used in the ADAPT -PD Trial.  
aDBS Dual Threshold Mode  
Dual threshold mode includes both an upper and lower control threshold on the LFP SOI and aDBS makes changes to the stimulation amplitude to attempt to maintain the LFP SOI between the two 
threshold s.  In this scheme, when the LFP SOI is “high”, then stimulation is increased, whereas when the 
LFP SOI is “low” stimulation is decreased to control the LFP SOI.  When the patient tailored LFP Alpha - 
Beta  power SOI remains between the upper and lower thresholds, stimulation amplitude is held 
constant. When the Alpha - Beta  power SOI exceeds the upper threshold, stimulation increments. When 
the Alpha - Beta  power SOI dips below the lower threshold, stimulation decrements. This aDBS mode is 
shown in Figure 2.   
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 39 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Figure 2 : Dual Threshold aDBS Mode  
 
aDBS Single Threshold Mode 
Single threshold mode includes a single control threshold on the LFP SOI and aDBS makes changes to the 
stimulation amplitude based on the measured LFP and whether it is above or below the threshold.  In 
this scheme, when the LFP SOI is above the threshold, then stimulation is incremented and when the 
LFP SOI is below the threshold, the stimulation is decremented.  This mode has shorter default 
stimulation ramp up and ramp down durations than dual mode.  This aDBS mode is illustrated in  Figure 
3. 
Figure 3 : Single Threshold aDBS Mode  
 
Investigational Model B35200 Percept PC INS with aDBS Firmware Enabled  

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 40 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Although no physical changes are made to the Model B35200 Percept PC INS, it becomes investigational 
at the aDBS Setup visit when the investigational aDBS FW is enabled by [CONTACT_248959]. When the firmware is enabled, the device has the ability to 
adapt stimulation based on the sensed bioelectric data from  the DBS leads implanted in the bra in. 
The estimated number of times the investigational aDBS firmware  will be enabled on the commercially 
available Model B35200 Percept PC is 70 . Once for each patient that enters the aDBS Setup and 
Adjustment phase.   
Investigational Clinician Programmer System Components ( Model 8880T2 Clinician Telemetry Module; 
Model CT900 Clinician Programmer Tablet , with Model A610 Clinician Programmer Application, Model 
A901 Communication Manager  and Model A902 Patient Data Services  installed ) 
The Medtronic Model A610 DBS Version 3.0  Clinician Programmer Application ( CPA) utilized for the 
study will have investigational aDBS software enabled by [CONTACT_13735]. The investigational aDBS feature allows the physician to program aDBS on the Percept PC INS, including selecting an LFP signal of interest 
(Alpha  -Beta  for this study), programming electrode configuration, capturing LFP thresholds, setting 
upper and lower stimulation limits, transition durations and suspend amplitude. The software version 
number ( 3.0) is the same for the commercial and investigational versions. A feature identifier will 
indicate if the aDBS feature is enabled or disabled (i.e. whether it can configure/modify aDBS).   
The Model 8880T2 Communicator ; the Model CT900 clinician programmer tablet, with Android® -based 
operating system  with  the Model A901 Version 1.0 Communication Manager Application and t he Model 
A902 Version 1.0 Patient Data Service Application installed are unchanged from the commercially 
available versions.  
Although only the CPA  will be modified from the commercially available version  by [CONTACT_248960] g 
investigational screens which allow programming of aDBS, all components will be considered 
investigational as they are packaged together as a system.   
The estimated number of Investigational  Clinician Programmer System s to be used in the study is 24  
clinician systems, two  for each participating center. These systems will be provided to the participating 
centers exclusively for use in this study.  
Investigational Patient Programmer System Components ( TH91 package kit includes: Model TM9 1 
PTM and Model HH90 Patient Programmer Phone  with Model A620 Patient Programmer Application 
installed) 
The patient programmer system components utilized in the study will be investigational marked 
versions of the commercially available product. When the patient programmer system is paired with a 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302700] to pause and resume Adaptive Therapy. The software version number 
(2.0) is the same for the commercial and investigational versions. A feature identifier will indicate if the aDBS feature is enabled or disabled (i.e. whether it can configure/modify aDBS).  
The Model HH90 Patient Programmer Handset and the Model TM91 PTM are unchanged from the 
commercially available versions. Although only the Patient Programmer Application will be modified 
from the commercially available version  by [CONTACT_248961], all three components will 
be considered investigational as they are packaged together as a system.   
The estimated number of Investigational  Patient Programmer System s to be used in the study is [ADDRESS_302701], Minneapolis, MN [ZIP_CODE], [LOCATION_003] , is the legal manufacturer of the 
Percept PC System for the ADAPT- PD Trial. Detailed manufacturing information for the investigational 
products used in this study is listed in Table 2 below.  
Table 2: Manufacturing Information for Investigational Products  
Facility  Responsibility  
Medtronic Puerto Rico Operations Co., Juncos  
Road 31, Km. 24, Hm 4  
Ceiba Norte Industrial Park  
Juncos, Puerto Rico [ZIP_CODE]  
Establishment Registration: #[PHONE_5221]  Manufacturer for:  
• Model B35200 Percept PC INS  
Medtronic Rice Creek Facility  
Medtronic Neuromodulation  
[ADDRESS_302702] NE  
Minneapolis, MN [ZIP_CODE]  
Establishment Registration #[ADDRESS_302703] specification developer for:  
• Model A610 Clinician Programmer 
Application  
• Model 8880T2 Communicator  
• Model A620 Patient Programmer 
Application  
• Model TM91 Communicator  
Application of investigational labeling for:  
• Study Patient Programmer System  
• Study Clin ician Programmer System  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 42 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Plexus Manufacturing Sdn. Bhd.  
Bayan Lepas Free Industrial Zone, Phase II  
Bayan Lepas, Penang, Malaysia [ZIP_CODE]  
Establishment Registration #[PHONE_5222]  Contract Manufacturer for:  
• Model 8880T2 Communicator  
Jabil Circuit (Shanghai), LTD.  
[ADDRESS_302704]  
Shanghai, China 200233  
Establishment Registration #[PHONE_5223]  Contract Manufacturer for:  
• Printing the labeling for A620 PPA  
• Placing A620 PPA labeling inside the 
TM9 1 box 
• Manufacture the TM9 [ADDRESS_302705]  
Memphis, TN [ZIP_CODE]  
Establishment Registration #[PHONE_5224]  Kit Assembler for:  
• Placing the TM9 1 box and the HH90 
Handset box into the TH9 1 box 
• Print the TH9 [ADDRESS_302706] on the box  
6.3. Packaging 
The following investigational components (physical components of the Clinician Programmer System and Patient Programmer System) and their immediate package will be affixed with a sticker which 
contains a statement acc ording to local requirements:  
• Clinician Programmer System  
o Model CT900 Clinician Programmer Tablet  
o Model 8880T2 Communicator (also referred to as the Clinician Telemetry Module 
(CTM)) 
• Patient Programmer System  
o Model HH90 Patient Programmer Handset  
o Model TM9 1 Communicator (also referred to as the Patient Telemetry Module (PTM))  
o Model TH91 Package Kit that contains the above parts  
The Percept PC Model B35200 Neurostimulator will not be physically labeled as an investigational device as the device will have bee n implanted as part of a commercially available DBS System.  
In the US, t he Medtronic investigational DBS System components listed above or their  immediate 
package will be labeled with the following information according to 21CFR§812.5: 
• Name [CONTACT_29773], packer or distributor  
• The quantity of the contents, if appropriate  
• The statement “CAUTION – Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to 
investigational use”  
• A description of all relevant contraindications, hazards, adverse effects, interfering substances 
or devices, warnings, and precautions will be provided in labeling under a separate cover.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 43 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  In the EU  and the [LOCATION_006] , labeling for the investigational device s listed above  will follow the applicable 
ISO14155:[ADDRESS_302707] 2017/745 requirements. This shall include a statement indicating the  
device is “exclusively for clinical investigation, ” and foll ow applicable  local labeling language 
requirements  in accordance with national regulations . 
In Canada, following Medical Devices Regulations / SOR98 -282, the Medtronic investigational device s 
listed above  will be labeled with the following information:  
• The name [CONTACT_122729] 
• The name [CONTACT_132656]  
• The statements “Investigational Device” and “Instrument de recherche”, or any other 
statement, in English  and French, that conveys that meaning 
• The statements “To Be Used by [CONTACT_248962]” and  “Réservé uniquement à l’usage 
de chercheurs compétents”, or any other statement, in  English and French, that conveys that 
meaning  
Labeling for the investigational devices will be  provided under a separate cover  and will also be labeled 
with a statement ac cording to local requirements .  
Products used in this study that are commercially available are packaged and labeled accordingly  
consistent with local regulations .  Labeling and patient material are provided in local language for CE 
marked devices.  
6.4. Intended Population  
The intended study population is subjects  with idiopathic Parkinson’s d isease  implanted with  a 
Medtronic  DBS system, including bilateral leads targeted to the internal globus pallidus ( GPi) or the 
subthalamic nucleus (STN) , extensions  and a single Percept PC implantable neurostimulator.  
6.5. Equipment  
The Global Kinetics Corporation (GKC)  PKG® or Personal KinetiGraph®(US) /Parkinson’s Kinetigraph (EU)  
system will be used to  provide a continuo us, objective monitoring of key movement symptoms of 
Parkinson’s disease, including bradykinesia, dyskinesia  and tremor . The PKG system consists of a wrist -
worn movement recording device known as the PKG Watch, proprietary algorithms and a data- driven 
report known as the PKG. GKC will provide a processed data file to Medtronic for analysis. GKC  will be 
responsible for mainte nance and calibration of the PKG Watch.   
In Canada, the PKG system is considered investigational and will be used in the study under an 
Investigational Testing Authorization (ITA).  Investigational product requirements in Section s 6.[ADDRESS_302708] will be described in the Investigator’s Brochure  (IB), provided 
under separate cover.  The investigator agrees not to use the  investigational device s on any person 
except subjects enrolled in this study.  
6.7. Product Training Requirements  
Selected investigators will have experience wit h commercially available Medtronic DBS Therapy 
products. Investigators and delegated site staff will receive training on the use of the investigational 
products prior to enrollment of the site’s first subject.  
6.8. Product Receipt and Tracking  
In order to allow  shipment of non-implantable investigational product  (Clinician Programmer System 
and Patient Programmer System)  to a study center  and for a study center to enable aDBS FW on a 
commercially available Percept PC INS , Medtronic must declare in writing that t he study center is 
activated and ready to enroll subjects. The investigational product must only be used for the purpose of 
the ADAPT -PD Trial and in compliance to the clinical investigation plan.  
Upon receipt of  non-implantable  investigational product  (Clinician and Patient Programmer Systems) , 
the principal investigator [INVESTIGATOR_248921], will visually inspect and notify Medtronic of any 
noted issues or discrepancies.   
The investigational product s listed in  Table [ADDRESS_302709] accountability log , 
with the exception of the TH91 package kit ( box). Refer to Section  6.11 : Product Accountability. Detailed 
instructions on the maintenance of records related to investigational product receipt and tracking will be provided under a separate cover.  
6.9. Product Storage  
Investigational products  must be stored in a secured and locked location accessible only to those 
delegated individuals who are authorized by [CONTACT_458] [INVESTIGATOR_248922]. It is the responsibility of the investigator to correctly handle, store, and track the investigational products 
maintained at the study center.   
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302710] will be identified using serial, lot, or part number  and installed software /firmware  
version(s) . A product accountability log must be updated at each investigational center when  non-
implantable  investigational components are received, opened but not used , distributed to a subject,  
explanted, disposed of, or returned to Medtronic  or when aDBS FW is enabl ed or turned off  on the 
Percept PC INS . Products that are unused, expi[INVESTIGATOR_248923]. A Medtronic 
monitor, or trained Medtronic staff, will review the product accountability log during monitoring or 
study visits. The product acc ountability log will indicate dates and the quantity and description, including 
serial, lot , or part number , installed software /firmware  version(s) and expi[INVESTIGATOR_320] ( if applicable for 
non-implantable products) , subject ID (if applicable) , reason(s) for and method of destruction/disposal 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 46 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  for explanted components not returned to Medtronic (if applicable), and name [CONTACT_249033]/disposal (if applicable ) of all investigational DBS System 
components on hand at any time during the study.  
Medtronic will perform periodic reconciliation of the investigational product to ensure traceability.  
7. Study Site Requirements  
7.1. Investigator/Investigation Site Selection  
All investigators managing the subject’s Parkinson’s disease must be qualified practitioners and experienced in the diagnosis and treatment of subjects with PD. All investigators  must be experienced 
and trained in the use of  DBS.   
The role of the principal investigator [INVESTIGATOR_54365] -to-day conduct of the clinical 
investigation as well as ensure data integrity and the rights, safety and well- being of the subjects 
involved in the clinical investigation.  
The principal investigator [INVESTIGATOR_67417]:  
• Be qualified by [CONTACT_8640], training, and experience to assume responsibility for the proper conduct of the clinical investigation  
• Be experienced in the field of application and training in the use of Deep Brain Stimulation 
• Disclose potential conflicts of interest, including financial, that interfere with the conduct of the clinical investigation or interpretation of results  
• Be able to demonstrate that the proposed investigational study site:  
o Has the required number of eligible subjects needed within the recruitment period  
o Has one or more qualified investigators, a qualified investigational study site team and 
adequate facilities for the foreseen duration of the clinical investigation  
Study site personnel training will be completed and documented prior to participation in this study.  
7.2. Study Site Activation  
During the activation process (prior to subject enrollment), Medtronic will train study site personnel on the clinical investigation plan, on relevant standards and regulations  (as required) , informed con sent, 
and on data collection and reporting tools. If new members join the study site team, they will receive 
training on the applicable study requirements relevant to their role before contributing to the study.  
Prior to performing study related activities, all regulatory requirements shall be fulfilled, including, but not limited to the following:  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 47 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • IRB/ EC approval (and voting list, as required by [CONTACT_1769]) of the current version of the CIP and 
Informed Consent ( IC) 
• Regulatory Approval  (RA) or notification (as required per local law)  
• Fully executed C linical Trial Agreement (CTA)   
• Financial disclosure (if applicable)  
• Current Curriculum Vitae ( CV) of investigators and key members of the investigation study site 
team  
• Documentation of delegated tasks  
• Documentation of study training  
Additional requirements imposed by [CONTACT_427], the IRB/ EC and RA shall be followed, if 
appropriate.  
In additi on, all participating study site staff must be trained on the current version of the CIP as well as 
on the applicable study requirements ( depending on their role ) and must be delegated by [CONTACT_1961] [INVESTIGATOR_180984].  
Medtronic will provide each study site with documentation of study site/investigator readiness; this 
letter must be received prior to performing study related activities.  
7.3. Role of the Sponsor Representatives  
Sponsor  representatives who are qualified and designated on the sponsor technical support list  may 
participate in the conduct of the study under the direct supervision of the investigator as described 
below. The investigator or authorized study center personnel designated on the delegation of authority form (eg, programmer, neurologist) must be present to collect data, record the study activities, and to 
be responsive to the subject’s needs during an activity performed by a Medtronic representative.  
In addition to performing monitoring and auditing activi ties, Medtronic personnel may:  
• Provide technical support during study  visits  under the supervision of a study investigator . This 
support may include technical assistance for products, systems, and programming, and the 
training of study center personnel on the use of Medtronic equipment or CIP -related procedures 
and other study activities  
• Take responsibility for product transfer, but will not have direct access to the locked device storage area  
• Clarify and troubleshoot device behavior, operation , or diagnostic output as requested by [CONTACT_248963]  
• Privately discuss any issues with programming or subject compliance with the Principal Investigator [INVESTIGATOR_248924]  
• Observe study -related procedures to provide information relevant to study -required data 
collection  
• Review collected data and study documentation for completeness and accuracy  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 48 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • Perform device interrogation while under the direction of the investigator or study center 
personnel with delegated responsibili ty for device programming  
• Facilitate device data transfer to Medtronic  
Medtronic personnel may not:  
• Practice medicine provide medical diagnoses or make decisions related to subject treatment/care  
• Assist the subject by [CONTACT_248964] -related 
task to be conducted  
• Discuss a subject’s condition or medical treatment with the subject or a member of the subject’s family  
• Provide the subject with any form/questionnaires related to the product(s) used in this stud y 
• Create source documentation on data collection and reporting tools (unless tools are explicitly created to be completed by [CONTACT_248965])   
8. Selection of Subjects  
8.1. Study Population  
The intended Primary Cohort study population is subjects 18 years of age or older with idiopathic 
Parkinson’s disease implanted with a full Medtronic DBS system, including bilateral leads targeted to the 
internal globus pallidus (GPi) or the subthalamic nucleus (STN), extensions and a single Percept PC 
implantable neurostimulator. The subject and/or caregiver must be able to utilize the patient programmer. In addition, subjects must be responsive to DBS Therapy , and have a Alpha - Beta  band (8 -
30 Hz) amplitude ≥1.2 µVp detected on left and/or right DBS leads on sensing channels 0 -2, 0-3, or 1 -3; 
8-10, [ADDRESS_302711]  Informed 
Consent ( IC). The date the subject signed the IC must be documented in the subject’s medical records.  
There are two sets of criteria for study participation prior to the investigational use of aDBS.  
• Subjects must meet all general inclusion/exclusion criteria (as assessed at the Enrollment Visit)  
• Subjects must meet the  LFP screening inclusion criterion (as assessed at the LFP Screening Visit)  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302712] meet all the following inclusion criteria:  
General  (Primary Cohort): 
1. Subject has idiopathic Parkinson’s disease 
2. Subject is implanted with Percept PC (Model B35200) and Medtronic DBS leads  (Model 3387 , 
3389, B33005 or B33015) and extensions  (Model  [ZIP_CODE] , [ZIP_CODE]  or B34000 ) bilaterally in the 
same target (physician confirmed) , STN or GPi  
3. In the opi[INVESTIGATOR_871], the subject responds to DBS Therapy.  
4. Based on the opi[INVESTIGATOR_871], the subject’s cDBS parameters and PD medications are 
stable and expected to remain stable from enrollment through the end of the aDBS Evaluation  
phase  
5. Subject is configured to ring mode monopolar or dual monopolar stimulation using contacts 1 
and/or 2 (9 and/or 10) on at least one side .  
6. Subject is willing and able to attend all study -required visits and complete the study procedures 
(e.g. 1 -month recall questionnaires, MDS- UPDRS III)  
7. Subject has the ability to understand and provide written informed consent for participation in the study prior to th e study -related procedures being conducted  
8. Subject is a male or non -pregnant female. If female of child -bearing potential, and if sexually 
active, must be using, or agree to use, a medically acceptable  method of birth control as 
confirmed by [CONTACT_1188] 
9. For subjects with the SenSight system:  Subject is configured to the following stimulation rates: 
55, 85, 110, 125, 145, 164 or 180 Hz (as required for sensing/aDBS)  
General  (Directional Stimulation  Cohort):  
Subjects must meet the same inclusion criteria  as the primary cohort except for revised #2 and # 5. 
Revised inclusion criteria:  
2. Subject is implanted with Percept PC (Model B35200) and Medtronic DBS leads (Model B33005 
or B33015 ) and extensions (Model B34000 ) bilaterally in the same target (physician co nfirmed), 
STN or GPi  
5. Subject is configured to  directional  monopolar or dual monopolar stimulation using contacts 1 
and/or 2 (9 and/or 10)  
LFP Screening : 
1. Subject has Alpha - Beta  band ( 8-30 Hz) amplitude ≥ 1.2 µVp detected on either left and/or  right 
DBS leads on sensing channels 0 -2, 0-3, or 1 -3; 8-10, [ADDRESS_302713] who meets any of the following criteria will be excluded from participating in the 
study : 
General  (Primary Cohort):  
1. Subject and/or caregiver is unable to utilize the patient programmer  
2. Subject has more than one lead in each hemisphere  of the brain  
3. Subject has cortical leads or additional unapproved hardware implanted in the brain  
4. Subject  has more than one INS  
5. At enrollment, the subject’s INS has a predicted battery life of <[ADDRESS_302714] has Beck Depression Inventory II (BDI -II) > [ADDRESS_302715] requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)  
8. Subj ect has a metallic implant in the head, (eg, aneurysm clip, cochlear implant)  
9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (eg, cardiac pacemaker, defibrillator, spi[INVESTIGATOR_55441])  
10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson’s 
disease  (eg, DUOPA
TM infusion pump) and/or portable infusion pump  
11. Based on the opi[INVESTIGATOR_871], the subject has an abnormal neurological examination 
that would  preclude them from study participation  
12. Subject is breast feeding  
13. Subject is under the age of [ADDRESS_302716] is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determine d by [CONTACT_248966]  
15. Subject is unable to use or tolerate wearable  
16. Subjects with signal artifact on all 6 aDBS sense pathways  (3 each on both DBS leads ) which 
preclude the clinician from setting thresholds  
General  (Directional Stimulation  Cohort):   
General exclusion criteria for the Directional Stimulation Cohort are the same as for the P rimary Cohort.  
9. Study Procedures  
The study schedule, procedures, and methods of assessment are defined in detail to enable compliance with the required activities, and to ensure that the resulting data meet the criteria for evaluability  Figure 
4. Case report forms (CRFs) will be provided for use in collecting data for all subjects; the pertinent CRFs 
along with the applicable source documentation will be completed for each subject at the time of each 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302717].  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 52 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  9.1. Schedule of Events  
Figure 4 : Study Schematic  
       

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 53 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  9.2. Data Collection  
Data collection requirements are summarized in Table 3 below.  
Table 3: Study Procedures and Data Collection by [CONTACT_248967] -term Follow -up Phase  Extended  
Access Phase    
VISIT NAME  [CONTACT_249034] 1  Visit 2*  Visit [ADDRESS_302718] 
Withdrawal / 
Discontinuation  Unsched . 
Visit  System 
Mod. 
Informed Consent  X               
Demographics  X               
Medical & surgical 
history  X               
PD history  X               
C-SSRS ( screening ) X               
BDI-II X               
Pregnancy test  X               
Device information  X              X 
Signal Test  X X  X            
Concomitant 
medication  X X X X X X X X X X X X  X X 
PD medication at 
visit    X            
PD medication 
prior to visit   X  X            
PDQ -39   X   X X X X X X X    
EQ-5D-5L   X   X X X X X X X    
MDS -UPDRS I A   X   X X         
MDS -UPDRS 
Patient 
Questionnaire 
(Part IB & II) Worst 
condition    X   X X         
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 54 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  PHASE NAME   [CONTACT_249035] -term Follow -up Phase  Extended  
Access Phase    
VISIT NAME  [CONTACT_249034] 1  Visit 2*  Visit [ADDRESS_302719] 
Withdrawal / 
Discontinuation  Unsched . 
Visit  System 
Mod. 
MDS -UPDRS 
Patient 
Questionnaire (Part IB & II)  Best 
condition    X   X X      
  
    
MDS -UPDRS III  
On stim (cDBS) / 
On med    X             
MDS -UPDRS III  
Off stim (cDBS) / 
Off med   X              
MDS -UPDRS III  
On stim (aDBS) / 
On med       X X         
MDS -UPDRS IV    X   X X         
PD Home  Diary    X   X X         
C-SSRS (follow -up)      X X         
VHI  
Worst condition    X   X X         
VHI  
Best condition    X   X X         
PDSS -2   X   X X         
BrainSense setup   X  X            
aDBS 
programming     X          X**  
Physician 
programming 
survey     X**          X**  
Patient preference 
questionnaire       X X         
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 55 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  PHASE NAME   [CONTACT_249035] -term Follow -up Phase  Extended  
Access Phase    
VISIT NAME  [CONTACT_249034] 1  Visit 2*  Visit [ADDRESS_302720] 
Withdrawal / 
Discontinuation  Unsched . 
Visit  System 
Mod. 
Patient 
satisfaction 
questionnaire            X  X***    
GIC     X           
Preferred aDBS 
mode        X         
Wearable data    X   X X X X X X     
Event Markers  
with LFP capture **        X X X X     
Programming 
session  upload via 
CDU  X X X X X X X X X X X X X X X****  
AEs As they occur  
Device deficiencies  As they occur  
Protocol 
Deviations  As they occur  
Reason for exit              X   
* If two aDBS modes are set up  
** Optional  
*** If early  discontinuation following aDBS Evaluation Phase  
**** If INS is modified  
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302721] be reported and the original follow -up schedule 
maint ained for subsequent visits.  
Table 4: Visit Windows  
Visit  Visit ranges  
LFP Screening  1-45 days after enrollment  
cDBS Baseline  30-45 days after LFP Screening  
aDBS Setup  1-45 days after Baseline  
aDBS Adjustment  0-60 days after aDBS setup complete  
Randomization / Day 0  No greater than 60 days after aDBS setup 
complete  
aDBS Evaluation  Visit 1  30-45 days after  Day 0  
aDBS Evaluation Visit 2 * 30-45 days after Evaluation visit 1  
Visit 3  45-60 days after Evaluation Visit 2 (or Evaluation 
Visit [ADDRESS_302722] is only configured to one 
aDBS mode)  
Visit 4  45-60 days after Visit  3 
Visit 5  90 +/ - 14 days after Visit 4  
Visit 6  90 +/ - 14 days after Visit 5 
Extended Access Visits  Every 180 +/ - 60 days  beginning after  Visit 6  and 
every 6 months thereafter following the 
previous extended access visit 
 
* If two aDBS modes are set up  
9.4. Subject Screening  
Subjects may be recruited through the investigator’s practice, referring physicians, and/or the use of 
recruitment tools approved by [CONTACT_3488] /EC. Potential subjects may be identified through a 
study center database query ( e.g. chart reviews) or as new or existing patients attend clinic visits.  
The investigator, or authorized center personnel, will screen potential subjects by [CONTACT_248968]’s 
inclusion/exclusion criteria. A screening log will be provided for use in tracking potential subjects. All 
subjects that are considered for the study must  be included on the study screening log. The reason  for 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302723] fails the inclusion/exclusion criteria, and is discontinued from the study, and it is the 
investigator’s medical judgment that re -screening may be appropriate at a later date during the study, 
the investigator may  contact [CONTACT_248969] -screen the subject 
prior to proceeding. Approval will be provided in writing by [CONTACT_248970].  
9.5. Prior and Concomitant Medications  
All concomitant medications, except for  over -the-counter  medications and herbal supplements, will be 
collected for this study. All Parkinson’s disease medications will be collected for this study. Subjects ’ 
Parkinson’s disease medication must  be stable at the time of enrollment in the trial  through the end of 
the aDBS Evaluation Phase. During this time, the investigator should make only clinically necessary 
changes to PD medication .  
There are no medication restrictions in the study unless they are investigational and may confound the 
study results, in which case, prior approval would be needed from Medtronic . 
Parkinson’s disease medications will be held prior to the LFP Screening  and aDBS Setup visits. See  Table 
5: PD Medication Off/On Definitions . 
9.6. Subject Consent  
Informed consent is defined as a legally effective documented confirmation of a subject’s voluntary 
agreement to participate in a particular study after information has been given and explained to the 
subject on all aspects of the study that are relevant to the subject’s decision to participate. This process includes obtaining an IC form and an Authorization to Use and Disclose Personal Health Information/Research Authorization/other privacy language as required by [CONTACT_248971]’s IRB/ EC and signed and dated by [CONTACT_423]. A subject may only consent after 
information has been given and explained to the subject on all aspects of the clinical investigation that are relevant to the subject’s decision to participate.  
Prior to enr olling subjects, the site IC and the Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language as required by [CONTACT_248972]/ EC.  The document(s) must be controlled (i.e. versioned and/or dated) to ensure it is clear which 
version(s) were approved by [CONTACT_1201]/ EC.  Any adaptation of the sample IC must be reviewed and 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 58 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  approved by [CONTACT_169267]/ EC reviewing the application prior to enrolling subjects  or if the IC is  
updated at any time during the study .  
The investigator must notify the subject of any significant new findings about the study that become 
available during the course of the study which are pertinent to the safety and well- being of the subject, 
as this could impact a subject’ s willingness to participate in the study. If relevant, consent may be 
requested from subjects to confirm their continued participation.  
Templates for the study -specific subject IC and Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language  for this study are provided by [CONTACT_248973] a separate cover.  
Prior to initiation of any study -specific procedures, IC must be obtained from the subject. Likewise, 
privacy or health information protection regulation  may require subjects to sign additional forms to 
authorize study sites to submit subject information to the study sponsor. The IC process must be 
conducted by [CONTACT_458] [INVESTIGATOR_169225], and the IC Form and Authorization to 
Use and Disclose Personal Health Information/Research Authorization/other privacy language as 
required by [CONTACT_248974] a language he/she is able to read and understand. The process of IC must be conducted without using coercion or undue i mproper influence on or inducement 
of the subject to participate by [CONTACT_248975]. The IC process shall not waive or appear to waive subject’s legal right. The language used shall be as non -technical as possible 
and must be  understandable to the subject and the impartial witness, where applicable.  
The subject must have ample time and opportunity to read and understand the IC form, to inquire about details of the study, and to decide whether or not to participate in the stud y. All questions about the 
study should be answered to the satisfaction of the subject.  
When the subject decides to participate in the study, the IC must be signed and personally dated by [CONTACT_248976], as required by [CONTACT_248977], and ensured by [CONTACT_458] [INVESTIGATOR_022]/her authorized designee.  
A copy of the IC and the Authorization to Use and Disclose Personal Health Information/Research 
Authorization/other privacy language, signed and dated as required by [CONTACT_2371], mu st be provided to the 
subject.  
If the IC is obtained the same day the subject begins participating in study -related procedures, it must 
be documented in the subject’s case history that consent was obtained prior to participation in any 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302724]’s case 
history, regardless of circumstance.  
In the event the subject or legally designated representative cannot read, the IC process shall be 
obtained through a supervised oral process. An independent and impartial witness must be present during this process. The IC and any other information must be read aloud to the prospective subject or 
his/her legally designated representative. Whenever possible, either the su bject or his/her legally 
designated representative shall sign and personally date the informed consent form. The witness signs 
and personally dates the IC attesting that the information was accurately explained and that informed consent was freely give n. 
The original signed IC must be filed in the hospi[INVESTIGATOR_307]/clinical chart and/or with the subject’s study 
documents.  
The IC and Authorization to Use and Disclose Personal Health Information/Research Authorization/other 
privacy language as required by [CONTACT_248978]. Any Medtronic Field 
personnel who support the  study procedure s must be able to review the subject’s signed and dated IC 
and verify its completeness prior to proceeding with the aDBS setup. In the event the Medtronic Field personnel identify IC as being incomplete, the aDBS setup  will not be allowed to occur until the consent 
of the subject can be adequately and appropriately obtained.  
Consistent with the DoH, vulnerable adults (i.e. those subjects mentally incapable of giving consent) are 
excluded from this protocol.  Any subjects with mental incompetence (e.g. Alzheimer’s, dementia, 
psychiatric disorders, developmental disorders) should be assessed for vulnerable status. This protocol defines vulnerable adult as those subjects mentally incapable of giving consent, in the Investigator’s 
opi[INVESTIGATOR_1649].  The Investigator should consider the definition of vulnerable adult per ISO [ZIP_CODE], which 
defines vulnerable adults as: “individuals who are unable to fully understand all aspe cts of the 
investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of a retaliatory 
response. ” For example, this could include I ndividuals with loss of autonomy due to immaturity or 
through mental disability, persons in nursing homes, children, impoverished persons, subjects in 
emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and those 
incapable of giving IC. Other vulnerable subjects could include, for example, members of a group with a 
hierarchical structure such as university students, subordinate hospi[INVESTIGATOR_248925], employees of the sponsor, members of the armed forces, and persons  kept in detention.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302725] the option to indicate that in the consent (e.g., via a 
checkbox or via a separate signature).  
9.7. Enrollment  and Screening Phase  
This phase begins at consent and includes an Enrollment visit and an LFP Screening visit.  
9.7.1.  Enrollment  
Subjects who have a complete Medtronic DBS system, including Percept PC, leads and extensions and 
whose cDBS parameters and PD medications are stable may be approached to participate in the study.  
From enrollment to the end of the aDBS Evaluation Period , the investigator should make only c linically 
necessary changes to cDBS settings.  
A subject is considered enrolled when the consent process has been fully executed . The date the subject  
signed the IC and Data Protection Authorization, as required by [CONTACT_2371], must be documented in the subject’s medical records. A log of all subjects enrolled in the study will be maintained. Once consent is 
obtained, report adverse events/deaths, study deviations and subject exits as they occur.   
The study -specific IC will be signe d and dated prior to completion of any study -related procedures. 
Enrolled subjects who do not meet all inclusion criteria or who meet any exclusion criteria will be discontinued from the study. No further study -related procedures will be completed, and sub jects will 
be followed according to the center’s standard procedures.  
The subject will arrive for the visit  with PD medications and cDBS  according to  the center’s  standard 
procedures . After consent, the clinician will perform a Signal Test , using a commercially available 
Clinician Programmer System , to ensure the subject has adequate signal quality. The clinician should 
ensure the subject movement is minimized  during this test . 
If signal artifact is detected on all six aDBS sense pathways  (3 each on  both DBS leads ), the Signal Test 
may be re peated . If signal artifact is persistent on all six aDBS sense pathways, the clinician should 
determine whether this precludes them from setting thresholds. If not, the subject can continue in the 
study. If the su bject will not  continue , device identification information  will be collected , the 
programming session, with BrainSense data included in the JSON session data report, will be uploaded to Medtronic  via CDU, and an AE and device deficiency assessment will be performed. T he subject will 
then be discontinued from the study, and no further study -related procedures will be completed.  
Following the Signal Test, data will be collected and assessments administered. The following data will 
be collected at enrollment:  
• Demographics  
• Medical & surgical history  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 61 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • PD history  
• Concomitant medications  
• Columbia Suicide Severity Rating Scale (C -SSRS) ( screening) 
• Beck Depression Inventory II (BDI -II) 
• Pregnancy test (for female  subjects  of child -bearing potential)  
• Device identificat ion information , including historical DBS implant information  
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report   
• AE and device deficiency assessment  
The clinician will ensure the INS  device  time matches that of the clinician programmer tablet (network 
enabled). If the INS time does not match the network time, the INS time will be updated.  
The subject will be instructed on the use of the PD Home D iary. For at least [ADDRESS_302726], in 30- minute  
intervals, whether they were A sleep, “Off,” “On” with out dyskinesia, “On” with non-troublesome 
dyskinesia , or “On” with troublesome dyskinesia . The subject will also be instructed on the use of the 
PKG Watch .  
The subject will leave the visit on their current cDBS settings (including BrainSense  settings ). 
9.8. cDBS Baseline Phase  
This phase begins when the enrollment visit  is complete and includes an LFP screening visit, cDBS 
Baseline period and cDBS Baseline visit.  
9.8.1.  LFP Screening Visit  
1-[ADDRESS_302727]’s PD medication 
was appropriately withheld as specified in Table 5. If the subject’s PD medications were not 
appropriately withheld, consider rescheduling the study visit.  
Table 5: PD Medication Off/On Definitions  
Term  Definition  
Off PD Medication  Subject stops taking PD medication(s) for the following time periods 
prior to a study visit:  
• 72 hours extended -release  forms of dopamine agonists  
• 24 hours regular form of dopamine agonists, controlled release 
forms of carbidopa/levodopa  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 62 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • 12 hours regular carbidopa/levodopa, entacapone, rasagiline, 
selegiline, amantadine  
On PD Medication  Optimal motor response to PD medication (“best” On). The clin ical 
symptoms should be stable for at least [ADDRESS_302728] On of the patient has been reached.  
Current PD Medication(s)  Medication the subject is taking for treatment of PD on the day prior to initiating the hold requirements for the Off medication state  
Data will be collected, including the following:  
• MDS -UPDRS III (Off stim/Off med)  
• BrainSense setup and Signal test  
• Conc omitant medications  
• Time of last dose of PD medications taken prior to the visit  
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report  
• Adverse Event and device deficiency assessment  
At the start of the visit, the clinician will turn off the subject’s cDBS for approximately [ADDRESS_302729] the MDS -UPDRS III Off med/Off stim 
assessment.  
Next, the clinician should follow the BrainSe nse setup workflow  and perform a Signal Test , using the 
commercially available Clinician Programmer System , to assess LFP the screening inclusion criterion . The 
subject must have Alpha  - Beta  band amplitude ≥ 1.[ADDRESS_302730] one (left or right) DBS 
lead on sensing channels 0 -2, 0-3, or 1 -3; 8-10, [ADDRESS_302731] does not meet all of the LFP screening inclusion criteria and/or meets the LFP screening 
exclusion criterion, they will be exited from the study following the process in Section  9.19 , including a 
programming session  upload to Medtronic via CDU.  No further study -related procedures will be 
completed, and subjects will be followed according to the center’s standard procedures.  
At the end of the visit, the programming session, with BrainSense data included in the JSON session data 
report, will be uploaded to Medtronic  via CDU. The subject may resume taking their normal PD 
medication.  
The subject will be reminded of the use of the PD Home Diary  and the use of the PKG Watch.  
The subject will leave the visit on their current cDBS settings with BrainSense set to Passive Sensing Only 
in all groups  where BrainSense setup was utilized. 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302732]’s home. Upon receipt, the subject will put on and activate the PKG  Watch . The PKG Watch  will 
be worn on the most affected side for at least [ADDRESS_302733]  3 consecu tive days in  the 14 days prior to the scheduled cDBS Baseline  visit. If possible, the PD 
Home  Diary will be completed at the same time as the PKG Watch is worn.  
Some assessments may be completed prior to each scheduled visit. See Section  9.15  for detailed 
information about the administration of each assessment.  
Subjects should be contact[CONTACT_248979]- visit activities (PKG Watch , PD Home  Diary and assessments (if applicable) ). 
9.8.3.  cDBS Baseline Visit  
30-45 days after LFP screening  
Baseline data will be collected , including the following:  
• PDQ -39 
• EQ-5D-5L 
• VHI (worst condition)  
• VHI (best condition)  
• Parkinson’s Disease Sleep Scale ( PDSS-2) 
• MDS -UPDRS I  (Part A)  – trained rater  
• MDS -UPDRS Patient Questionnaire (Part IB and II) (best condition)  
• MDS -UPDRS Patient Questionnaire (Part IB and II) (worst condition)  
• MDS -UPDRS III (On stim (cDBS)/On med) – train ed rater 
• MDS -UPDRS IV  – trained rater  
• Collect PD Home D iary and review for completeness  
• Concomitant medications  
• Collect PKG Watch or confirm it was returned  
• AE and device deficiency assessment  
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302734]’s source documentation  and 
report as a deviation . 
9.9.1.  aDBS Setup Visit  
1-[ADDRESS_302735]’s PD medication 
was appropriately withheld as specified in  Table 5. If the subject’s PD medications were not 
appropriately withheld, consider rescheduling the study visit.  
Data will be collected, including the following:  
• Concomitant medications  
• Time of last dose of PD medications taken prior to the visit  
• PD medication dose given at the visit  (if applicable)  
• Adverse Event and device deficiency assessment  
The clinician should follow the BrainSense setup workflow using the investigational Clinician 
Programmer System. The subject must have Alpha  - Beta  band amplitude ≥  1.[ADDRESS_302736] 
one (left or right) DBS lead on sensing channels 0 -2, 0-3, or 1 -3; 8-10, 8- 11, or 9- 11.  
Utilizing Signal T est, if the subject no longer meet s the LFP screening inclusion criterion , it is allowable to 
re-assess LFP inclusion criterion , at the investigator’s discretion , at the start of the first day of aDBS 
Setup Visit.  If the subject does not meet the inclusion criterion,  they will be exited from the study 
following the process in Section  9.19 , including uploading the programming session, with BrainSense 
data included in the JSON session data report, to Medtronic  via CDU.  No further study -related 
procedures will be completed, and subjects will be followed according to the center’s standard 
procedures.  
The clinician will set up both aDBS Dual and Single Threshold Modes  while the subject is Off PD 
medication . As part of the Off PD medication aDBS setup, the clinician configures the stimulation 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302737] flexion tasks  may be  utilized as assessments for each mode . Following the 
Off PD medication aDBS setup , the clinician will assess the programmed aDBS settings  (both Dual and 
Single Threshold Modes)  while the subject is On PD medication.   
In cases where only one hemisphere has LFP Alpha - Beta  signal which meets the inclusion criterion, the 
following configurations will be used to set up aDBS.  
Dual Threshold (DT) Mode: 
If only one hemisphere has LFP Alpha - Beta  signal >=1.2μVp when setting up the Dual Threshold  mode, 
the clinician should configure adaptive therapy in both hemispheres, using sensing from the hemisphere with LFP Alpha - Beta  signal >=1.2μVp.  
For example, when utilizing BrainSense Setup, if the Left hemisphere has LFP Alpha - Beta  signal 
>=1.2μVp, and the Right hemisphere does not, then proceed with the following: 
• Set up D ual Threshold  mode in the Left hemisphere with the sensing electrode configuration 
that has met the LFP Alpha - Beta  signal inclusion criterion (Preferably the active cDBS card).  
• In the Right hemisphere, at Signal Test, select Left STN/GPi [INVESTIGATOR_248926].  
• Note: the stimulation electrode(s) or cathode(s) in the Right hemisphere is not constrained to a 
sensing configuration.  
Single Threshold (ST) Mode: 
If only one hemisphere has LFP Alpha - Beta  signal >=1.2μVp when setting up S ingle Threshold  mode, 
the clinician should  configure adaptive therapy in only that hemisphere with LFP Alpha - Beta  signal 
>=1.2μVp. 
• cDBS should be setup in the hemisphere with LFP Alpha  - Beta  signal <1.2uVp (set to Passive 
Sensing, if possible) .  
• Note: that the stimulation electrode(s) or cathode(s) in the hemisphere set to cDBS is not constrained  to a sensing configuration.  
If one aD BS mode cannot be set up, the subject should continue with the study using only the mode that 
can be set up  and the subject will not be randomized . 
If neither aDBS mode can be set up, the subject will be exited from the study  following the process in 
Secti on 9.19 , including uploading the programming session, with BrainSense data included in the JSON 
session data report, to Medtronic  via CDU. No further study -related procedures will be completed, and 
subjects will be followed according to the center’s standard procedures.  
Following  each  aDBS setup  visit day , the programming session s, with BrainSense data included in the 
JSON session data report, will be uploaded to Medtronic  via CDU.  
Once aDBS is set up , and prior to the subject leaving the study center On aDBS,  the subject’s 
commercially available Patient Programmer System will be replaced  with an investigational- marked 
Patient Programmer System,  and the subject will be given the investigational patient  labeling. T he 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302738] to pair the investigational 
Patient Programmer System with the INS.  
Subjects will be instructed on how to pause  aDBS any time they feel like the therapy is not working for 
them by [CONTACT_248980] . This Pause Adaptive Therapy  (amplitude last delivered in 
that group prior to starting aDBS therapy  (i.e. the suspend amplitude) ) is defined by [CONTACT_248981], following the  streaming  transition schemes testing and prior to starting 
adaptive therapy. Subjects will notify the investigator when they pause  aDBS to assess the scenario and 
need for any adjustments.  
If the visit o ccurs over [ADDRESS_302739]  the other aDBS mode within 
the aDBS Adjustment Period  (if applicable) . Event markers may be set up  to further capture information 
about the patient’s out of clinic experience with aDBS .  
Every attempt will be made to blind the subject to the aDBS mode being adjusted. The clinician should set on the investigational Clinician Programmer the group name s of the aDBS modes being adjusted  in a 
manner which will not unblind the subject. For example, “aDBS 1” and “aDBS 2”  or “aDBS” and  “Do not 
use.” These group names will be displayed on the investigational Patient Programmer.  
9.9.2.  
aDBS Adjustment Period  (optional)  
0-[ADDRESS_302740] settings  for one or both  aDBS modes may be conducted as 
needed for up to 60 days following the final aDBS setup visit  to ensure the aDBS mode(s)  will be 
acceptable to the subject . These visits will be completed either at the study center, by [CONTACT_248982] /video consult . The subject will remain blinded to the programmed aDBS mode.  Any aDBS 
adjustment  visit will be recorded as an unscheduled visit  (see Section 9.13 ). The physician may also be 
surveyed to understand rationale for programming settings.  
If programming session s or device int errogations occur , these sessions with BrainSense  data included in 
the JSON session data report, will be uploaded to Medtronic via CDU.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 67 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  9.9.3.  Randomization  
Day 0 (no greater than 60 days after aDBS setup complete)  
Randomization may occur at the aDBS setup visit , at an unscheduled visit during the aDBS Adjustment 
Period, or as a standalone visit.  All subjects for whom aDBS was set up will complete this visit.  
The investigator will assess each aDBS mode that was set up utilizing the aDBS Global Impression of 
Change ( GIC) provided in  Appendix  A - aDBS Global Impression of Change Score ( GIC). Efficacy and side 
effects are assessed on a scale from [ADDRESS_302741] is comfortable remaining in the aDBS mode(s) for the duration of the trial.  
If only one  aDBS mode was set up for a subject, they will not be randomized, but the physician should 
still complete the aDBS GIC  and data collection for the visit . 
Data will be collected, including the following:  
• Concomitant medications  
• GIC value for each aDBS mode that was set up  
• Adverse Event and device deficiency assessment  
For subjects in whom  both aDBS modes  are acceptable as compared to cDBS (using the aDBS GIC ), 
unblinded site personnel will obtain the randomization assignment via Remote Data Capture (RDC) . The 
randomization assignment can be obtained upon completion of the aDBS GIC and randomization CRFs.  
Randomization will occur to one of two possible treatme nt sequences if both aDBS modes are 
acceptable as compared to cDBS (using the aDBS GIC ) (dual threshold mode followed by [CONTACT_248983])  and will be stratified by [CONTACT_248984] (STN/G Pi). The two sequences will be 
randomly permuted in blocks of two and four. If an aDBS mode is unacceptable as compared to cDBS 
(using the aDBS GIC ), that subject will be assigned the mode which was acceptable. The  randomization 
schedule will be prepared by [CONTACT_248985]. Subjects will continue to 
be blinded to the aDBS mode during the aDBS  Evaluation Phase.  If the blind is broken, document the 
reasons for unblinding in the subject’s source documentation  and report as a deviation . 
Following randomization, the clinician  will program one group to the randomized aDBS mode.  
Subjects for whom one aDBS mode is unacceptable as compared to cDBS ( using the aDBS GIC) or for 
whom only one mode could be acceptably configured  will not be randomized and will complete one 
aDBS evaluation visit in the aDBS mode that was acceptable to the subject . 
In order to blind the subject to the aDBS mode assigned, the clinician will se t the group name [CONTACT_249036] “aDBS,” and the group name [CONTACT_249037] “Do not use” on the Clinician Programmer. These group names will be displayed on the 
Patient Programmer.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302742] will be 
followed according to the center’s standard procedures . 
If randomization is conducted as a separate visit, the programming session, with BrainSense data 
included in the JSON session data report, will be uploaded to Medtronic  via CDU. 
The subject will be instructed on the use of the PKG Watch and PD Home D iary in the aDBS Evaluation 
Phase.  
9.10.  aDBS Evaluation Phase  
This phase consists of up to two treatment periods ; one per acceptable aDBS mode.  After each 
treatment period, there is an aDBS evaluation visit. The subject’s PD medications will remain stable from 
enrollment  through the end of the  aDBS Evaluation Phase, unless changes are clinically necessary.  
During th e aDBS Evaluation P hase, the subject may return to the study center  for further aDBS 
adjustment in each randomized aDBS mode. All adjustments must be completed at least [ADDRESS_302743]’s home. Upon receipt, the subject will put on and activate the PKG  Watch . The PKG Watch  
will be worn on the most affected side for at least [ADDRESS_302744] 3 
consecutive days  in the 14 days prior to each scheduled aDBS Evaluation V isit. If possible, the PD Home 
Diary will be completed at the same time as the PKG Watch is worn.  
Some assessments may be completed prior to each scheduled visit. See Section  9.15  for detailed 
information about the administration of each assessment.  
Subjects should be contact[CONTACT_248986] -visit activities (PKG Watch , PD Home  Diary and assessments (if applicable) ). 
9.10.1.  Evaluation Visit [ADDRESS_302745] aDBS mode.  
The following data will be collected:  
• PDQ -39 
• EQ-5D-5L 
• C-SSRS  
• MDS -UPDRS I  (Part A)  – trained rater  
• MDS -UPDRS Patient Questionnaire (Part IB and II) (best condition)  
• MDS -UPDRS Patient Questionnaire (Part IB and II) (worst condition)  
• MDS -UPDRS III (On stim (aDBS)/On med) – trained rater 
• MDS -UPDRS IV  – trained rater  
• VHI (worst condition)  
• VHI (best condition)  
• PDSS-2  
• Patient preference questionnaire  
• Collect PD Home Diary  and review for completeness  
• Concomitant medications  
• Collect PKG Watch or confirm it was returned via mail  
• Adverse Event and device deficiency assessment  
At the end of the visit, the programming session, with BrainSense data included in the JSON session data 
report, will be uploaded to Medtronic  via CDU. 
Next, the clinician will program the subject to the other assigned aDBS mode  and label that group 
“aDBS.” The group for the  aDBS mode the subject just completed evaluation  of will be re -labeled “Do 
not use”  on the Patient Programmer.  
The subject should be reminded that they will receive  the PKG Watch prior to the aDBS Evaluation Visit 
[ADDRESS_302746] aDBS mode.  
The following data will be collected:  
• PDQ -39 
• EQ-5D-5L 
• C-SSRS  
• MDS -UPDRS I  (Part A)  – trained rater  
• MDS -UPDRS P atient Questionnaire (Part IB and II) (best condition)  
• MDS -UPDRS Patient Questionnaire (Part IB and II) (worst condition)  
• MDS -UPDRS III (On stim (aDBS)/On med) – trained rater 
• MDS -UPDRS IV  – trained rater  
• VHI (worst condition)  
• VHI (best condition)  
• PDSS-2  
• Patient preference questionnaire  
• Collect PD Home Diary  and review for completeness  
• Concomitant medications  
• Patient and physician preferred aDBS mode and r eason for selecting preferred mode (at end of 
visit)  
• Collect PKG Watch or confirm it was returned via mail  
• Adverse Event and device deficiency assessment  
At the end of the visit, the programming session, with BrainSense data included in the JSON session data 
report, will be uploaded to Medtronic  via CDU. 
Following the final aDBS visit, the clinician will program  the subject to the  chosen  DBS mode (clinician & 
patient preference) for the long -term follow -up phase  and record the reason for selecting that mode. 
If the chosen DBS mode  is cDBS, the subject will be exited from the study following the process in 
Section  9.[ADDRESS_302747] will be followed 
according to the center’s standard procedures.  
The subject should be reminded that they will receive  the PKG Watch prior to the next visit and will put 
on and activate the PKG Watch upon receipt. The subject will wear the PKG Watch on th e most affected 
side for at least 6 consecutive days in the 14 days prior to the scheduled visit.   
9.11.  Long -term Follow -up Phase  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 71 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Once subjects complete the aDBS Evaluation Phase (one or two evaluation visits), they enter a Long -
term Follow -up Phase.  During th is Phase, the investigator may choose to switch aDBS modes  as needed, 
so long as the subject received both modes during the aDBS Evaluation Phase. Any changes to the aDBS 
mode must be done at a study visit, either scheduled or unscheduled.  
Prior to each scheduled long- term follow -up visit  (visit #3 through #6 inclusive) , the PKG Watch will be 
given to the subject or mailed to the subject’s home. Upo n receipt, the subject will put on and activate 
the PKG  Watch . The PKG Watch will be worn on the most affected side for at least [ADDRESS_302748] will return the PKG Watch in the pre -paid 
mailer or bring it to the site for return at the visit.  
The PDQ -39 and EQ -5D-5L may be completed prior to each scheduled visit. See Section  9.15 for detailed 
information about the administration of each assessment.  
In the Long- term Follow -up Phase, subjects may choose to participate in optional data collection of 
Events with LFP capture (snapshots) . The clinician may set up a maximum of 4 event ty pes, selected 
from the following options: dyskinesia, tremor, rigidity, freezing, sleep disturbance, took PD medication.  
Study personnel will instruct the subject on how to record each event type utilizing the Patient 
Programmer System.   
9.11.1.  Visit 3  
45-60 days  after Evaluation Visit 2 (or Evaluation Visit [ADDRESS_302749] is only configured to one aDBS 
mode)  
The subject will arrive for the visit on their preferred aDBS mode.  
Data collection:  
• Concomitant medications  
• PDQ -39  
• EQ-5D-5L 
• Collect PKG Watch or confirm it was  returned via mail 
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report  
• Adverse Event and device deficiency assessment  
The subject should be reminded that they will receive  the PKG Watch prior to the next visit and will put 
on and activate the PKG Watch  upon receipt. The subject will wear the PKG Watch  on the most affected 
side for at least [ADDRESS_302750] will arrive for the visit on their preferred aDBS mode.  
Data collection:  
• Concomitant medications  
• PDQ -39 
• EQ-5D-5L 
• Collect PKG Watch or confirm it was returned via mail  
• Programming session upload to Medtronic, with BrainSense data included in the JSON session 
data report  
• Adverse Event and device deficiency assessment  
The subject should be reminded that they will receive  the PKG Watch prior to the next visit and will put 
on and activate the device upon receipt. The subject will wear the PKG Watch on the most affected side 
for at least  [ADDRESS_302751] will return the PKG 
Watch in the pre -paid mailer or bring it to the site for return at Visit 5.  
9.11.3.  Visit 5  
90 +/ - [ADDRESS_302752] ion: 
• Concomitant medications  
• PDQ -39 
• EQ-5D-5L 
• Collect PKG Watch or confirm it was returned via mail  
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report  
• Adverse Event and device deficiency assessment  
The subject should be reminded that they will receive  the PKG Watch prior to the next visit and will put 
on and activate the device upon receipt . The subject will wear the PKG Watch on the most affected side 
for at least [ADDRESS_302753] will return the PKG 
Watch in the pre -paid mailer or bring it to the site for return at Visit 6.  
9.11.4.  Visit 6  
90 +/ - 14 days after Visit 5  
Data collection:  
• Concomitant medications  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 73 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • PDQ -39 
• EQ-5D-5L 
• Patient satisfaction  questionnaire  
• Collect PKG Watch or confirm it was returned via mail  
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report  
• Adverse Event and device deficiency assessment  
At the completion of this visit, if aDBS is not commercially approved , the subject may choose to continue 
participation in the study as described in Section  9.12. If the subject chooses to exit the study after this 
visit and before aD BS is commercially approved, aDBS will be turned off as directed in Section  9.19 . 
9.12.  Extended  Access Phase  
Following the final long -term follow -up visit (Visit 6), subjects will be allowed extended  access to aDBS 
through aDBS is commercially approved in the geography in which the subject is enrolled. The subject 
will continue the study in aDBS and return for a visit every 6 months or until aDBS  is commercially 
approved  or closure of the study, whichever comes sooner.  
9.12.1.  Extended  Access Visits  
Every 18 0 +/- 60 days beginning after Visit 6 and every 6 months thereafter  following the previous 
extended access visit  
Data collection:  
• Concomitant medications  
• PDQ -39 
• EQ-5D-5L 
• Programming session upload to Medtronic, with BrainSense data included in the JSON session 
data report  
• Adverse Event and device deficiency assessment  
9.13.  Unscheduled Visit  
Any time the subject has  a visit  (in person , by [CONTACT_81455]/or telehealth /video consult ) for aDBS 
programming adjustment /optimization  (including resuming aDBS  if it was unintentionally turned off) or 
for an Adverse Event, the following data will be collected:  
• Reason for the vis it 
• Concomitant medications  
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report (if applicable)  
• Adverse Event and device deficiency assessment  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 74 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  9.14.  System Modification  
System modifications made to the DBS System will be completed according to the center’s standard 
procedures.  If the system modification occurs prior to randomization, the subject should be exited, prior 
to receiving the system modification if possible,  and considered for re -enroll ment  as applicable. If the 
system modification occurs after randomization, the investigator should assess if the subject should be 
exited from the study or proceed to the long term follow up phase on aDBS. The subject will not 
complete or repeat the aDBS evaluatio n period(s). If the subject proceeds to the long term follow up 
phase, aDBS will be programmed after (s) he is healed and stable on cDBS.   aDBS can be programmed by 
[CONTACT_248987]’s prior aDBS parameters and as sessing for 
acceptability.  Any visits for aDBS setup due to a system modification will be recorded as unscheduled 
visits. Once aDBS is set up, the subject will enter the long -term follow -up. If aDBS can not be acceptably  
set up, the subject will be exited from the study following the process in Section  9.19 . 
Data collection:  
• Device  information (if applicable)  
• Concomitant medications  
• Programming session upload to Medtronic  via CDU , with BrainSense data included in the JSON 
session data report (if INS is being modified)  
• Adverse Event  and Device deficiency assessment  
9.15.  Assessment of Efficacy  and Device Performance  
9.15.1.  Parkinson’s Disease (PD) Home  Diary  
The Parkinson’s Disease Home  Diary (Copyright © The University of South [LOCATION_012], 2000.  All rights 
reserved ) is a standard home diary to assess functional status in patients with PD. In [ADDRESS_302754] whether they were in the “On” condition, with or without dysk inesia, “Off” condition, or 
asleep.a In the On condition with dyskinesia, patients record whether they were On with troublesome or 
non-troublesome dyskinesia. For the purposes of t he PD home  diary , at least [ADDRESS_302755] 3 consecutive 24-hour periods . 
 
 
 
a Hauser, et al. “ A home diary to assess functional status in patients with Parkinson's disease with motor 
fluctuations and dyskinesia. ” Clinical Neuropharmacol ogy. 2000 Mar -Apr;23(2):75 -81. 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 75 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  9.15.2.  Total Electrical Energy Delivered (TEED) 
TEED is defined as the total energy delivered by [CONTACT_248988] . TEED is determined by [CONTACT_248989] (e.g., pulse width, 
frequency, amplitude) and the measured impedance.   
The calculation of TEED  when  using constant voltage is:   
TEED = (Voltage2 * Frequency * Pulse width) / Impedanceb  
The calculation of TEED when using constan t current  is: 
TEED = Current2 * Frequency * Pulse width  * Impedance  
9.15.3.  Wearable Data  
Wearable data will be collected via the PKG Watch as a continuous measure of bradykinesia  score (BKS), 
dyskinesia  score (DKS) and the % of wear time with  Tremor . A Fluctuation and Dyskinesia score (FDS) will 
also be derived from the wearable data.  
9.15.4.  European Quality of Life – 5 Dimensions ( EQ-5D-5L) 
The European Quality of Life – 5 Dimensions, version 5L (EQ -5D-5L), is a standardized measure of health 
status developed by [CONTACT_248990] a widely used validated tool to determine health -related 
quality of life.c The EQ -5D descriptive system consists of 5 dimensions: mobility, self- care, usual 
activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of severity: no 
problems, slight problems, moderate problems, severe problems, extreme problems. The subject will be 
asked to indicate his/her health state by [CONTACT_248991] 5 dimensions. This decision results in a 1 -digit number expressing the level selected for that dimension. 
The digits for 5 dimensions can be combined into a 5 -digit number describing the respondent’s health 
state. It should be noted that the numerals [ADDRESS_302756] no arithmetic properties and should not be used as 
a cardinal score.  In a second step , the responses to the five EQ- 5D dimensions (i.e. an EQ -5D health state 
or profile) will be converted into a single number called an index value  using the [LOCATION_008] value 
 
 
 
b Koss AM, et al. “Calculating Total Electrical Energy Delivered by [CONTACT_248992].” Annals of 
Neurology. Vol 58. No 1. July 2005. P. 168 -169.  
c The EuroQol Research Foundation. "EQ -5D-5L User Guide: Basic information on how to use the EQ -5D-5L 
instrument." https://euroqol.or g/wp -content/uploads/2016/09/EQ -5D-5L_UserGuide_2015.pdf  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 76 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  set. The index value reflects how good or bad the health state is according to the preferences of the 
general population of a country/region.  
This assessment may be completed either in person,  or over the telephone a maximum of 7 days prior 
to the study visit.  
9.15.5.  Parkinson’s Dis ease Questionnaire (PDQ -39) 
The Parkinson’s Disease Questionnaire is a self- completion  Patient Reported Outcome ( PRO ) designed to 
address aspects of functioning and well -being for those affected by [CONTACT_83068]’s disease.d There are 39 
questions in the long form Parkinson’s Disease Questionnaire, with 8 discrete scales:  
• mobility (10 items)  
• activities of daily living (6 items)  
• emotional well-being (6 items)  
• stigma (4 items)  
• social support (3 items)  
• cognitions (4 items)  
• communication (3 items)  
• bodily disco mfort (3 items)  
Patients are asked to think about their health and general well- being and to consider how often in the 
last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to 
indicate the frequency of each event by [CONTACT_128065] 5 options (Likert  Scale): 
never/occasionally/sometimes/often/always or cannot do at all.  
This assessment may be completed either in person,  or a copy may be sent to the subject to be 
completed a maximum of 7 days prior to the stu dy visit.  
9.15.6.  Movement Disorders Society Unified Parkinson’s Disease Rating 
Scale (MDS- UPDRS)  
The MDS -UPDRS is a MDS- sponsored revision of the UPDRS clinical rating scale for Parkinson’s disease. It 
has been the most widely used scale to assess impairment and disability in PD. The MDS -UPDRS is a 
comprehensive 50 question assessment of both motor and non -motor PD symptoms. The assessment 
has four parts: Part I (non- motor experiences of daily living), Part II (motor experiences of daily living), 
 
 
 
d Oxford University Innovation. “Parkinson’s Disease Questionnaire (PDQ -39 and PDQ -8).” 
https://innovation.ox.ac.uk/outcome -measures/parkinsons -disease -questionnaire -pdq- 39-pdq- 8/  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 77 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Part III (motor e xamination) and Part IV (motor complications).e Parts 1A, III and IV are assessed by [CONTACT_248993] a self- administered patient questionnaire that is completed with or 
without the aid of the caregiver.  
Each question is scored from [ADDRESS_302757]’s usual level of function; Normal, Slight, Mild, 
Moderate and Severe. Each part (I -IV) can be reported as sub -scores, or all parts can be reported as an 
overall score.  
This assessment must be completed in person whenever possible. In the event the assessment cannot be completed in person, Parts I A, IB, II and IV may be administered via telephone/ telehealth  a maximum 
of 7 days prior to the study visit , and a protocol deviation recorded.   
9.15.7.  
Parkinson’s Disease Sleep Sca le 2 (PDSS -2) 
The PDSS -2 assesses a wide spectrum of disease -specific sleep problems and is administer ed as a patient 
self- rating scale. 
The PDSS -2 consists of 15 questions about various sleep and nocturnal disturbances which are to be 
rated by [CONTACT_248994], from 0 (never) to 4 (very frequent). PDSS -2 total score 
ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance) .f 
This assessment must  be completed in person  whenever possible. In the event the assessment canno t 
be completed in person, the assessment may be administered via telephone a maximum of 7 days prior 
to the study visit, and a protocol deviation recorded.  
9.15.8.  Voice Handicap Index (VHI)  
The VHI has been designed to evaluate the quality -of-life specific to dysphonia. It was developed and 
validated with patients with a wide range of disorders, including neurological disorders  and quantifies 
the patients’ perceptions of the handicap they experience in everyday  life due to speech disorders.  
The [ADDRESS_302758] one 
of five response comprising an equal -appearing five -point scal e. The scale has the words “never” and 
“always” anchoring each end and the words “almost never”, “sometimes”, and “almost always” 
 
 
 
e Movement Disorder Society. “MDS -UPDRS.” https://www.movementdisorders.org/MDS -Files1/PDFs/Rating -
Scales/MDS- UPDRS_English_FINAL_Updated_June2019.pdf   
f Trenkwalder C, et al. “Parkinson’s Disease Sleep Scale – Validation of the Revised Version PDSS- 2.” Movement 
Disorders. Vol. 26. No. 4. March 2011. P. 644 -652.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 78 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  appearing in between. An “always” response was scored 4 points, a “never” response was scored [ADDRESS_302759] to be 
completed a maximum of 7 days prior to the study visit.  
9.15.9.  Patient Preference  
Patient preference for aDBS vs. cDBS and Single vs. D ual Threshold aDBS modes (if both were evaluated)  
will be assessed by a Medtronic -developed questionnaire.  
This assessment may be completed either in person,  or a copy may be sent to the subject to be 
completed a maximum of [ADDRESS_302760] to be 
completed a maximum of 7 days prior to the study visit.  
9.15.11.  aDBS Global Impression of Change  
Acceptability of each  aDBS  mode is be assessed by a Medtronic -developed aDBS Global Impression of 
Change . Efficacy and side effects are assessed on a scale from 1 to 21.  L ower score s represent  better 
efficacy and fewer  side effects .  A score of 8 or less indicates the aDBS mode is acceptable.  
9.16.  Assessment of Safety  
Subjects will be assessed for all potential A dverse Events  and device deficiencies, as applicable, at each 
study visit from the time the study informed consent form is signed until discontinuation from the study. 
Safety data collected for this study will include all device deficiencies, and all repor table AEs. Refer to 
Section  11: Adve rse Events and Device Deficiencies . 
 
 
 
g Jacobson B, et al. “The Voice Handicap Index (VHI): Development and Validation.” American Journal of Speech -
Language Pathology. Vol 6. No 3. August 1997. P. 66- 70. 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302761] ensure accuracy, completeness and timeliness of the data reported in the case 
report forms (CRFs) and in all other required reports. Source documentation is defined as the first time 
data appear, and may include original documents, data, and records (e.g., hospi[INVESTIGATOR_1097], clinical and 
office charts, procedure reports, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_35418], microfiches, photographic negatives, 
microfilm or magnetic media, X -rays, subject files, device data and records kept at the pharmacy, at the 
laboratories  and at medico -technical departments involved in the study).  
In general, eCRFs (or paper copi[INVESTIGATOR_014]) may not serve as source documents. Subject q uestionnaires (e.g. PD 
Home  Diary, MDS -UPDRS, VHI, PDQ -39, PDSS -2) and physician assessments (e.g. C -SSRS, GIC, MDS-
UPDRS) may be collected on paper forms provided by [CONTACT_248995]. If used, the paper forms of the questionnaires will be retained at the center as original source documentation. Source documentation for data elements not routinely captured in medical records may vary from study site to study site; the study site may use source document 
worksheets if identified as source documents.  Data reported on the CRFs, which are derived from source 
documents, mus t be consistent with the source documents and discrepancies need to be justified with 
documented rationale, and approved by [CONTACT_458] [INVESTIGATOR_9232].  The investigator must 
ensure the availability of source documents from which the information  on the eCRFs was derived. 
Where printouts of electronic medical records are provided as source documents, or where copi[INVESTIGATOR_248927], those should be certified. Certification must contain (1) the signature [CONTACT_249038], (2) the date the copy was made and (3) a 
statement attesting to the accuracy and completeness of the copy.  
The source documents must be made available for monitoring or auditing by [CONTACT_13735]’s representative 
or representatives of the competent authorities and other applicable regulatory agencies.  
The study will use the Oracle Clinical (OC) RDC system which allows the study centers to enter study data into the sponsor’s database over a secured internet connection. The system cont rols user access, 
ensures data integrity, and maintains an audit trail on entries, changes or corrections in CRFs. The 
principal investigator [INVESTIGATOR_248928]; user IDs and passwords may not be shared.  
Programming session files, with BrainSense data included in the JSON session data report , will be 
collected for the study and uploaded via CDU to the NPU (Neuro Programmer Upload) server and study 
database .  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 80 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  9.18.  Deviation Handling  
A study deviation is an event within a study that did not occur according to the clinical investigation 
plan, CTA, investigator agreement, IRB/EC policies or applicable standards, laws and regulations.  
The investigator  may not deviate from the CIP  unless the  deviation is necessary in an emergency 
situation to protect the rights, safety and wellbeing of the subject . or due to an unforeseen 
circumstance that is beyond the investigator’s control ( eg, subject failure to att end a scheduled follow -
up visit, inadvertent errors, equipment failure). All deviations must be documented in the study 
database  whether an inadvertent occurrence or taken to protect the subject in an emergency . Multiple 
deviations of the same type at the same visit may be reported on one case report form.  
In the event the deviation involves a failure to obtain a subject’s consent, or is made to protect the life 
or physical well-being of a subject in an emergency, the deviation must be reported to the IR B/EC as well 
as Medtronic within five (5) working days. Reporting of all other study deviations should comply with IRB/ EC policies and/or local laws and must be reported to Medtronic as soon as possible upon the study 
site becoming aware of the deviation. Rep orting of deviations must comply with IRB/ EC policies, local 
laws, and/or RA requirements. Refer to Section  15.8.1  for geography -specific deviation reporting 
requirements and timeframes for reporting to Medtronic and/or RAs.    
Deviations include, but are not limited to, the following:  
• Failure to obtain subject informed consent prior to beginning study activities  
• Subje ct does not meet general inclusion/exclusion criteria after the  enrollment  visit  
• Failure to report AEs or Device Deficiencies per Table 9: Safety Reporting Requirements   
• Failure to collect CIP -required assessments  
• Subject missed visit or visit outside  of win dow  
• Subject unblinding 
• Programming adjustments during the 14 days prior to each aDBS Evaluation Visit  
• For subjects with the SenSight system enrolled in the Primary Cohort: change of programming 
from ring mode to directional stimulation  before the end of the aDBS Evaluation Phase  
• For subjects enrolled in the Directional Stimulation Cohort: change of programming from 
directional stimulation to ring mode  before the end of  the aDBS Evaluation Phase  
Deviations will be reviewed by [CONTACT_248996]. Medtronic will assess the significance of 
all deviations for the study and evaluate the need for any corre ctive and/or preventative actions (e.g. 
amend the CIP , conduct additional training,  terminate the study ). Repetitive or serious investigator 
compliance issues may suggest a need to implement a corrective action plan with the investigator and 
study center. If needed, subject enrollment may be suspended until the compliance issues are resolved. 
If compliance iss ues are left unresolved, the investigator’s participation in the study may be terminated.  
Medtronic will provide study site -specific reports to investigators summarizing information on 
deviations that occurred at the investigational study site on a period ic basis.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302762]’s INS with a commercially available  
Clinician Programmer System . The subject will return the investigational Patient Programmer System to 
the study center  and t he investigator will re-pair the  subject’s  INS with  a commercially available Patient 
Programmer System . A final device interrogation  will be obtained to confirm that aDBS has been turned 
off. The programming session, with BrainSense data included in the JSON session data report, will be 
uploaded to Medtronic via CDU . Brain Sens e and passive sensing functionality will be on or off at the 
discretion of the clinician.  Once aDBS is no longer active , the subject’s INS is no longer considered 
Investigational, and subjects will be d iscontinued and followed according to the study center’s standard 
procedures.  
If a subject discontinues from the study prior to normal complet ion, the eCRFs for visits that have 
occurred up to the  point of withdrawal as well as the study exit eCRF must be completed.  
After study discontinuation, the updates for ongoing, and for any new events (eg, AEs or device 
deficiencies), will be reported through Neuromodulation Customer Quality  as required by [CONTACT_5151].  
9.19.1.  Study Exit  
A study exit eCRF is required for all subjects. S ubjects are urged to remain in the study as long as 
possible but may be exited from the study for any of the following situations: 
• Study completed  (visit #6) 
• Subject lost to follow- up 
• Subject death  
• Subject’s DBS Therapy System permanently explanted ( i.e., ne urostimulator, lead, extension)  
• Subject did not meet inclusion/exclusion criteria (prior to randomization)  
• Subject did not provide consent or data use protection authorization  
• Subject chooses to withdraw (e.g., consent withdrawal, relocation to another geo graphic 
location)  
• Investigator deems withdrawal necessary (e.g., medically justified, inclusion/exclusion criteria 
not met, failure of subject to maintain adequate study compliance)  
• Neither aDBS mode is acceptable  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302763]’s early 
discontinuation from the study:  
• Adverse event and device deficiency assessment  
• Programming session report, with BrainSense data included in the  JSON session data  report  
upload to Medtronic  via CDU  (after aDBS has been turned off)  
• A brief description of why the subject discontinued (if applicable)  
• Patient satisfaction questionnaire (if early discontinued  after the aDBS Evaluation Phase ) 
9.19.2.  Study Completed  
At the completion of Visit [ADDRESS_302764] are 
unsuccessful. The method of attempt (e.g., one letter and one phone record, or two letters) must be 
documented in the subject’s medical record. In addition, regulation set forth by [CONTACT_114021]/ EC 
must be followed . 
When subjects are lost to follow-up the investigator will make efforts to confirm the vital status of the 
subject, as described in the informed consent.  
9.19.4.  Subject Chooses to Exit (i.e. Revokes Consent)  
A subject can withdra w from the study at any time. If the subject wishes to exit from the study ( i.e., the 
subject revokes consent), the study site is required to document the reason for exit on the Exit CRF. In addition, study sites shall follow the regulations set forth by t he governing IRB/ EC. Permission may be 
requested to follow up with the subject outside of the study due to withdrawal based on problems 
related to the investigational feature safety or performance.   
If possible, the following data should be collected prior to subject withdrawal:  
• Adverse event and device deficiency assessment  
• Final device interrogation and data upload via CDU (after aDBS has been turned off)  
o Export JSON Session Data  
• A brief description of why the subject discontinued (if ap plicable)  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302765] in the study and perform study 
procedures/collect data to the extent possible. If an i nvestigator withdrawal is necessary, the following 
data should be collected prior to subject withdrawal if pos sible:  
• Adverse event and device deficiency assessment  
• Final programming session  upload to Medtronic  via CDU, with BrainSense data included in the 
JSON session data report  (after aDBS has been turned off)  
• A brief description of why the sub ject was withdra wn by [CONTACT_093]   
9.19.6.  Conditional Disengagement  
After a subject is enrolled/randomized every effort should be made to keep the subject in the study. However, it is recognized that there are circumstances where limited data may be collected, or study 
exit will need to occur. In these cases we will consid er either modified data collection requirements 
where subjects may conditionally disengage in study procedures but data from the subject can still be 
collected because the subject has not revoked consent, or exit when study participation is completely 
ende d. In randomized subjects, modified data collection is always preferred over exit.  
Subjects may be conditionally disengaged from study procedures for any of the following reasons:  
• Subject chooses to disengage (e.g., follow-up schedule cannot be adhered to,  study 
burden too large, relocation to another geographic location but telephone follow -up still 
acceptable)  
• Investigator deems conditional disengagement necessary (e.g. medically justified)  
If the subject wishes to disengage from the study, or the investigator deems it necessary, the study site 
is required to document the reason. Prior approval from the study team is required and a Limited Data 
Collection CRF needs to be completed. Data collection requirements no longer apply, but study sites are encoura ged to collect as much data as possible on the regular CRFs.  
10. Risks and Benefits 
10.1.  Potential Risks  
Deep Brain Stimulation Therapy is a reversible procedure (,i.e. , the system can be turned off or removed 
in most cases) with stimulation parameters that are adjustable to minimize or reverse complications and maximize therapeutic effects. Deep Brain Stimulation Therapy has CE Mark , Health Canada and FDA 
approval, and is commercially available in the European Union, Canada and the [LOCATION_002] . The risks 
associated with the Medtronic DBS Therapy are included in commercially available product information . 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302766] and/or unborn  child while receiving neurostimulation are unknown, female 
subjects of childbearing potential must have a negative pregnancy test at enrollment  and agree to not 
become pregnant during the study by [CONTACT_2329] a medically acceptable method of birth control. Shou ld a 
pregnancy occur during the study, the subjects are instructed to notify their physician immediately and the investigator will notify Medtronic in a timely manner. Careful considerations of the risks and benefits 
of continuation in the study will be weighed by [CONTACT_248997].  
10.1.2.  Potential aDBS risks  
The primary function of the aDBS is to adjust stimulation amplitude within clinician -defined stimulation 
limits. The risks of adaptive DBS are no different than the risks of commercially available cDBS risks, which are not increased due to participation in the study.   
10.1.3.  Potential Study Procedures Risks  
The clinical investigation has been designed to involve as little pain, discomfort, fear and any other 
foreseeable risk as possible for the subjects, and both the risk threshold and the degree of distress are 
specifically defined in the clinical investigation plan . Potential r isks related to study procedures include:  
• Subjects  may experience skin irritation from the PKG watch. Should irritation occur, the subject 
should remove the watch  
• There may be risks or side effects which are unknown at this time.  
10.1.4.  Potential Study Procedure Inconveniences  
• The patient assessments subjects are required to complete for the study may be burdenso me. 
• The patient assessments that are required for the study may request information of a personal 
nature  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302767] been successfully 
mitigated  as far as possible  (Table 6). Any potential risks associated with this study are further 
minimized by [CONTACT_248998]. Medtronic has 
also attempted to minimize risk to subjects implementing a DMC to review safety issues as part of the study . 
Risks will be minimized by [CONTACT_248999], during, and after enabling aDBS. 
In addition, investigators will be actively involved in the follow -up of the subjects with aDBS enabled on 
their Percept PC device . 
Medtronic has further minimized the possibility of risks by: [CONTACT_249000] -
clinical testing prior t o the ADAPT -PD study, implementing design assurance and quality control 
measures into production processes, providing guidelines for subject selection and evaluation, and providing adequate instructions and labeling.  
  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 86 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
   
Table 6: Poten tial Risks and Risk Minimization  
Potential Risk  Risk Minimization  
Non -optimum stimulation, due to noise to LFP  • System requirements ensures that patient 
has the capability to switch from aDBS to 
cDBS, if needed.   
• Product requirements and software requirements ensure that aDBS works 
reliably as designed.  
10.3.  Potential Benefits  
Some subjects may experience benefits from  aDBS, such as : Parkinson’s disease symptom management, 
improvement of movement symptoms, improved quality of life and/or energy savings of their device.  
The information gained from this study might benefit other patients in the future.  
10.4.  Risk-Benefit Rationale  
The benefit of the study lies in the knowledge to be gained from the results and the potential to improve 
future DBS therapi[INVESTIGATOR_014]. All the potential risks have been controlled to a level as far as possible. Based on 
the risk acceptance criteria for the ADAPT -PD Trial laid out in the Study Risk Management Plan, t he 
study -specific residual risk is determined to be acceptable given the expected benefits.   
10.5.  Risk Determination  
The Percept PC INS used in the ADAPT- PD Trial meets the definition for a significant risk device in 
21CFR§812.3(m), because it is an implanted device and presents a potential for serious risk to the 
health, safety, or welfare of a subject.    
The Percept PC INS used in the ADAPT- PD Trial is currently classified as AIMD in accordance with 
90/385/EEC and in the future will be classified as Class III in accordance Annex VIII, Rule 8 of EU 
Regulation 2017/745. The Percept PC INS is considered an investigational device in the ADAPT -PD Trial 
once aDBS is  enabled.  
As per Schedule 1 of the Canadian Medical Device Regulations (SOR -98-282), the Percept PC INS used in 
the ADAPT- PD Trial is classified as a Class IV Medical Device according to R ule 1(2) : A surgically invasive 
device that is intended to diagnose,  monitor, control or correct a defect of the central cardiovascular 
system or the central nervous system or of a fetus in utero is classified as Class IV.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 87 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  As per Schedule 1 of the Canadian Medical Device Regulations (SOR -98-282), the PKG Watch  used in the 
ADAPT -PD Trial is classified as a Class I I Medical Device according to Rule 1 0(1), which states: Subject to 
subrule (2), an active diagnostic device, including any dedicated software, that supplies energy for the 
purpose of imaging or monitoring physiological processes is classified as Class II.   
11. Adve rse Event s and Device Deficiencies  
11.1.  Adverse Events  
AE definitions are provided in Table 7. All AE information will be collected throughout the study 
duration, starting at the time of signing the IC.  
Reporting of these events to Medtronic will occur on an AE  eCRF . Each event must b e reported 
separately. Documented pre- existing conditions are not considered AEs unless the nature or severity of 
the condition has worsened.  
In all geographies, UAE, listed in  Table 7, need not be reported unless the adverse event worsens or is 
present outside the stated timeframe post- system modification. 
For AEs that require immediate reporting (see Table 9), initial reporting may be done by [CONTACT_648], email, or 
on the CRF completing as much information as possible. The completed AE CRF must be submitted to 
Medtronic as soon  as possible.   
Any medication/treatment associated with the treatment of an AE must be reported .  
All n on-subject AEs will be collected throughout the study duration  
Subject deaths are also required to be reported. Refer to Section  11.[ADDRESS_302768] Death collection and 
reporting requirements.  
11.2.  Device Deficiency  
The Device Deficiency ( DD) definition is provided in Table 7. All DD information will be collected 
throughout the study and reported to Medtronic  on the DD e CRF. Note that DD that result in an AE to 
the subject should be captured as an AE only.  
DD that did not lead to an AE but could have led to a SADE (i.e., if suitable action had not been taken, if 
intervention had not been made, or if the circumstances had been less fortunate) require reporting according to the timeframes listed in  Table 9. 
11.3.  Processing Updates and Resolution  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 88 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  For any changes in status of a previously reported AE  or DD (i.e. change in actions taken, change in 
outcome, change in relatedness), information needs to be updated on, or added to the original AE or DD 
eCRF . All AEs must be followed until the AE has been resolved, is unresolved with no further actions 
planned, the subject dies or exits the study, or until study closure, wh ichever occurs first.  
At the time of study exit, all collected AEs  that are unresolved must be reviewed and an update to the 
original AE must be reported. 
After study discontinuation, subjects will be followed according to the study center’s standard 
proc edures and updates for AEs that are ongoing, and any new events (eg, AEs or device deficiencies) 
will be reported through Neuromodulation Customer Quality as required by [CONTACT_5151].  
11.4.  Definitions/Classifications  
This study will be following ISO14155 :[ADDRESS_302769] all Adverse Events and Device Deficiencies 
from the time of enrollment through study exit/discontinuation.  It is the responsibility of the 
Investigator to identify the occurrence of all adverse events and device deficiencies and to ensure the 
required information is accurately documented in the medical records and reported to Medtronic.   
Where the definition indicates “device”, it refers to any device used in the study. This might be the device under investigation, or any market rele ased component of the system, and includes but is not 
restricted to  the components listed in  Table 1: Medtronic DBS System Components  and the PKG Watch . 
Table 7: Adverse Event and Device Deficiency Definitions  
General  
Adverse Event (AE)  Untoward medical occurrence, unintended disease or injury, or 
untoward clinical sign s (including abnormal laboratory findings) in 
subjects, users or other persons, whether or not related to the 
investigational medical device  and whether anticipated or unanticipated . 
Note 1: This definition includes events related to the investigational med ical device or the comparator.  
Note 2: This definition includes events related to the procedures involved.  
Note 3: For users or other persons, this definition is restricted to events related to  the use of investigational medical devices  or comparators .    
(ISO [ZIP_CODE]:2020, 3.2)  
Adverse Device Effect 
(ADE)  AE related to the use of an investigational medical device.  
Note 1: This definition includes AEs  resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.  
Note 2: This definition includes any event resulting from use error or 
from int entional misuse of the investigational medical device.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 89 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  NOTE 3: this includes ‘comparator’ if the comparator is a medical device  
(ISO [ZIP_CODE]:2020, 3.1)  
Device Deficiency  Inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, usability, safety or performance.  
Note 1: DD include malfunctions, use errors and inadequacy in the 
information supplied by [CONTACT_143143].   
Note 2 : This definition includes device deficiencies related to the 
investigational medical device or the comparator. (ISO [ZIP_CODE]:2020, 3.19)  
Relatedness  
Relationship of Adverse 
Events  
 
  
 
         
 
     The relationship of an adverse event will be classified as d evice -related , 
therapy /stimulation -related , procedure -related, related to the d isease 
under study , and/or related to an underlying condition or disease  
based on the following definitions:  
• Device Related: An adverse event that results from the presence or performance (intended or otherwise) of the DBS system or any of 
the DBS system components  
• Procedure Related: An adverse event that occurs due to any procedure related to the surgical modification , or explant  of the 
DBS system or any of the DBS system components.  
• Therapy/Stimulation Related: An adverse event related to therapy delivery by [CONTACT_249001] (i.e. stimulation).  Normally therapy -
related events resolve when the device is turned off  or 
reprogrammed.  
• Related to the disease under study:  An adverse event that is caused by [CONTACT_83068]’s disease  
•  
Each of the relatedness classifications will be assessed for causality using five different levels of causality based on the following definition s: 
• Not Related : relationship to the device , comparator or procedures 
can be excluded  when:  
o the event has no temporal relationship with the use of the investigational device or the procedures related to application of the investigational device;  
o the serious  event does not follow a known response pattern to 
the medical device (if the response pattern is previously known) and is biologically implausible;  
o the discontinuation of medical device application or the 
reduction of the level of activation/exposure - when clinically 
feasible – and reintroduction of its use (or increase of the level 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 90 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  of activation/exposure), do not impact on the serious adverse 
event;  
o the event involves a body -site or an organ not expected to be 
affected by [CONTACT_41491];  
o the serious event can be attributed to another cause (e.g. an 
underlying or concurrent illness/ clinical condition, an effect of another device, drug, treatment or other risk factors);  
o the event does not depend on a false result given by [CONTACT_75698], when applicable;  
In order to establish the non -relatedness, not all the criteria listed 
above might be met at the same time, depending on the type of device/procedures and the serious adverse event  
• Unlikely: the relationship with the use of the device seems not relevant and/or the event can be reasonably explained by [CONTACT_5748], but additional information may be obtained.  
• Possible: the relationship with the use of the investigational device or comparator is weak but cannot be ruled out completely. 
Alternative causes are also possible (e.g. an underlying or concurrent illness/ clinical condition or/and an effect of another device, drug or treatment). Cases were relatedness cannot be assessed or no information has been obtained should also be 
classified as possible.  
• Probable: the relationship with the use of the investigational 
device or comparator seems relevant and/or the event cannot 
reasonably be explained by [CONTACT_5748]  
• Causal relationship: the serious adverse event is associated  with 
the investigational device , comparator or with procedures beyond 
reasonable doubt when:  
o the event is a known side effect of the product category the 
device  belongs to or of similar devices and procedures;  
o the event has a temporal relationship with investigational 
device  use/application or procedures;   
o the event involves a body -site or organ that  
 the investigational device or procedures are applied to;  
 the investigational device or procedures have an effect on;  
o the serious  adverse  event follows a known response pattern to 
the medical  device (if the response pattern is previously 
known);  
o the discontinuation of medical device application (or reduction 
of the  level of activation/exposure) and reintroduction of its use 
(or increase of th e level of activation/exposure), impact on the 
serious adverse event (when  clinically feasible);  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 91 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  o other possible causes (e.g. an underlying or concurrent illness/ 
clinical condition or/and an effect of another device, drug or 
treatment) have  been adequately  ruled out;  
o harm to the subject is due to error in use;  
o the event depends on a false result given by [CONTACT_249002], when applicable;  
In order to establish the relatedness, not all the criteria listed 
above  might be met at the same time, depending on the type of  
device/  procedures and the serious adverse event.  
Events are considered “related” to the investigational medical device if their relationship to the device, procedure, or therapy is classified as 
“possible”, “probable” , or “causal” . 
Seriousness  
Serious Adverse Event 
(SAE) 
 
 AE that led to any of the following:  
a) death,  
b) serious deterioration in the health of the subject, users or other 
persons as defined by [CONTACT_10980]:   
1) A life -threatening illness or injury, or  
2) A permanent impairment of a body structure or a body 
function, including chronic diseases, or  
3) In -patient or prolonged hospi[INVESTIGATOR_059], or  
4) Medical or surgical intervention to prevent life -threatening 
illness o r injury, or permanent impairment to a body structure 
or a body function,  
c) foetal distress, foetal death, a congenital abnormality, or birth 
defect including physical or mental impairment . 
Note 1:  Planned  hospi[INVESTIGATOR_5912] -existing condition, or a 
procedure required by [CONTACT_10396], without serious deterioration in health, is not considered a SAE.  
(ISO [ZIP_CODE]:2020, 3.45)  
Serious Adverse Device 
Effect (SADE)  Adverse device effect that has resulted in any o f the consequences 
characteristic of a serious adverse event.  
(ISO [ZIP_CODE]:2020, 3.44)   
Unanticipated Adverse 
Device Effect (UADE)  
 Any serious adverse effect on health or safety or any life -threatening 
problem or death caused by, or associated with a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects. 
(US 21 CFR§812.3(s))  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 92 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
   
The following are  not considered an AE for the study.  
• Pregnancy   Unanticipated Serious 
Adverse Device Effect 
([LOCATION_003]DE)  
 Serious adverse device effect which by [CONTACT_5942], incidence, severity or 
outcome has not been identi fied in the current  risk assessment . 
Note  1: Anticipated serious adverse device effect (ASADE) is an effect 
which by [CONTACT_6073], incidence, severity or outcome has been identified in the risk  assessment. 
(ISO14155:2020  3.51) 
Serious Health Threat  Signal from any adverse event or device deficiency that indicates an 
imminent risk of death or a serious deterioration in the health in 
subjects, users or other persons, and that requires prompt remedial action for other subjects, users or other persons  
NOTE 1: This would include events that are of significant and unexpected 
nature such that they become alarming as a potential serious health hazard or possibility of multiple deaths occurring at short intervals.  
(ISO [ZIP_CODE]:2020, 3.46)  
Unavoidable Adverse 
Event (UAE)  An AE inherent to a surgical procedure that is expected to occur in all 
subjects for a projected duration according to the Investigator’s opi[INVESTIGATOR_1649], including, but not limited to:  
Event Description Timeframe 
(hours) from 
the Surgical 
Procedure  
Anesthesia related nausea / vomiting  24 
Low-grade fever (<100°F or 37.8°C)  48 
Pocket site / Incisional pain  72 
Mild to moderate bruising / ecchymosis  168 
Sleep problems (insomnia)  72 
Back pain related to laying on table  72 
Shoulder pain/discomfort/stiffness 
related to shoulder immobilization during procedure  72 
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 93 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • Documented pre- existing conditions unless the intensity, duration, or frequency of the condition 
is worsened from the time of enrollment  
• Programming adjustment  (optimizations)  or therapy suspension  (could be an action taken as  a 
result of an AE)  
• Transient (acute) stimulation -induced effects that occur during programming sessions or while 
running aDBS that resolve with or without programming adjustments prior to the subject leaving 
a study follow -up visit and do not require further follow -up or medical care outside of the visit  
• Neurostimulator replacement for battery depletion as disclosed in the product labeling (documented as a system modification)  
• Worsening quality -of-life patient -reported outcome scores  (e.g. EQ-5D-5L, PDQ -39, PDSS -2, VHI, 
MDS -UPDRS Part IB & II)  
• Expected side -effects of Parkinson’s disease medication 
11.5.  Reporting of Adverse Events  
All reportable AEs and device deficiencies must be recorded in the subject’s medical record, the study 
CRF, and promptly reported to Medtronic or its designee. Investigators are required to keep records on 
all relevant observations .  
Reportable adverse events and device deficiencies will include the following information, at a minimum:  
• Date of event 
• Diagnosis and description of the event  
• Assessment of the seriousness and relationship to the product(s) under investigation , therapy, 
and procedure (AE only)  
• Model and identifier (serial, lot number) for the involved device (if applicable)  
• Treatment  (AE only)  
• Outcome and date of resolution  (AE only) 
It is the responsibility of the investigator to identify the occurrence of reportable AEs and DDs and to ensure the required information is accurately documented on the CRF.  
For emergency reporting of SAEs and SADEs, the following Medtronic contact [CONTACT_249003]:  
Phone: +[PHONE_5225]  
Email :  rs.ADAPT -[EMAIL_4828]
  
Address: [ADDRESS_302770] NE, RCE375 | Minneapolis, MN [ZIP_CODE]  |  [LOCATION_003]  
11.5.1.  Adverse Event and Device Deficiency Classification  
All AE and DD will be reviewed by a Medtronic representative. AEs will be classified according to the 
definitions provided.  
Upon receipt of AE /DD at Medtronic, a Medtronic representative will review the AE/DD for 
completeness and accuracy and when necessa ry, will request clarification and/or additional information 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 94 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  from the Investigator. Medtronic will utilize MedDRA for Regulatory Activities, to assign a MedDRA term 
for each AE /DD based on the information provided by [CONTACT_093]. Copi[INVESTIGATOR_99606] -identified source 
documentation regarding an adverse event or device deficiency (eg, clinician notes or summaries) will be provided to Medtronic upon request.   
Regulatory reporting of AEs and DDs will be completed according to local regulatory requirements. Refer 
to Table [ADDRESS_302771] of required investigator and Medtronic reporting requirements and timeframes. It is 
the responsibility of both to abide by [CONTACT_249004]/EC 
responsible for oversight of the study.  
For emergency contact [CONTACT_169280] a UADE, [LOCATION_003]DE, SAE and/or SADE, contact a study representative immediately (refer to the study contact [CONTACT_230997]’s study documents binder/investigator site file or refer to the Sponsor contact [CONTACT_131484]).  
AEs will be classified according to the standard definitions as outlined below  in Table 8: 
Table 8: Event Classification Responsibilities  
*Adverse events that are classified as having a relationship of possible, probable or causal to the investigational device, procedure  or 
therapy/stimulation are considered to be related to the investigational medical device  and are classified as ADEs.   
In addition, all ADEs  and deaths will be reviewed and adjudicated ( seriousness, relationship/causality) by 
[CONTACT_249005]. Refer to Section  12.2 . 
11.5.2.  Adverse Event and Device Deficiency Reporting Requirements  
Regulatory reporting of AEs and DDs will be recorded and reported according to local requirements. It is the responsibility of the I nvestigator and the sponsor to abide by [CONTACT_249006]’s IRB/ EC. Refer to Table 9: Safety Reporting Requirements  for 
more details related to reporting timelines.  What is Classified Who Classifies  Classification s 
Relatedness * • Investigator  
• Sponsor  • Relationship to the : 
o Procedure  
o Device 
o Therapy/Stimulation  
o Disease under study  
[LOCATION_003]DE/UADE potential  Sponsor  [LOCATION_003]DE/UADE  
Seriousness  Investigator  SAE, DD with SADE  potential  
Sponsor  SAE, DD with SADE potential  
Diagnosis  Investigator  Based on presenting signs and symptoms and 
other supporting data  
Sponsor  MedDRA term assigned based on the data 
provided by [CONTACT_249007] -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 95 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Table 9: Safety Reporting Requirements  
SAE 
Investigator  shall  submit to:  
Medtronic  Europe: To the sponsor in acceptable timely conditions, but not later 
than within 3 calendar days after investigational site study personnel’s 
awareness of the event  or of new information in relation with an already 
reported event . 
All other geographies: Report to the sponsor, without unjustified delay, 
all serious adverse events  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: As per local requirement.  
Sponsor shall submit to:  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: Reporting timeframe as per local requirement.  
SADE  
Investigator shall submit to:  
Medtronic  Canada: SADEs on the patient, the user or any other person must be 
reported to the regulator and to the Sponsor within 72 hours after it 
comes to the attention of the qualified investigator.  
Europe: To the sponsor in acceptable timely conditions, but not later 
than within 3 calendar days after investigational site study p ersonnel’s 
awareness of the event  or of new information in relation with an already 
reported event  
US: Report to the sponsor, without unjustified delay, all serious adverse 
device events  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  Canada: SADEs on the patient, the user or any other person must be 
reported to the regulator and to the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
All other geographies: As per local requirement.  
Sponsor shall submit to:  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: Reporting timeframe as per local requirement.  
UADE  
Investigator shall submit to:  
Medtronic  US: As soon as possible, but in no event later than [ADDRESS_302772].  
IRB/EC  US: As soon as possible, but in no event later than [ADDRESS_302773].  
Regulatory Authority  US: As per local requirement.  
Sponsor  shall  submit to:  
IRB/EC  US: Submit to IRB/EC as per local requirement.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 96 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Regulatory Authority  US: Reporting timeframe as per local requirement.  
[LOCATION_003]DE  
Investigator shall submit to:  
Medtronic  Canada:   [LOCATION_003]DEs on the patient, the user or any other person must be 
reported within 72 hours after it comes to the attention of the qualified 
investigator.  
Europe:  To the sponsor in acceptable timely conditions, but not later than within 3 calendar days after investigational site study personnel’s awareness of the event  or of new information in relation with an already 
reported event . 
IRB/EC  Canada:   Submit to IRB/EC as per local requirement.   
Europe:  Submit to IRB/EC as per local requirement.  
Regulatory Authority  Canada:   [LOCATION_003]DEs on the patient, the user or any other person must be 
reported within 72 hours after it comes to the attention of the qualified investigator.  
All other geographies: As per local requirement.  
Sponsor shall submit to:  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: Reporting timeframe as per local requirement.  
Deaths  
Investigator shall submit to:  
Medtronic  All geographies: Without unjustified delay after learning of a subject’s 
death, regardless of whether the death is related to the device system or 
therapy.  
IRB/EC  Canada:  All subject deaths must be reported the EC as soon as possible, 
but no more than [ADDRESS_302774]’s death, regardless of 
whether or not the death is related to the device system or therapy.  
All other geographies: Submit to IRB/EC as per l ocal requirement.  
Regulatory Authority  All geographies: As per local requirement.  
Sponsor  shall  submit to:  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: Reporting timeframe as per local requirement.  
All other  AEs 
Investigator shall submit to:  
Medtronic  All geographies: Submit in a timely manner after the Investigator 
first learns of the event  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: As per local requirement.  
Sponsor shall submit to:  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: Reporting timeframe as per local requirement.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 97 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  IRB/EC and Competent Authority (CA) reporting must be completed in accordance with the local 
reporting policies of the governing IRB/EC and CA .  
11.6.  Subject Death  
The investigator must notify Medtronic and the governing IRB/EC  (as required)  without unjustified delay 
after learning of a subject’s death, regardless of whether the death is related to the device system or 
therapy. The Investigator should also attempt to determine, as conclusively as possible, whether such deaths are related to the device , procedure  or therapy.  Investigational DDs with SADE potential  
Investigator shall submit to:  
Medtronic  Canada:  DDs that have resulted in any of the consequences 
characteristic of an SAE on the patient, the user or any other person or 
could do so were it to reoccur must be reported to the regulator and the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
Europe: To the sponsor in acceptable timely conditions, but not later 
than within 3 calendar days after investigational site study pers onnel’s 
awareness of the event  or of new information in relation with an already 
reported deficiency . 
US: Reporting timeframe as per local requirement  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  Canada:  DDs th at have resulted in any of the consequences 
characteristic of an SAE on the patient, the user or any other person or could do so were it to reoccur must be reported to the regulator and the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
All other geographies: As per local requirement.  
Sponsor  shall  submit to:  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: Reporting timeframe as per local requirement.  
All other Device Deficiencies  
Investigator  shall  submit to:  
Medtronic  All geographies:  Submit in a timely manner after the Investigator first 
learns of the device deficiency  
IRB/EC  All geographies: Reporting timeframe as per local IRB/EC requirement.  
Sponsor shall submit to:  
IRB/EC  All geographies: Submit to IRB/EC as per local requirement.  
Regulatory Authority  All geographies: Reporting timeframe as per local requirement.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302775] Return.  
A copy of the death certificate, if available and allowed by [CONTACT_54443]/local law, should be sent to the 
Medtronic clinical study team. When a death occurs in a hospi[INVESTIGATOR_307], a copy of the death summary report 
and all relevant hospi[INVESTIGATOR_1097], if available should be  sent to the Medtronic clinical study team. When 
the death occurs at a remote study site, it is the investigative study site’s responsibility to attempt 
retrieval of information about the death.  If a death certificate or summary report are unavailable, and  
investigator summary of the death is acceptable.  Additionally, device disposition information should be 
updated.  
In summary, the following data will be collected:  
• Date of death  
• Detailed description of death  
• Cause of death  
• Relatedness to system and proce dure  
• Device interrogation information/reports (if available)  
• Device disposition information 
• Death summary/hospi[INVESTIGATOR_1097] (if available and allowed by [CONTACT_54443]/local law)  
• Autopsy report (if available and allowed by [CONTACT_54443]/local law)  
• Death certificate (if available and allowed by [CONTACT_54443]/local law)  
11.7.  Product Complaint Reporting  
Product complaint reporting and vigilance reporting are applicable and AEs related to any market -
released device during the study must be reported. The reporting of product complaints is not part of 
the study and should be done in addition to the AE report ing requirements.  Refer to local regulations 
for reporting requirements.  
Product Complaint: Any written, electronic or oral communication that alleges deficiencies related to 
the identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that has been placed on the market.  
It is the responsibility of the investigator to report all product complaint(s) associated with a medical 
device distributed by [CONTACT_13735], regardless of whether they are related to intended use, misuse or 
abuse of the product. Reporting must be done immediately and via the regular channels for market -
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302776] Operating Procedures. Medtronic will notify the RAs (e.g. CA) as applicable for the 
following incidents immediately upon learning of them and is not limited to AEs and DDs only:  
• Any malfunction or deterioration in the characteristics and/or performance of a device, 
as well as any inadequacy in the labeling or instructions for use which led or might have 
led to the death or serious deterioration in the state of health of a patient, user, or 
other person.  
• Any technical or medical reason resulting in withdrawal of a device from the mark et by 
[CONTACT_3455].  
• Any serious deterioration in the state of health, including:  
 Life-threatening illness or injury  
 Permanent impairment of a body function or permanent damage to a body 
structure  
 A condition necessitating medical or surgical intervention to prevent permanent impairment of a body function or permanent damage to a body structure  
12. Data Review Committees  
12.1.  Data Monitoring Committee  
The main objective of the ADAPT -PD Trial  Data Monitoring Committee ( DMC ) is to advise Medtronic 
regarding the continued safety of study subjects and those yet to be recruited to the stud y; and to 
ensure the validity and scientific merit of the stud y. 
The DMC  will be external to Medtronic and independent of the study investigators. The physician 
members will have specialties appropriate to the therapeutic area and  all members will meet 
requirements established in the DMC  charter.  
The DMC will be responsible for:  
• Assessing the progress of the ADAPT -PD trial, including the accumulation of safety dat a  
• Evaluating study conduct (eg, data quality) for the impact on validity and scientific merit of the ADAPT -PD Trial  
• Considering factors external to the study when relevant information becomes available, such as scientific or therapeutic developments that may have an impact on the safety of the participants or the ethics of the study  
• Recommending to the  sponsor whether to continue, modify, or stop the study  
Medtronic personnel (eg, statistician, Medtronic study management team) may facilitate the DMC 
meetings, provide study progress updates and answer questions. Medtronic personnel will not be voting 
members.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302777] of the study.  
12.2.  Clinical Events Committee  
This study will utilize a Clinical Events Committee (CEC) to  review and adjudicat e all reportable  
stimulation /therapy, procedure and device related (S)AEs and death s for seriousness  and relationship  to 
the procedure, device, and therapy/stimulation using the definitions provided in  Section  11.[ADDRESS_302778] clarification and/or additional 
information from the principal investigator [INVESTIGATOR_248929]. If the conclusion of the review 
differs from the principal investigator’s assessment, both opi[INVESTIGATOR_248930]. Incidence rates will be tabulated using the final CEC 
determination.  
13. Statistical Design and Methods  
13.1.  General Aspects of Analysis 
The ADAPT -PD Trial will be considered successful when the primary objective of th e study is met for one 
or both aDBS algorithms  independently or the algorithms combined .  
The main analysis of the study objectives will use the Full Analysis Set (FAS) which includes all Primary 
Cohort subjects, using the intention -to-treat (ITT) principle, who initiate the aDBS Evaluation Phase using 
the randomized treatment assignment for each subject that was randomized and the programmable 
treatment assignment for those subjects that may only be configured to one aDBS m ode (dual or single 
threshold).   
The main analysis will include data from all contributing geographies  and centers . A poolability analysis 
for a center effect will be performed  as described in Section  13.2.10.   
The subjects’ baseline status will be summarized with standard descriptive summary statistics, including counts and percentages for categorical variables, and mean, standard deviation for contin uous 
variables. Safety data will be summarized as specified  in Section  13.[ADDRESS_302779] disposition will be illustrated in a CONSORT diagram and attrition will be identified and summarized.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 101 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  The handling of missing data  for the primary and secondary objective is describe d generally in Section  
13.2.5 and also with each objective. Subgroup analyses are described in Section  4.1.4  
13.2.  General Statistical Considerations  
Data analysis will be performed by [CONTACT_13735] -employed statisticians or designees. A validated statistical 
software package will be used to analy ze the study results.  
Additional  details of the analyses outlined in this section  will be described  in a separate Statistical 
Analysis Plan prior to the data freeze for the Primary Analysis  Report. Any deviations from this section  
and/or the Statistical Analysis Plan will be described and justified in the Primary Analysis  Report, as 
appropriate or in an  amended CIP, if applicable.  
13.2.1.  Analysis sets 
All-Consent ed (AC) : includes all subjects who properly signed the study -specific informed consent (IC). 
This patient set will be used to summarize patient disposition . 
Full Analysis Set (FAS): includes all Primary  Cohort subjects, using the intention -to-treat (ITT) principle, 
who initiate the aDBS Evaluation Phase  using the randomized treatment assignment for each subject  
that was randomized and the programmable treatment assignment for those subjects that may only  be 
configured to one aDBS mode (dual or single threshold) . 
As-Treated  (AT): includes all Primary Cohort subjects who are treated with continuous Deep Brain 
Stimulation (cDBS) and/or adaptive Deep Brain Stimulation (aDBS) during the cDBS Baseline Evaluatio n 
Phase and/or the aDBS Evaluation Phase , and Long-term Follow -up Phase  and uses the observed 
treatment used for each subject in each phase . 
All-Randomized (AR) : includes all Primary Cohort subjects who were randomized in the aDBS Evaluation 
Phase, excludes those that were not configured to both modes.  
Complete -Case (CC) : FAS without imputation that includes all Primary Cohort subjects who have 
available measures for the respective analysis and are analyzed in their randomization group  for those 
rand omized or the programmable treatment for those configured to one aDBS mode. 
Directional Stimulation As -Treated (DSAT) : includes all Directional Stimulation Cohort subjects who have 
SenSight leads in a directional stimulation configuration who are treated with continuous Deep Brain 
Stimulation (cDBS) and/or adaptive Deep Brain Stimulation (aDBS) during the cDBS Baseline Evaluation 
Phase and/or the aDBS Evaluation Phase, and Long-term Follow -up Phase and uses the observed 
treatment used for each subject in each phase . 
Directional Stimulation Complete -Case  (DSCC) : includes all Directional Stimulation Cohort subjects who 
completed the aDBS Evaluation Phase.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302780] is in the 
wrong treatment assignment or stimulation is inactive will be included in analyses, following Section  
13.4.5.  
PD Home  Diary compliance will be continuously monitored throughout the duration of the study to 
ensure that  compliance is maintained.  
13.2.3.  Familywise error rate and hypothesis testing  
The familywise error rate will be controlled us ing one -sided tests with an overall alpha- level of 0.025 . 
Each primary hypothesis (one for each aDBS mode) will be assigned a Bonferroni corrected alpha 
(0.0125) for the respective primary hypothesis ( 0.025/2, see Section  13.4.1) . The primary hypothesis will 
serve as a gatekeeper for the secondary hypothesis within each mode.  
13.2.4.  Sample size rationale  
Since  the device implant will occur o utside of the study and the study require s participants to be stable 
on cDBS  prior to enrollment , the standard deviation of the change from cDBS to aDBS in  “On” time 
without troublesome dyskinesia  will be used  to establish a threshold  for assessing the  performance goal. 
The thres hold will be set  as [ADDRESS_302781] deviation. If the difference between aDBS and cDBS (aDBS -cDBS) 
for a subject is at least  -[ADDRESS_302782] (alpha=0.0125)  
for a proportion (PASS 2011 module Tests for One Proportion [Differences]) to compare to a 
performance goal of 50%. Assuming the alternative hypothesis of 85 % of subjects exceeding the 
threshold , a minimum of [ADDRESS_302783] 90% power to reject a performance goal of 50%.  
Simulations have shown that this sample size is sufficient to cover possible deviations from normality 
such as a uniform dis tribution. The threshold criterion will remain the same as the standard deviation is 
robust to moderate departures from normality.  
Sample size in the Primary Cohort may be increased to a maximum of [ADDRESS_302784] 8 subjects per 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 103 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  aDBS mode and  8 subjects per  target site (STN/GPi ). Criteria for increasing sample size is described in 
Section  13.2.6 .  
For the safety analyses, a minimum of 30 subjects followed for approximately 30 days with aDBS out -of-
clinic in the subjects’ real- world environments provides at least 95% probability that all events with a 
true event rate of at least 10% would be reported at least once.  
It is estimated that approximately [ADDRESS_302785] 1 
aDBS mode is acceptable and who enter  the aDBS Evaluation Phase . Accounting for a 10% dropout 
during the aDBS Evaluation  Phase , a minimum of 36 subjects (at least 8 per brain target site (STN/GPi) 
and 8 per aDBS mode) will complete the aDBS Evaluation phase.  
In addition, approximately [ADDRESS_302786] 1 aDBS mode is acceptable and who enter the aDBS Evaluation Phase. Accounting for dropout during the aDBS Evaluation Phase, a minimum of 8 subjects will complete the aDBS Evaluation Phase.  
13.2.5.  Handling of missing data  
All attempts will be made to minimize missing data. If
 5% of the data or fewer are missing for the 
analysis, no imputation will be used.h Otherwise, i f missing data are observed, multiple imputation wil l 
be used for  the analysis of the primary  and secondary  objective s, as described in the objective section s 
below . If an aDBS mode is not programmable to a subject no imputation will occur for th ose subjects for  
that aDBS mode.  
Appropriate standard errors will be computed to account for the multiple imputations.i,j A Complete -
Case  Analysis Set and As -Treated Analysis Set will be used for sensitivity analys es of the primary  and 
secondary  objective  analyses.  
 
 
 
h Buhi, E, Goodson, P, Neilands T. Out of Sight, Not Out of Mind: Strateg ies for Handling Missing Data. Am J Health 
Behav. 2008 Jan -Feb;32(1):83 -92, doi: 10.5555/ajhb.2008.32.1.83. 
i Rubin, D. B. (1976). “Inference and Missing Data.” Biometrika 63:581 –592.  
j Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Surveys. [LOCATION_001]: John Wiley & Sons.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 104 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  13.2.6.  Interim sample size adjustment  
Sample siz e for the Primary Cohort  may be increased to a maximum of 55 subjects  based on 
acceptability of the aDBS modes during the aDBS S etup Phase  and to ensure a minimum number of 
subjects in each target site (STN/GPi) as described in 13.2.[ADDRESS_302787] reached the end of their aDBS Evaluation Phase (randomized or programmable 
mode)  a Pre -Market Approval (PMA) supplement will be submitted to request FDA approval of aDBS ; a 
Technical Docum ent will be submitted to request TUV approval of aDBS . These requests  will include 
available data through the final aDBS Evaluation Phase visit and any available  safety  data for those 
subjects in the long- term follow -up phase . A final study report, which will include data covering all 
phases of subject follow -up, will be prepared after all subjects have completed  the study.  
13.2.8.  Demographics and baseline variables  
Demographics and baseline characteristics will be summarized for the AC , FAS, and DSCC  analysis sets.  
13.2.9.  Pooling of aDBS mode  
Most planned analyses for the Primary Cohort are to be done separately for each mode. Summary 
statistics will be computed to summarize the percentage  who were programmed to each  mode  and 
subject characteristics of each  subgroup.  If fewer than 2 4 subjects are programmed to one of the aDBS 
modes because aDBS is unacceptable as compared to cDBS (using the aDBS GIC), the evaluation of aDBS 
effectiveness will use data from the first period of the aDBS Evaluation Phase from all subjects. If the 
modes are considered poolable, the modes would be combined and the alpha level of the test would be alpha=0.025 (one -sided).  To test for a treatment difference in the first period  by [CONTACT_249008], 
subjects will be categorized based o n the modes they are programmable to: aDBS – Dual Threshold only; 
aDBS – Single Threshold only; and aDBS – both modes . The  Freeman and Halton’s extension of Fisher’s 
exact test will be computed testing for differences between aDBS modes in the proportion o f subjects 
exceeding  threshold for the primary outcome  using data only from the first period . The same 
categorization  of mode  will be used and tested using F -tests using linear regression models for the 
secondary outcome  measure . P-values >0.[ADDRESS_302788] and the data will be considered poolable across aDBS mode groups.  If the aDBS mode group factor approaches statistical significance 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 105 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  (defined as ≤0.1),k the data will not be considered poolable. A minimum of [ADDRESS_302789] 1 aDBS mode is acceptable 
and who enter  the aDBS E valuation Phase  (~25% of the total planned n umber of subjects). For the 
Directional Stimulation Cohort,  each study center will stop enrollment after they have identified a 
maximum of [ADDRESS_302790] 1 aDBS mode is acceptable  and who enter the aDBS Evaluation 
Phase . The actual number of subjects at a study center may be slightly larger due to the number of 
subjects that are enrolled prior to cessation of enrollment. This restriction is intended to reduce the possibility that the results from one study center will be overly influential in the overall study results.   
Tests for a treatment difference  in the Primary Cohort  among centers are described in the supporting 
analyses of the objective section s below.  When testing for differences between centers, centers with 5 
or more  FAS subjects will each be tested as separate centers. Those with less than 5 FAS subjects will be 
combined into a “pooled” pseudo -center to minimize the impact of small samples on the analysis. If the 
pseudo -center contains more than 50% of the subjects, the cen ters will be combined into more than 
one pseudo -center. If more than one pseudo -center is needed, the centers will be randomly ordered 
and divided as near the midpoint as possible. If ambiguity between assigning a center to the first or 
second pseudo -center exits, the center will be assigned to the first pseudo -center.  
13.3.  Analysis Execution  
A formal analysis for the ADAPT -PD Trial  will occur when all active subjects in the Primary Cohort  have 
completed the Evaluation Phase of the study . Analysis will include b oth the primary and secondary 
 
 
 
k Fleiss JL. The statistical basis of meta -analysis. Stat Methods Med Res. 1993; 2(2):[ADDRESS_302791] been exited.  The inferential analysis for the primary and secondary objectives will not be 
updated for the final report. Additional  objectives will be addressed based on complete data.  
13.4.  Primary Objective 
To demonstrate that the proportion of aDBS subjects with “ On” time without troublesome dyskinesia 
during the Evaluation Phase exceeds a performance goal of 50%.  
13.4.1.  Hypothesis  
Two hypotheses are being tested for the primary objective in order to compare each aDBS mode relative 
to cDBS at baseline, separately. The alternative hypotheses are:  
• H11: The proportion of subjects  with “On” time without troublesome dyskinesia during aDBS  
dual threshold mode  Evaluation P eriod  exceeding threshold > 50% 
• H21: The proportion of subjects  with “On” time without troublesome dyskinesia during aDBS  
single threshold mode  Evaluation P eriod  exceeding threshold > 50% 
13.4.2.  Endpoint definition  
The primary endpoint is the p roportion of aDBS subjects with “ On” time without troublesome dyskinesia 
that exceed threshold . This endpoint will combine the diary categories of “On” time without dyskinesia 
and “On” time with non -troublesome dyskinesia . Since  the device implant will occur outside of the study 
and the stud y require s participants to be stable on cDBS, the within -subject standard deviation of the 
change between  cDBS and DBS in “ On” time without troublesome dyskinesia  will be used  to establish a 
threshold  for assessing the performance goal. The thres hold will be set  as [ADDRESS_302792] deviation . If the 
difference between aDBS and cDBS (aDBS -cDBS) for a subject is at least  -[ADDRESS_302793]. Using this threshold, the proportion of subj ects who  exceed the 
threshold will b e computed.  The primary endpoint  proportion of subjects above  threshold  will be 
compared to a  performance goal of 50% using a binomial exact  test. The lower bound of the 97.5% 
confidence limit will also be presented.  Data will be imputed as described in 13.2.5 prior to computing 
the mean “ On” time without troublesome dyskinesia for all periods when using the FAS . 
Rationale for e ndpoint  
Continuous Deep Brain Stimulation (cDBS) is a proven FDA -approved therapy in the treatment of 
Parkinson’s disease symptoms . This study aims to show that aDBS is a viable optional  feature that can 
provide similar benefit and safety to cDBS for some subjects. The primary endpoint for this study 
compares aDBS to cDBS directly for each subject to ensure some level of consistent comparability 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302794] d eviation was chosen as it is an acceptable amount of statistical variability in the 
PD Home  Diary endpoint given the fluctuating nature of Parkinson’s disease and the percentiles of a 
normal distribution.  
Rationale for 50% performance goal  
A performance goal of 50% was chosen for this study in order to demonstrate that at least 50% of the 
subjects are able to achieve the threshold with 95% confidence demonstrating some level of efficacy.   
13.4.3.  Sample size justification  
The sample size justification for the primary objective is provided in Section  13.2.4.  
13.4.4.  Analysis methods  
The primary analysis will use the FAS as described in Section  13.2.[ADDRESS_302795] 3 consecutive days (24 hour “periods”)  prior to each visit to evaluate the primary objective . 
Complete diary periods collected anytime during the cDBS Baseline period will be used for analysis as 
subjects should be on stable cDBS stimulation from enrollment through the end of this period. In the 
aDBS Evaluation Phase, diary periods will be defined starting with the first completed diary record wh ich 
is no more than [ADDRESS_302796] 21 hours
l (defined as 42 30 -minute records) of diary were 
completed during the [ADDRESS_302797] to the visit will be used for the 
 
 
 
l Neurostimulation for Parkinson's disease with early motor complications. Schuepbach WM, Rau J, Knudsen K, 
Volkmann J, Krack P, Timme rmann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen 
S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-
Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto  JL, Bataille B, Maltête D, Damier P, Raoul S, 
Sixel -Doering F, Hellwig D, Gharabaghi A, Krüger R, Pi[INVESTIGATOR_248931], Amtage F, Régis JM, Witjas T, Thobois S, Mertens 
P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade -Brittinger C, Deuschl G; E ARLYSTIM Study 
Group. N Engl J Med. 2013 Feb 14;368(7):610- 22. doi: 10.1056/NEJMoa1205158.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302798] 1 complete period available will be used  for analysis. Data from non -contiguous complete 
periods may be used in the analysis . 
The change  in daily “On” time without troublesome dyskinesia  from cDBS to aDBS  will be computed for  
each subject . The overall standard deviation of the change will be computed for the FAS. The threshold 
will be set as [ADDRESS_302799] deviation. If the difference between aDBS and cDBS (aDBS -cDBS) for each 
subject is at least  -[ADDRESS_302800]. Using this threshold, 
the proportion of subjects who exceed  the threshold will be computed. The proportion with “ On” time 
without troublesome dyskinesia during the respective aDBS Evaluation Period that exceed the threshold 
will be compared  to the performance goal of 50%  for each aDBS mode separately using a binomial exact 
test. The objective will be considered pas sed if the p -value is less than 0.0125.  The lower bound of the 
97.5% confidence interval will also be presented.   
13.4.5.  Handling of missing data  
All attempts will be made to minimize missing data. If  5% of the data or fewer are missing (as defined in 
Section  13.4.4 ) for the analysis, no imputation will be used  and the data will be analyzed as specified in 
the prev ious section . Otherwise, if missing data are observed, multiple imputation will be used for the 
analysis of the key primary objective.  
Prior to the MI, the distribution of the continuous variables will be assessed for normality (using the 
Shapi[INVESTIGATOR_2152] -Wilk tes t) to determine whether regression (P ≥0.05) or predictive mean matching (P<0.05) 
multiple imputation will be used for each variable . First, multiple imputation will be applied  to impute 
missing values  in continuous hours of “ On” time without troublesome dyskinesia  for each mode 
separately (aDBS single threshold, aDBS dual threshold).  Variables for target site (STN or GPi) and cDBS 
hours of “ On” time without troublesome dyskinesia will  be considered for  the model . The fully 
conditional specification (FCS) method within SAS (version 9.4 or higher) with 5 repetitions and 100 
burn -in iterations will be used for imputation. No limits will be defined  for imputed values. Following 
imputation, the “ On” time without troublesome dyskinesia will be assessed against the “On” time 
threshold, and the estimate for the proportion of subjects meeting threshold will be determined for 
each imputation  and combined using MI analysis methods . The lower bound of the 97.5% confidence 
limit will be determined from the  MI Clopper -Pearson mean success approachm.  In addition, the 
 
 
 
m Mandan, Arpi[INVESTIGATOR_17399]  (2018).  Two Applications of Summary Statistics: Integrating Information Across Genes and 
Confidence Intervals With Missing Data.  Master's thesis, Duke University.  Retrieved 
from https://hdl.handle.net/[ZIP_CODE]/[ZIP_CODE]  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 109 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  objective will b e tested by [CONTACT_249009] 50% for each i mputation, and t he overall  p-
value will be computed as the median of the  p-values from the multiply imputed datasets.n 
13.4.6.  Supporting analyses  
Supporting analyses for the primary objective in the Primary Cohort include verifying the lack of a period 
or carryover effect  (randomized subjects only) , a target site effect  (STN/GPi), a lead  type  effect (legacy 
Model s 3387  and 3389  compared to SenSight Models B33005 and B33015), or a center effect. 
Summarized results from the Directional Stimulation Cohort will be provided as supporting analyses to 
the Primary Cohort results.  In addition, sensitivity  analys es will be conducted using the CC and the AT 
Analysis Set.  
An analogy of Prescott’s testo will be computed to test for a period or carryover effect and p -values >0.[ADDRESS_302801] is accepted, target  site (STN/GPi), lead  type , and center pooling 
assessments will be made  using data from all subjects treated with aDBS in the aDBS evaluation phase . If 
a period effect exists, only data from the first period will be used for the analysis.  
To test for a treatment difference by [CONTACT_249010] (STN/GPi) , lead  type , and center within each mode , 
Fisher’s exact test and Freeman and Halton’s extension of Fisher’s exact test, respectively, will be 
computed testing for differences between target sites , lead type,  or ce nters in the proportion of 
subjects exceeding  threshold for the primary outcome using data from both periods. P- values >0.[ADDRESS_302802], 
respectively, and the data  will be considered poolable across the respective variable. If the p- value  
approaches statistical significance (defined as ≤0.1),k the proportion exceeding threshold and the lower 
bound of the 97.5% confidence interval  will also be estimated at each target site , lead type, or center, as 
applicable  (eg, if the target sites  (STN/GPi) do not allow for pooling the analysis will be conducted by 
[CONTACT_232798] s ite for that mode. ) 
If center(s) causing the significance are identified, variables relating to patient characteristics and other 
factors will be analyzed to try to identify why this center is showing a different treatment effect.   
 
 
 
n Ekhout, I., van de Wiel, M.A., and Heymans, M.W. (2017), Methods for significance testing of categorical 
covariates in logistic regression models after multiple imputation: power and applicability analysis. BMC Med. Res. 
Methodol.17: 129. doi: 10.1186/s12874 -017- 0404 -7 
o Nagelkerke, N.J.D., Hart, A.A.M. and Oosting, J. (1986), The Two Period Binary Response Cross ‐Over Trial. Biom. 
J., 28: 863- 869. doi:10.1002/bimj.[PHONE_5226]  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 110 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  As part of the additional objectives, “ On” time without troublesome dyskinesia will be summarized as 
absolute change from  cDBS  Baseline  Phase  to the Evaluation Phase .  
13.5.  Secondary Objective  
13.5.1.  Secondary Objective  
To demonstrate decreased stimulation energy use during the  aDBS Evaluation Phase  as compared with 
cDBS.  
13.5.2.  Hypothesis  
Two secondary hypotheses are being tested using independent gatekeeper  procedures  to control the 
alpha -level  as described  in Section  13.4.1 . The two secondary alternative hypotheses comparing aDBS 
(Evaluation Phase) to cDBS (Baseline Phase) separately, are:  
• H12: Mean Difference between  aDBS dual threshold (Evaluation Phase) minus cDBS (Baseline 
Phase) for TEED < 0  
• H22: Mean Difference between aDBS single threshold (Evaluation Phase) minus cDBS (Baseline 
Phase) for TEED < 0  
13.5.3.  Endpoint definition  
The secondary endpoint is to d ecrease energy use as measured by [CONTACT_249011].  The Total TEED will be calculated as a 
sum of the energy use in the left and right leads .  There will be one value per patient for each mo de 
evaluated (eg, cDBS, aDBS Dual Threshold, aDBS Single Threshold).  
The reduction in TEED will be calculated as:  
TEED Δ aDBS dual threshold mode  = TEED aDBS dual threshold mode  – TEED cDBS 
and 
TEED Δ aDBS single threshold mode  = TEED aDBS single threshold mode  – TEED cDBS  
Computing TEED in cDBS  
To compute TEED using the formula in  Section  9.15.2  in the cDBS mode, the current drain, pulse -width, 
frequency, and impedance will be determined from the JSON session data at the cDBS Baseline visit.  
Computing TEED in aDBS  
To compute TEED using the formula in Section  9.15.2  in an aDBS mode , the average current drain  from 
the JSON session data  will be computed using the average stimulation currents  from the timeline 
feature. This will be computed as the average of the  currents  from the timeline feature using the epochs 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 111 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  that align with the analysis set (e.g., As -Treated analysis set uses the actual aDBS mode as reported from 
the device).  Included days should be in the 14 days prior to the visit . The pulse -width, frequency, and 
impedance will be determined  from the JSON session data  at the aDBS Evaluation visit .  
Impedance   
Leads  programmed with monopolar settings  will use the  electrode unipolar impedance  between the 
case and the active electrode. I f 2 cathodes are used  (dual monopolar settings ), TEED will be calculated 
for each contact [CONTACT_249012], and total TEED will be determined for the lead as the sum of the two TEED.  
Leads programmed to bipolar will use the impedance between the active electrodes. In case electrode 
impedance was not collected at cDBS Baseline or aDBS Evaluation Phase, impedance from aDBS Setup 
would be used.  
13.5.4.  Sample Size justification  
The sample size was estimated using a one-sided test (alpha=0.0125) for one mean  (PASS 2011 module 
Tests for One Mean) to compare  the difference in aDBS TEED to cDBS  TEED  of [ADDRESS_302803] 90% power . 
Based on the registry data and the bench testing, a conservative estimate based on the first quartile of TEED data for initial devices in the registry, TEED is expected to decrease [ADDRESS_302804] will be used to compare the difference in 
TEED for each aDBS mode (Evaluation Phase) to cDBS (Baseline Phase), separately.  Normality of the 
outcome will be assessed  with the  Shapi[INVESTIGATOR_2152] -Wilk test. If large violations to the normality assumption are 
observed  (p<0.05) , the primary analysis will use a Wilcoxon sign ed-rank  test to assess statistical 
significance . 
13.5.6.  Handling of missing data  
All attempts will be made to minimize missing data. If
 5% of the data or fewer are missing for the 
analysis, no imputation will be used  and the data will be analyzed as specified in the previous section . 
Otherwise, if missing data are  observed, multiple imputation will be used for  the analysis of the 
secondary objective.  
Prior to the MI, the distribution of the continuous variables will be assessed for normality (using the 
Shapi[INVESTIGATOR_2152] -Wilk test) to determine whether regression (P≥0.05) or predictive mean matching (P<0.05) 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302805], multiple imputation will be applied to impute 
missing values in TEED for each mode separately (aDBS single threshold, aDBS dual threshold). Variables 
for target site (STN or GPi) and cDBS TEED  will be included in the model. The fully conditional 
specification (FCS) method within SAS (version 9.4 or higher) with [ADDRESS_302806]  (randomized subjects only) , tests for poolability by [CONTACT_249010] (STN/GPi) , tests 
for poolability by [CONTACT_247673] (legacy Model s 3387  and 3389  compared to SenSight Models B33005  and 
B33015 ), and tests for poolability by [CONTACT_384] . The test for a carryover effect will use a two -sample t -test, 
all other supporting analysis tests will use  linear regression models . In addition, results from  the 
Directional Stimulation Cohort  will be described  as a supportive analysis . The test of no period or 
carryover effect will be computed first, and if the assumption of no period or carryover effect is 
accepted, data from both periods from all subjects treated with aDBS in the aDBS E valuation Phase  will 
be used for the models to ass ess poolability by [CONTACT_249010] , lead  type , and center.  The models will use the 
change between aDBS and cDBS and include an intercept and a covariate for the respective parameter. P-values >0.[ADDRESS_302807].  If large violations to the normality assumption are 
observed  (p<0.05) , the secondary endpoint may be transformed (e.g., log-transformation) or apply non -
parametric method for the supporting analyses.  
In addition, sensitivi ty analys es will be conducted using the CC and AT  Analysis Sets without imputation.   
13.6.  Safety Assessment  
The safety assessment is to characterize:  
• Stimulation -related adverse events during the aDBS evaluation and the cDBS baseline phases.  
• Serious adverse eve nts, adverse events, and device deficiencies throughout the study.  
Stimulation -related adverse events will be summarized during the cDBS Baseline and aDBS Evaluation 
Phases for all subjects, with tabulations individualized by [CONTACT_249013] t, by [CONTACT_249014], by [CONTACT_249015], and the Directional Stimulation  Cohort 
(DSAT analysis set) . Summarized results from the Directional Stimulation Cohort will be provided as 
supporting analyses to the Primary Cohort results . In the Primary Cohort, i f statistical comparisons of 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302808] for a difference in safety by [CONTACT_249010] (STN/GPi)  and lead type , Fisher’s exact test 
will be computed testing for differences between target sites and lead types  in the proportion of 
subjects with a stimulation -related adverse event during the aDBS evaluation phase using data from 
both periods. A repeated  measures logistic regression model will be used to test for a difference 
between aDBS modes in the proportion of subjects with stimulation -related adverse events.  P-values 
>0.[ADDRESS_302809] , 
respectively, and the data will be considered poolable across the respective variable. If the p- value 
approaches statistical significance (defined as ≤0.1),k safety summaries will not be provided as a 
combined summary  for that variable .   
Serious adverse events , adverse events, and device deficiencies that occur from the time of enrollment 
through study exit/discontinuation will be summarized for all enrolled subjects. The denominator will 
include the appropriate number of subjects for each respective phase and period . Events will be 
summarized by [CONTACT_107102] r of events, number of subjects who experienced the event, and percentage  of 
subjects who experienced the event.   
13.7.  Additional Objectives  
To characterize each aDBS mode as compared to cDBS, the additional objectives described in Section 
4.1.4  will be evaluated for the FAS separately for each aDBS mode.  In addition, the subgroup analyses  as 
described in Section  4.1.4 will be performed  for the FAS and DSAT . 
Summary statistics will be presented for continuous measures (N, means, medians, standard deviations, 
minimums and maximums) and categorical measures (N, percent age, frequency distributions) with 95% 
confidence intervals as appropriate.  No adjustment will be made for multiple testing  of the additional 
study objectives . 
13.8.  Minimization of Bias 
Selection of subjects, treatment of subjects, and evaluation of study data are potential sources of bias. 
Methods incorporated in the study design to minimize potential bias include (but are not limited to):  
• Single -blind of subjects during the Evaluation Phase  
• Randomized crossover to evaluate the dual threshold and single threshold modes   
In summary, potential sources of bias that may be encountered in this study have been considered and 
minimized by [CONTACT_54415].  
14. Ethics  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 114 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  14.1.  Statement(s) of Compliance  
This study will be conducted in compliance with international ethical and scientific quality standards, 
known as GCP. GCP includes review and approval by [CONTACT_249016] a study, 
continuing review of an ongoing study by [CONTACT_76467], and obtaining and documenting the freely given 
informed consent of a subject before initiating the study.  
The ADAPT -PD Trial was designed to reflect the Good Clinical Practice ( GCP) principles outlined in ISO 
[ZIP_CODE]:[ADDRESS_302810] and 
credibility of the clinical investigation and the definition of responsibilities of the sponsor and 
investigators. In accordance with ISO [ZIP_CODE]:2020, the sponsor shall avoid improper influence on, or 
inducement of, the subject, monitor, any investigator(s) or other parties participating in, or contributing 
to, the clinical investigation. All investigators shall avoid improper influence on or inducement of the subject, sponsor, monitor, other investigator(s) or other parties participating in or contributing to the clinical investigation. AE and DD handling in the ADAPT -PD Trial is ISO [ZIP_CODE]:[ADDRESS_302811] been implemented through the IC process, EC approval, study training, clinical trial registration, pre -clinical testing, risk -benefit assessment and publication policy.  
Ultimately, all study sites in all geographies will follow and comply with:  
• Principles of DoH  
• ISO [ZIP_CODE]:2020 
• 21 CFR Part 11 (Electronic Records, Electronic Signatures)  
• 21 CFR Part 54 (Financial Disclosure by [CONTACT_6230])  
• The CTA  
• The procedures described within this CIP  
• Local IRB/EC  Requirements  
• Local regulatory authority requirements  
In addition to the regulatory requirements outlined above, the study will be conducted according to federal, national and local laws, regulations, standards, and requirements of the countries/geographies 
where the study is being conducted. These include but are not limited to:  
• In the [LOCATION_002], the study will be conducted under an FDA IDE in  compliance with 
21 CFR Parts:  
 50: Protection of Human Subjects  
 54: Financial Disclosure by [CONTACT_6230]  
 56: IRBs  
 812: IDEs  
• In Canada, SOR/98 -282, section  59-88 will be followed and Mandatory Problem 
Reporting 59(1), 59(2), 60 (1)).  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 115 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • In Europe the  study will be conducted in compliance with the AIMDD 90/385/EEC and  
EU MDR  2017/[ADDRESS_302812] enrollment in accordance with the 2007 FDAAA 
and DoH on http://clinicaltrials.gov (PL 110 -85, section  810(a)). In addition, the study may be registered 
in local regulatory databases where required by [CONTACT_1769].  
Study investigators will be required to sign and date a n investigator agreement or CIP signature [CONTACT_249039].  
Approval of the CIP and CIP amendments is required from the following groups prior to any study 
procedures at a study site:  
• Medtronic  
• Principal Investigators (where required by [CONTACT_1769]/regulations)  
• Geography -specific regulatory authorities (if regulatory approval is required)  
• An independent medical EC or IRB.  
Similarly, approval of subsequent revisions to the CIP is required at each st udy site from the above -
mentioned groups prior to implementation of the revised CIP at the study site.  
Medtronic contracts with participating institutions/investigators through a Clinical Trial Agreement that 
defines the scope and responsibilities and associated compensation related to carrying out the obligations under a clinical study sponsored by [CONTACT_13735].   
15. Study Administration  
15.1.  Monitoring  
It is the responsibility of Medtronic to ensure proper monitoring of this study.  Trained Medtronic 
personnel or de legates appointed by [CONTACT_249017], the CTA, and the applicable regulatory 
and local requirements. Medtronic, or delegates, must therefore be allowed direct access to the 
subjects’ case histories ( all clinic and hospi[INVESTIGATOR_1097], and other source data/documentation) upon 
request as per the IC, Research Authorization (where applicable) and CTA.  The principal investigator 
[INVESTIGATOR_131437].   
Contact [CONTACT_249018]:  
Medtronic Clinical & Regulatory Solutions  
[ADDRESS_302813] enrollment, study compliance, number of 
adverse events, number of deviations, observations from previous monitoring visits and any suspected 
inconsistency in data that requires investigation. Regulatory documents will be reviewed at each study 
site. Monitoring for the study  including site initiation visits, interim monitoring visits, and closeout visits, 
will be done in accordance to the study -specific monitoring plan.  
Monitoring visits may be conducted periodically to assess study site progress, th e investigator’s 
adherence to the CIP, regulatory compliance including but not limited to IRB/ EC approval and review of 
the study, maintenance of records and reports, and review of source documents against subject CRFs in accordance to the study -specific m onitoring plan. Monitors review study site regulatory and study 
compliance by [CONTACT_249019] -compliance and communicating those observations along 
with recommendations for preventative/corrective actions to study site personnel.  Monitors may work 
with study personnel to determine appropriate corrective action recommendations and to identify 
trends within the study or at a particular study site.  
15.2.  Data Management  
Medtronic personnel will perform routine edit and consistency checks for items such as missing data or 
inconsistent data. Identified data inconsistencies will be resolved by [CONTACT_249020]; 
investigators and center personnel will review data discrepancies and respond to the discrepancies in a 
timely manner. The resolved dis crepancy will become a part of the CRF record for the subject.  
The Oracle Clinical Remote Data Capture (RDC) system is a fully validated system and 21CFR§[ADDRESS_302814] review all data for accuracy and provide his/her approval 
of the CRF and sign each form with an electronic signature. If a person only authorized to complete CRFs 
makes changes to an already signed CRF, the system will require the principal investigator, or authorized delegate, to re- sign the CRF.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302815] Access to Source Data/Documents  
Medtro nic or third -party auditors representing Medtronic may perform clinical center audits to verify 
the performance of the monitoring process and study conduct, and to ensure compliance with applicable regulations. IRB s/ECs, r epresentatives for regulatory bodies such as the FDA, CA and Notified 
Body may also perform center inspections related to this clinical study. The investigator and/or 
institution shall permit Medtronic, IRB s/ECs and RAs direct access to source data and documents during 
monitoring, audits and regulatory inspections.  
15.4.  Confidentiality  
Subject confidentiality is assured through use of subject identification numbers, and the de -identifying 
of photocopi[INVESTIGATOR_248932]. In addition to the review of records at the center, relea se of de -identified records to Medtronic may be necessary, such as in the evaluation of adverse 
events. The investigational center personnel must de-identify and label source documentation with the 
subject’s study -specific identification number prior to submission to Medtronic.  
Data relating to the study might be made available to third parties (for example in case of an audit 
performed by [CONTACT_14687]), provided the data are treated as confidential and that the subject’s privacy is guaranteed. No identifiable subjec t information will be published.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302816] (HIPAA) language will be required to be included at 
every center in the [LOCATION_002]. HIPAA language may be included within the IC according to the 
center’s policy.  
15.5.  Liability/Insurance Information  
The compensation and covered liability associated with this study conduct will be documented in a 
separate financial agreement signed by [CONTACT_13735], the Principal Investigator, and /or the management 
of study site/institution.  Medtronic maintains appropriate clinical study liability insurance coverage as 
required under applicable laws and regulations and will comply with applicable local law and custom concerning specific insurance coverage. If required, a Clinical Trial insurance statement/certificate will 
be provided to the IRB/EC. 
15.5.1.  
Insurance (Canada)  
Medtronic of Canada Ltd. is a wholly owned subsidiary of Medtronic, which as the parent company of 
such entity maintains appropriate general liability insurance coverage as required under applicable laws 
and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a General Liability insurance statement/certificate will be provided to the EC.  
15.5.2.  Insurance (E urope)  
Medtronic Bakken Research Site B.V. is a wholly owned subsidiary of Medtronic, which as the parent company of such entity maintains appropriate clinical study liability insurance coverage as required under applicable laws and regulations and will comply with applicable local law and custom concerning specific insurance coverage. If required, a Clinical Trial insurance statement/certificate will be provided 
to the EC.  
15.6.  CIP Amendments  
Clinical investigation plan amendments may be initiated by [CONTACT_249021]. Protocol amendments will be submitted to the appropriate regulatory 
authorities  for their approval, if required, and to the IRB s/ECs. Prior to a study center’s implementation 
of a CIP amendment and/or associated changes to the IC, approval must be obtained, in writing, by [CONTACT_54455] /EC and Medtronic except:  
• When necessary to eliminate an immediate/or apparent immediate hazard to participating 
subjects  
• When the change  involves pur ely administrative or logistical aspects of the study  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302817] Retention  
The principal investigator [INVESTIGATOR_248933] a minimum of 2 years after the date the investigation is completed or terminated or 
the records are no longer required to support a marketing application (or longer in compliance to local 
requirements). The retention period may be longer if required by [CONTACT_249022] . Medtroni c will not store any personal data longer than necessary and always in line with 
the required storage periods defined by [CONTACT_249023].  
The principal investigator [INVESTIGATOR_248934].  The investigator should take measures to prevent 
accidental or premature destruction of documents.  Medtronic will be notified in writing prior to the 
transfer of study documentation.  
Medtronic will retain the study records according to Medtronic corporate policy and record retention 
schedule.  
15.7.1.  Investigator Records  
At a minimum, the investigator is responsible for the preparation, review, and retention of the records 
listed below. The below records  pertaining to the study, with the exception of case history records and 
case report forms, should be kept in the Investigator Site File (i.e., the study binder provided to the investigator) or Subject Study Binder. CRFs must be maintained and signed electronically within the electronic data capture system during the study. The following records are subject to inspection and mus t be retained for a period of two years (or longer as local law or hospi[INVESTIGATOR_54387]) 
after product approval or the date on which the investigation is terminated or the date that the records are no longer required for purposes of supporting a pre -market approval application.  
• Correspondence with another investigator, an IRB/EC, the sponsor, a monitor or regulatory body 
(eg, FDA, CA, Notified Body) including required reports  
• Device receipt/use/disposition records ( i.e., product accountability)  
• Records of each subject’s  case history and exposure to the device. Case histories include the 
CRFs and supporting data (source documentation), such as:  
o Signed and dated IC  (In U.S. and Canada, signed by [CONTACT_1130]. In Europe, Middle East, 
Africa, signed by s ubject and investigator ) 
o Observations of AEs/ADEs/DDs  
o Medical records, including, for example, progress notes of the physicians, the subject’s hospi[INVESTIGATOR_248935](s) and the nurse’s notes  
• Subject Screening log and Enrollment  log  
• Signed and dated CTA  
• Signed investigator agreement  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 120 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • Current Curriculum vitae of principal investigators and key members of investigation study site 
team  
• Documentation of delegated tasks  
• IRB/ EC approval documentation. Written information that the investigator or other study staff, 
when member of the IRB/ EC, did not participate in the approval process. Approval 
documentation must include the IRBs/ ECs composition, where required per local law.  
• RA notification, correspondence and approval, where required per local law.  
• All approved versions of the CIP, IC and IB/Report of Prior Investigations  
• Signed financial disclosure forms for all investigators  
• Study personnel training records  
• Insurance certificates (Europe and Canada only)  
• Final Study Report including the statistical  analysis  
A list of the study sponsor staff, and a list of the investigator names, emergency contact [CONTACT_8972], 
addresses and professional positions of the principal clinical investigators will be kept separately from 
the CIP. The sponsor will maintain updated lists.  
15.7.2.  Sponsor Records  
Medtronic shall maintain the following accurate, complete, and current records:  
• All correspondence which pertains to the investigation  
• Investigational device traceability record containing Model and serial numbers of devices, 
shippi[INVESTIGATOR_248936], location (if 
different than person shipped to), transfer and receipt by [CONTACT_231011].  
• Sample of label attached to investigational device  
• Signed Investigator Trial Agreements, FD (if applicable) and current CV of principal investigator [INVESTIGATOR_248937] (as required by [CONTACT_1769]), delegated task list  
• All approved IC templates, and other information provided to the subjects and adver tisements, 
including translations  
• Randomization records  
• Copi[INVESTIGATOR_28078]/ EC approval letters and relevant IRB/ EC correspondence and IRB/ EC voting 
list/roster/letter of assurance  
• Names of the institutions in which the study will be conducted  
• RA corresp ondence, notification and approval as required by [CONTACT_54458]  
• Insurance certificates (Europe, Canada)  
• Names/contact [CONTACT_54459]  
• Monitoring visit reports  
• Statistical analyses and underlying supporting data  
• Final report of the study  
• The CIP, IB and study related reports, and revisions  
• Study training records for study site personnel and Medtronic personnel involved in the study  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 121 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • Any other records that local regulatory agencies  require to be maintained.  
Medtronic records and reports w ill be maintained in a password -protected document management 
system, and paper documents (where applicable) will be stored in stored in secured file cabinets at 
Medtronic during the course of this study.  
After closure of the study Medtronic will archive records and reports in accordance with the required storage periods defined by [CONTACT_249023] . 
15.8.  Reporting Requirements  
15.8.1.  Investigator Reports  
The investigator is responsible for the preparation (review and signature) and submission to the sponsor 
of all case report forms, adverse events and adverse device effects (reported per the country -specific 
collection requirements), device deficiencies, d eaths, and any deviations from the clinical investigation 
plan.  If any action is taken by [CONTACT_2717]/ EC with respect to this study, copi[INVESTIGATOR_248938] a timely manner. Reports are subject to inspection and to the retention requirements as described above for investigator records.  
Safety reporting requirements are listed in Table 9. The investigator shall prepare and submit in a 
complete, accurate and timely manner the applicable reports listed in this section  (Table 10, Table 11 
and Table 12).
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 122 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Table 10: Investigator reports applicable for all geographies per Medtronic requirements  
Report  Submit to  Description/Constraints  
Withdrawal of IRB/EC 
approval  Sponsor and Relevant 
Authorities  The investigator must report a withdrawal of approval by [CONTACT_3488]/EC of the 
investigator’s part of the investigation within 5 working days.  
Study Deviations  Sponsor and  IRB/EC   Any deviation from the clinical investigational plan shall be recorded together with the 
explanation of the deviation.  
Notice of deviations from the CIP to protect the life or physical well- being of a subject in 
an emergency shall be given as soon as possible, but no later than 5 working days after the 
emergency occurred.  Except in such emergency, prior approval is required for changes in 
the plan or deviations.  
IRBs/ECs will be notified only if required by [CONTACT_54460]/EC . 
Final Report  IRBs/ECs and Relevant 
Authorities  This report must be submitted within 3 months of study completion or termination.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 123 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Table 11: Additional Investigator reports applicable to the [LOCATION_002] per FDA regulations  
Report  Submit to  Description/Constraints  
Withdrawal of IRB/EC 
approval (either 
suspension or termination)  Sponsor  The investigator must report a withdrawal of approval by [CONTACT_3488]/EC of the 
investigator’s part of the investigation within 5 working days.  (21 CFR 812.150(a)(2))  
Progress report  Sponsor and  IRB/EC  The investigator must submit this report to the sponsor and IRB/EC at regular intervals, 
but in no event less than yearly intervals. (21 CFR 812.150 (a)(3)).   
Study deviations  Sponsor and  IRB/EC  Notice of deviations from the CIP to protect the life or p hysical wellbeing of a subject in an 
emergency shall be given as soon as possible, but no later than [ADDRESS_302818] be approved by 
[CONTACT_13735], the IRB/EC, and the FDA/applicable RA.  If the deviation does not affect these 
issues then only Medtronic must approve it.  (21 CFR 812.150(a)(4))  
Failure to obtain IC prior to 
investigational device use  Sponsor and  IRBs/ECs If an investigator uses a device without obtaining IC, the investigator shall report such use 
within 5 working days after device use.  (21 CFR 812.150(a)(5))  
Final report  Sponsor , IRBs/ECs and 
Relevant Authorities  This report must be submitted within 3 mo nths of study completion or termination of the 
investigation or completion or termination of the investigator’s part of the investigation.  (21 CFR 812.150(a)(6))  
Other  IRB/EC and FDA  An investigator shall, upon request by a reviewing IRB/EC, FDA or any other RA, provide 
accurate, complete, and current information about any aspect of the investigation. (21 CFR 
812.150(a)(7))  
 
  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 124 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Table 12: Investigator reports applicable to Europe, Middle East and Africa per ISO [ZIP_CODE]  
Report  Submit to  Description/Constraints  
Withdrawal of IRB/EC 
approval  Sponsor  Report if required by [CONTACT_1769].  
Progress Report  Sponsor  IRB/EC  Provide if required by [CONTACT_54456]/EC.  
Study Deviations  Sponsor , Competent 
Authority and  IRB/EC  Any deviation from the CIP shall be recorded together with an explanation for the 
deviation.  Deviations shall be reported to the sponsor who is respons ible for analyzing 
them and assessing their significance.   
Note: When required , ECs, CAs  or the appropriate RAs should be informed  by [CONTACT_249024] . 
(ISO [ZIP_CODE]:20 20) 
Failure to obtain IC  Sponsor and  IRBs/ECs IC shall be obtained in writing and documented before a subject is enrolled into the clinical 
investigation.  (ISO [ZIP_CODE]:20 20) 
15.8.2.  Sponsor Reports  
Medtronic shall prepare and submit the following complete, accurate, and timely reports listed in the tables below (by [CONTACT_13736]).  In addition to 
the reports listed below, Medtronic shall, upon request of the reviewing IRB/ EC, RA or FDA, provide accurate, complete and current information 
about any aspect of the investigation.  
Table 13: Sponsor reports for Canada  
Report  Submit to  Description/Constraints  
Premature termination or suspension of the clinical investigation  Investigators, IRB/EC,  
Relevant regulatory 
authorities, and  
Head of the Institution  Provide prompt notification of termination or suspension and reason(s).  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 125 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Report  Submit to  Description/Constraints  
Recall and device 
disposition  Investigators,  Head of 
Institution,  IRB/EC,  relevant 
authorities, and  Health 
Canada Notification within [ADDRESS_302819] that an 
investigator return, repair, or otherwise dispose of any devices.   
Study deviation  Investigators  Ensure that all deviations from the CIP are reviewed with the appro priate clinical 
investigator(s), are reported on the CRFs and the final report of the clinical investigation.  
Study c enter specific study deviations will be submitted to investigators periodically.   
Table 14: Sponsor reports for Europe, Middle East and Africa  
Report  Submit to  Description/Constraints  
Normal closure of the clinical investigation  Investigators,  IRB/EC,  and 
Relevant regulatory authorities (if applicable)  Provide prompt notification of national/global study closure.  
Premature termination or suspension of the clinical investigation  Investigators,  IRB/EC,  
Relevant regulatory 
authorities and  Head of the 
Institution  Provide prompt notification of termination or suspension and reason(s). (ISO [ZIP_CODE]:20 20) 
Withdrawal of IRB/EC 
approval  Investigators,  Head of 
Institution,  and relevant 
regulatory authorities  Investigators, IRBs/ECs will be notified only if required by [CONTACT_54460]/EC.  
Withdrawal of CA approval  Investigators,  Head of 
Institution,  IRB/EC  Investigators, IRBs/ECs will be notified only if required by [CONTACT_54460]/EC.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 126 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Report  Submit to  Description/Constraints  
Progress Reports  IRB/EC and  Regulatory 
authoritie s This will be submitted to the IRB/EC only if required by [CONTACT_1201]/EC  and regulatory 
authoritie s). 
Final report  Investigators, IRB/EC, and  
RAs if required  • The investigator shall have the opportunity to review and comment on the final 
report.  
• If a clinical investigator does not agree with the final report, his/her comments 
shall be communicated to the other investigator(s).    
• The coordinating investigator [INVESTIGATOR_131447]. If no coordinating investigator [INVESTIGATOR_54396], then the signature [CONTACT_249040] [INVESTIGATOR_248939].    (ISO [ZIP_CODE]: 2020) 
Study deviation  Investigators  and 
Regulatory authorities  Ensure that all deviations from the CIP are reviewed with the appropriate clinical 
investigator(s), are reported on the CRFs and the final report of the clinical investigation.  
(ISO [ZIP_CODE]:20 20) 
Study center specific study devi ations will be submitted to investigators periodically.   
Table 15: Sponsor reports for the [LOCATION_002]  
Report  Submit to  Description/Constraints  
Withdrawal of IRB/EC 
approval  Investigators, IRB/EC,  and 
FDA Notification within five working days  of receipt of notice .  (21 CFR 812.150(b)(2))   
Withdrawal of FDA 
approval  Investigators  and 
IRB/EC  Notification within five working days  of receipt of notice .  (21 CFR 812.150(b)(3))  
Investigator List  FDA Submit at [ADDRESS_302820] of the names and addresses of all investigators 
participating in the investigation.  (21 CFR 812.150(b)(4))  
Progress Reports  IRB/EC and  
FDA Progress reports will be submitted at least annually.  (21 CFR 812.150(b)(5), 812.36(f)   
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 127 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Report  Submit to  Description/Constraints  
Recall and device 
disposition  Investigators,  Head of 
Institution,  IRB/EC,  relevant 
authorities, and FDA  Notification within [ADDRESS_302821] that an investigator return, repair, or otherwise dispose of any devices.  (21 CFR 812.150(b)(6))  
Final report  Investigators,  IRB/EC, RAs 
upon request, and FDA  Medtronic will  notify FDA within 30 working days of the completion or termination of the 
investigation.  A final report will be submitted to the FDA, investigators, and IRBs/ECs 
within six months after completion or termination of this clinical study.  (21 CFR 812.150(b )(7))  
Failure to obtain informed 
consent  FDA Investigator’s report will be submitted to FDA within five working days of notification.  (21 
CFR 812.150(b)(8))  
Study deviation  Investigators  Ensure that all deviations from the CIP are reviewed with the appropriate clinical 
investigator(s), are reported on the CRFs and the final report of the clinical investigation.  
Study c enter specific study deviations will be submitted to investigators periodically.   
Other  IRB/EC, FDA  Accurate, complete, and current information about any aspect of the investigation. (21 
CFR 812.150(b)(10))  
Premature termination or 
suspension of clinical study  IRB/EC, Investigators, and 
RAs, where applicable  Medtronic will provide prompt notification of termination or suspension and reason(s) to 
investigator and where required to IRB/EC and RAs.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302822] Operating Procedures and 
as indicated in the CTA.  
15.9.1.  Publication Committee  
Medtronic may form the ADAPT-PD Trial Publication Committee from study investigators. Medtronic 
personnel may serve as members of the committee. This committee will manage study publications with 
the goal of publishing findings from the data. The Publication Committee will develop the final 
Publication Plan as a separate document.  
The Publication Committee’s role is to: 1) develop the final Publication Plan under separate cover, 2) 
execute the Publication Plan, 3) oversee the publication of primary, secondary and ancillary study 
results, 4) review and prioritize publication proposals, 5) provide input on publication content, and 6) 
determine author ship. In addition, the committee will apply and reinforce the authorship guidelines set 
forth in the Publication Plan.  
Membership in the Publication Committee does not guarantee authorship. The committee will meet as 
needed.  
15.9.2.  Management of Primary, Secondary, and Ancillary Publications  
The Publication Committee reviews, prioritizes, and manages all publications including primary, secondary and ancillary publications.  Primary and secondary publications are those that address analyses of any or all primary objectives or secondary objectives, respectively, as specified in the CIP.  
An ancillary publication is any publication that does not address the study objectives identified in the 
CIP.  They include publications proposed and developed by [CONTACT_249025], 
clinicians participating in this study, and clinicians not participating in this study.  The committee will 
work with Medtronic to ensure that requests do not present conflicts with other proposals, are not 
duplicative, and to  determine which ancillary publication proposals, if any, will be supported.   
The committee may decide that no publications, including abstracts, will be published prior to the end of 
the study or with individual study site data.  Requests for publications on study objectives utilizing subset data (e.g., regional) will be evaluated for scientific validity and the ability of Medtronic to provide 
resources.   
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 129 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  15.9.3.  Criteria for Determining Authorship  
Publications will adhere to authorship criteria defined by [CONTACT_65646] (ICMJE, Uniform requirements for manuscripts submitted to biomedical journals, 
www.icmje.org).  Individual authorship criteria defined by [CONTACT_131503].  
Authors, including Medtronic personnel, must at a minimum meet all of the conditions below: 
• Substantial contributions to conception and design of the work, or the acquisition, analysis, or interpretation of data for the work; AND  
• Draftin g the work or revising it critically for important intellectual content; AND  
• Final approval of the version to be published; AND  
• Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.  
Decisions regarding authorship and contributor -ship will be made by [CONTACT_942]. The selected 
authors will be responsible for drafting the publication. All selected authors must fulfill the au thorship 
conditions stated above to be listed as authors, and all contributors who fulfill the conditions must be listed as authors.  
All investigators not listed as co -authors will be acknowledged as the “Medtronic ADAPT -PD Study 
Investigators” and will be  individually listed according to the guidelines of the applicable scientific 
journal when possible and affiliation. Any other contributors will be acknowledged by [CONTACT_169297].  
15.9.4.  
Transparency  
Transparency of clinical study results will be maintained by [CONTACT_54465]:  
• A final report, describing the results of all objectives and analysis, will be distributed to all 
investigators, ECs and CAs of participating countries when required by [CONTACT_1769]  
• Registering  and posting the study results on ClinicalTrials.gov based on the posting rules 
stipulated  
• Submitting for publication the primary study results after the study ends  
• Disclosing conflicts of interest (e.g., financial) of the co -authors of publications according to the 
policies set forth by [CONTACT_54466]  
• Making an individual study sites study data accessible to the corresponding investigator after the completion of the study, if requested  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 130 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  15.10.  Suspension or Early Termination  
Medtronic reserves the right to suspend or terminate the study at any time. Reasons for study 
suspension or termination may include, but are not limited to:  
• Insufficient enrollment to complete the study within the expected timeframe  
• Identificat ion of unacceptable safety profile (suspi[INVESTIGATOR_248940] a 
suspension, confirmation of an unacceptable risk will result in termination)  
• Product performance/product supply issues  
15.10.1.  Planned Study Closure  
Study Closure is a process initiated by [CONTACT_57661] a study closure letter. Study closure is defined as closure of a study that occurs when Medtronic and/or regulatory requirements have been satisfied per the CIP and/or by a decision by [CONTACT_239102], whichever occurs first. The study closure process is 
complete upon distribution of the Final Report or after final payments, whichever occurs last. Ongoing 
IRB/ EC oversight is required until the overall study closure process is complete . Refer to Section  9.[ADDRESS_302823]. This is possible for the whole study or a 
single study site.  
[IP_ADDRESS].  Study -wide termination or suspension  
Possible reasons for considering study -wide suspension or termination of the study include but are not 
limited to:  
• AEs associated with the system or product under investigation which might endanger the safety 
or welfare of the subject  
• Observed/suspected performance different from the product’s design intent  
• Decision by [CONTACT_239102] (where the study is operating under RA)  
• Recommendation  of early termination by [CONTACT_1363]  
[IP_ADDRESS].  Investigator/study site termination or suspension  
Possible reasons for investigator or study site termination or suspension include but are not limited to:   
• IRB/EC approval lapse/expi[INVESTIGATOR_1516]  
• Persistent n oncompliance with the clinical investigation plan  
• Lack of enrollment  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 131 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • Noncompliance to regulations and the terms of the CTA (e.g. failure to submit data in a timely 
manner, failure to follow up on data queries and monitoring observations in a timely manner, etc.)  
• Loss of appropriately trained study center personnel  
• Insufficient or lack of investigator oversight  
• IRB/ EC suspension of the study site  
• Fraud or fraudulent misconduct is discovered (as defined by [CONTACT_54468])  
• Investigator request (e.g. no longer able to support the study)  
15.10.3.  
Procedures for Termination or Suspension  
In cases of study suspension/termination, standard medical care will continue to be provided to subjects 
enrolled in the study and IRB/EC /CA requirements will be followed. Subjects will be notified by [CONTACT_249026]/termination due to unacceptable risk or of termination due to any other 
cause.  
If applicable, an attempt will be made to transfer active subjects to another study center prior to 
termination whenever possible.  
Individual study centers may be closed by [CONTACT_249027].  
[IP_ADDRESS].  Medtronic -initiated and regulatory authority initiated  
• Medtronic will promptly inform the clinical investigators of the termination or suspension and 
the reasons and inform the RAs where required  
• In the case of study termination or suspension for reasons other than a temporary IRB/ EC 
approval lapse, the IRB/ EC will be promptly informed as required per local regulation  
• In the case of study termination, the investigator must inform the subjects and may  inform the 
personal physician of the subjects to ensure appropriate care and follow -up is provided  
• In the case of a study suspension, subject enrollment must stop until the suspension is lifted by [CONTACT_13735]  
• In the case of a study suspension, enrolled subjects should continue to be followed out of consideration of their safety, rights and welfare  
[IP_ADDRESS].  Investigator -initiated  
• The investigator will inform Medtronic and provide a detailed written explanation of the termination or suspension  
• The investigator will promptly inform the institution (where required per regulatory requirements)  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 132 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  • The investigator will promptly inform the IRB/ EC 
• The investigator will promptly inform the regulatory authorities  
• The investigator will promptly inform the subjects and/or the personal physician of the subjects 
to ensure appropriate care and follow -up is provided  
• In the case of a study suspension, subjects enrolled should continue to be followed out of consideration of their safety, rights and welfare  
[IP_ADDRESS].  Ethics Committee- initiated  
• The investigator will inform Medtronic and provide a detailed written explanation of the termination or suspension within 5 business days  
• Subject enrollment must stop until the suspension is lifted  
• Subjects already enrolled s hould continue to be followed in accordance with EC policy or its 
determination that an overriding safety concern or ethical issue is involved  
• The investigator will inform his/her institution (where required per local requirements)  
• The investigator will promptly inform the subjects and/or the personal physician of the subjects with the rationale for the study termination or suspension  
• The investigator will promptly inform the RAs  
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 133 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  16. References  
 
 
 
1 Williams -Gray  CH, Worth PF. Parkinson’s disease . In Neurology (Part 2 of 2), Medicine. 2016; 44(9):542- 546.  
[ADDRESS_302824] coupling across the motor circuit in 
Parkinson's disease. Neurobi ology of Disease. 2018;117:217 -225.  
3 Wang DD, de Hemptinne C, Miocinovic S, Ostrem JL, Galifianakis NB, Luciano M.S, Starr PA. Pallidal deep -brain 
stimulation disrupts pallidal beta oscillations and coherence with primary motor cortex in Parkinson’s disea se. 
Journal of Neuroscience. 2018;38(19):4556 -4568  
4 Hammond C, Bergman H, Brown P. Pathological synchronization in parkinson's disease: networks, models and 
treatments. Trends Neurosci. 2007;30:357– 364.  
5 Jankovic J. Parkinson’s disease: clinical features  and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79 (4):368–
376.  
[ADDRESS_302825] resting state networks in parkinson's disease. Brain. 
2016;139(5):1482 -1496.  
7 Weinberger M, Mahant N, Hutchison WD, Lozano AM, Moro E, Hodaie M, Lang AE, Dostrovsky JO. Beta oscillatory 
activity in the subthalamic nucleus and its relation to dopaminergic response in parkinson 's disease. Journal of 
Neurophysiology. 2006;96(6):248- 3256.  
8 Kleiner -Fisman G, Herzog J, Fisman DN, Filippo T, Lyons KE, Pahwa R, Lang, AE, Deuschl G. Subthalamic nucleus 
deep brain stimulation: summary and meta -analysis of outcomes. Mov Disord. 2006;21(14):S290- S304.  
9 Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal vs subthalamic nucleus deep brain 
stimulation in parkinson dis ease. Arch Neurol. 2005;62:554 –560.  
10 Fasano A, Romito LM, Daniele A, Pi[INVESTIGATOR_5533] C, Massimiliano Z, Bentivoglio AR, Albanese A. Motor and cognitive 
outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain. 2010;133:2664 -76. 
11 Krack  P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, 
Benabid AL, Pollak P. Five -year follow -up of bilateral stimulation of the subthalamic nucleus in advanced 
parkinson's disease. N. Engl. J. Med. 2003 ;349:1925 –1934.  
12 Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid, A -L. Electrical stimulation of the 
subthalamic nucleus in advanced parkinson’s disease. N Engl J Med. 1998;339:[ADDRESS_302826] evidence on target selection in deep brain stimulation for 
parkinson’sdisease. J. Clin. Neurosci. 2014;21:22 –27. 
14 Moro E, Lozano AM, Pollak P, et al. Long -term results of a multicenter study on subthalamic and pallidal 
stimulation in parkinson’s disease. Mov Disord. 2010;25:578- 586.  
15 Ramirez -Zamora A, Ostrem JL. Globus pallidus interna or subthalamic nucleus deep brain stimulation for 
parkinson disease : a review. JAMA Neurol. 2018;75:367 –372.  
  
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 134 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
   
 
 
16 Rodriguez -Oroz MC, Obeso JA, Lang AE, Houeto J -L, Pollak P, Rehncrona S, Kulisevsky J, et al. Bilateral deep brain 
stimulation in parkinson’s disease: a multicenter study with 4 years follow -up. Brain. 2005;128:2240– 2249.  
17 Toft M, Lilleeng B, Ramm -Pettersen J, et al. Long -term efficacy and mortality in parkinson’s disease patients 
treated with subthalamic stimulation. Mov Disord. 2011;26:1931– 1934.  
18 Deuschl G, Schade -Brittinger C, Krack P, Volkmann J, Schäfer H,Bötzel K, Daniels C, Deutschländer A, Dillmann U, 
Eisner W, et al. A randomized trial of deep brain stimulation for parkinsons’s disease. N Engl J Med. 2006;896-
908.  
[ADDRESS_302827] K, Samii A, Horn S, Bronstein JM, Stoner G, et al. Pallidal versus 
subthalamic deep- brain stimulation for parkinson’s disease. N Engl J Med 2010;362:2077 –2091.  
20 Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, 
Contarino MF, Mink MS, Bour LJ, van den Munckhof P, Schmand BA, de Haan RJ, Schuurman PR, de Bie RM. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation  for advanced parkinson’s disease 
(NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12:37– 44. 
[ADDRESS_302828] H, Rodriguez RL, Foote KD. Cognition and mood in 
parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE 
trial. Ann Neurol 2009;65:586 –595.  
22 Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack  P, Timmermann L, et al. Neurostimulation for parkinson’s 
disease with early motor complications. N. Engl. J. Med. 2013;368:610– 622.  
[ADDRESS_302829] medical therapy for patients with advance parkinson’s disease: a randomized 
controlled trial. JAMA. 2009;301:63 -73. 
24 Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, et al. Randomized trial of deep brain stimulation for 
parkinson disease: thirty- six-month outcomes. Neurology. 2012;79:55– 65. 
[ADDRESS_302830] dynamics in Parkinson's disease off 
and on dopaminergic medication. Brain (2017) 140:11 (2968- 2981). Date of Publication: 1 Nov 2017.  
26 Bouthour W. Mégevand P. Donoghue J. Lüscher C. Birbaumer N. Krack P. Biomarkers for closed -loop deep brain 
stimulation in parkinson disease and beyond. Nature Reviews Neurology. 2019;Published online at https://doi.org/10.1038/s41582- 019- [ADDRESS_302831] imulation. 
Frontiers in Neuroscience. 2017;11:564.  
28Kuhn AA, Tsui A, Aziz T, Ray N, Brüke C, Kupsch A, Schneider G -H, Brown P. Pathological synchronization in the 
subthalamic nucleus of patients with parkinson’s disease relates to both bradykinesia and rigidity. Exp Neurol 
2009;215:380 –387.  
29 Little S, Brown P. What brain signals are suitable for feedback control of deep brain stimulation in parkinson’s 
disease? Ann N Y Acad Sci. 2012;1265:9 –24. 
  
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 135 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
   
 
 
30 Brown P, and Williams D. Basal ganglia local field potential activity: character and functional significance in the 
human. Clin Neurophysiol. 2005;116(11):2510- 913.  
31 Chen CC, Hsu YT, Chan HL, et al. Complexity of subthalamic 13- 35 Hz oscillatory activity directly correlates with 
clinical impairment in patients with Parkinson’s disease. Exp Neurol 2010; 224:234 –240.  
32 Pogosyan A, Yoshida F, Chen CC, Martinez -Torres I, Foltynie T, Limousin P, Zrinzo L, Hariz MI, Brown P. 
Parkinsonian impairment correlates with spatially extensive subthalamic oscillatory synchronizati on. 
Neuroscience. 2010;171:245– 257.  
33 Thompson JA, Lanctin D, Ince NF, Abosch A. Clinical implications of local field potentials for understanding and 
treating movement disorders. Stereotactic and Functional Neurosurgery. 2014;92(4):251- 263.  
34 Abosch A, La nctin D, Onaran I, Eberly L, Spaniol M, Ince NF. Long -term recordings of local field potentials from 
implanted deep brain stimulation electrodes. Neurosurgery. 2012;71(4):804 -814.  
35 Giannicola G, Rosa M, Servello D, Menghetti C, Carrabba G, Pacchetti C, Zangaglia R, Cogiamanian F, Scelzo E, 
Marceglia S, Rossi L, Priori A. Subthalamic local field potentials after seven -year deep brain stimulation in 
parkinson's disease. Experimental Neurology. 2012;237(2):312- 317.  
36 Quinn EJ, Blumenfeld Z, Velisar A, Koop MM, Shreve LA, Trager MH, Hill BC, Kilbane C, Henderson JM, Brontë -
Stewart H. Beta oscillations in freely moving parkinson's subjects are attenuated during deep brain stimulation. 
Mov Disord. 2015;30(13):1750- 1758.  
37 Beudel M, Brown P. Adaptive deep brain stimulation in parkinson's disease. Parkinsonism and Related Disorders. 
2016;22(1):S123- S126.  
38 Neumann WJ, Staub- Bartelt F, Horn A, Schanda J, Schneider GH, Brown P, Kühn AA. Long term correlation of 
subthalamic bet a band activity with motor impairment in patients with parkinson's disease. Clinical 
Neurophysiology. 2017;128(11):2286- 2291.  
39 Swann NC, de Hemptinne C, Miocinovic S, et al. Chronic multisite brain recordings from a totally implantable 
bidirectional neural interface: experience in 5 patients with parkinson's disease. J Neurosurg. 2018;128(2):605-
616.  
40 Trager MH, Koop MM, Velisar A, Blumenfeld Z, Nikolau JS, Quinn EJ, Martin T, Bronte -Stewart H. Subthalamic 
beta oscillations  are attenuated after withdrawal  of chronic high frequency neurostimulation in parkinson's 
disease.  Neurobiol Dis. 2016;96:22 -30. 
41 Eusebio A, Thevathasan W, Doyle Gaynor L, Pogosyan A, Bye E, Foltynie T, Zrinzo L, Ashkan K, Aziz T, Brown P. 
Deep brain stimulation can suppress pathological synchronisation in parkinsonian patients. J Neurol Neurosurg 
Psychiatry. 2011;82(5):569- 573.  
42 Kuhn AA, Kupsch A, Schneider G -H, Brown P. Reduction in subthalamic 8 -35 Hz oscillatory activity correlates with 
clinical improvement in parkinson’s disease.  Eur J Neurosci 2006;23:1956 –1960.  
43 Ray NJ, Jenkinson N, Wang S, Holland P, Brittain JS, Joint C, Stein JF, Aziz T. Local field potential beta activity in 
the subthalamic nucleus of patients with parkinson’s disease is associated with improvements in bradykinesia 
after dopamine and deep brain stimulation. Exp Neurol. 2008;213:108– 113.  
 
 
 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 136 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
   
 
 
44 Kuhn AA, Kempf F, Brucke C, et al. High -frequency stimulation of the subthalamic nucleus suppresses oscillatory 
beta activity in patients with Parkinson’s disease in parall el with improvement in motor performance. J Neurosci 
2008;28:6165 –6173.  
45 Malekmohammadi M, Herron J, Velisar A, Blumenfeld Z, Trager MH, Chizeck HJ, Brontë- Stewart, H. Kinematic 
adaptive deep brain stimulation for resting tremor in parkinson's disease. Mo v Disord. 2016;31(3):426 -428.  
46 Afzal M.F. Velisar A. Anidi  C. Neuville R. Prabhakar V. Bronte -Stewart H. Subthalamic Neural Closed -loop Deep 
Brain Stimulation for Bradykinesia in Parkinson's Disease. Brain Stimulation. 2019;12(4):e152- e154.  
47 Velisar A, Syrkin -Nikolau J, Blumenfeld Z, Trager MH, Afzal MF, Prabhakar V, Bronte -Stewart H.  Dual threshold 
neural closed loop DBS in PD patients. Brain Stimulation, https://doi.org/10.1016/j.brs. 2019.02.020  
48 Little S, Pogosyan A, Neal S, Zavala B, Zrinzo L, Hariz M, Foltynie T, Limousin P, Ashkan K, FitzGerald J, Green AL, 
Aziz TZ, Brown P. Adaptive deep brain stimulation in advanced parkinson disease. Ann Neurol. 2013;74(3):449 -
57. 
49 Little S, Beudel M, Zrinzo L, Foltynie T, Limousin P, Hariz M, Neal S, Cheeran B, Cagnan H, Gratwicke J, Aziz TZ, 
Pogosyan A, Brown P. Bil ateral adaptive deep brain stimulation is effective in parkinson's disease.  J Neurol 
Neurosurg Psychiatry. 2016;87(7):717 -721.  
50 Little S, Tripoliti E, Beudel M, Pogosyan A, Cagnan H, Herz D, Bestmann S, Aziz T, Cheeran B, Zrinzo L, Hariz M, 
Hyam J, Limou sin P, Foltynie T, Brown P. Adaptive deep brain stimulation for parkinson's disease demonstrates 
reduced speech side effects compared to conventional stimulation in the acute setting. J Neurol Neurosurg 
Psychiatry. 2016;87(12):1388 -1389.  
51 Arlotti M, Rossi  L, Rosa M, Marceglia S, Priori A. An external portable device for adaptive deep brain stimulation 
(aDBS) clinical research in advanced parkinson's disease. Med Eng Phys. 2016;38(5):498 -505.  
52 Arlotti M, Marceglia S, Foffani G, Volkmann J, Lozano A.M, Moro E, Cogiamanian F, Prenassi M, Bocci T, Cortese 
F, Rampi[INVESTIGATOR_9384] P, Barbieri S, Priori A. Eight -hours adaptive deep brain stimulation in patients with parkinson disease. 
Neurology. 2018;90(11):e971 -e976.  
53 Arlotti M, Palmisano C, Minafra B, Todisco M, Pacchetti C, Canessa A, Pozzi NG, Cilia R, Prenassi M, Marceglia S, 
Priori A, Rampi[INVESTIGATOR_9384] P, Barieri S, Servello D, Volkmann J, Pezzoli G, Isaias IU. Monitoring subthalamic oscillations for 24 hours in a freely moving parkinson’s disease patient.  Movement Disorders. 20 19;34(5):[ADDRESS_302832]. 2017;32(4):628- 629.  
55 Piña -Fuentes D, Little S, Oterdoom M, Neal S, Pogosyan A, Tijssen MAJ, van Laar T, Brown P, van Dijk JMC, 
Beudel M. Adaptive DBS in a parkinson's patient with chronically implanted DBS: a proof of principle.  Mov Disord. 2017; 32(8):1253 -1254.  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 137 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Appendix  A - aDBS Global Impression of Change Score ( GIC) 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302833] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
1.0 Not Applicable, New Document  Not Applicable, New Document  Not Applicable, 
New Document  Not Applicable, 
New Document   
 
 
2.0 4. Updated visit schedule 
to move LFP screening 
earlier in the study as a 
standalone visit  
5. Corrected motor diary to PD Home Diary and updated patient diary categories  
6. Removed risks of commercially available DBS and included reference to labeling  
7. Added section s: 
• 7: Study Site 
requirements  1. CIP V1.0 not approved by 
[CONTACT_249028] ; 
internal version only  
2. Updated to new Medtronic template CIP  
3. Additional revisions made to improve execution of CIP procedures  
 Not Applicable  1. IC  
2. CRFs   
 
 

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302834] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
• 9.19.6 Conditional 
disengagement  
• 10.2 Risk Minimization  
• 11.3 Processing Updates 
and Resolution  
• 11.5.1 AE and DD Classification  
• AE and DD Reporting requirements  
• 11.[ADDRESS_302835] Complaint Reporting  
• 13.1 General Aspects of Analysis  
• 13.8 Minimization of Bias 
• 15.1.1 Monitoring Visits  
• Clerical updates  
3.[ADDRESS_302836]  cohort  
4. New SW version available  
5. Clarification  
6. TH91 is a box, not a medical device  None  • IC 
• CRFs  
• IB  
 
 
 
 

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302837] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
Directional Stimulation  
Cohort  
• 2 Synopsis  
• 3 Purpose  
• 4 Objectives and 
Endpoints  
• 5 Study Design  
• [ADDRESS_302838] Description  
• 8 Selection of Subjects  
• 9 Study Procedures  
• 10 Risks and Benefits  
• 13 Statistical Design and 
Methods  
4. Section  6.1: updated 
software versions for Model A610  
5. Section  6.5: Equipment . 
Clarified that PKG watch will be used under an ITA in Canada 
6. Section  6.8: Clarified 
that TH91 package kit 
will not be tracked  7. Technical requirement for SenSight  
8. Detected a rtifact may not preclude 
programming of aDBS  
9. COVID -[ADDRESS_302839] s who do not take 
controlled release  carbidopa/ 
levodopa  or dopamine  agonists  to 
be seen earlier as they will have fully withdraw n from medication 
(per Table 5 ) in [ADDRESS_302840] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
7. Section  8.3: Added 
inclusion #9  
8. Section  8.4: Updated 
exclus ion #16  
9. Updated Section  9 Study 
Procedures  to allow 
administration of 
assessments outside of the visit when necessary . 
Section  9.15 provides 
guidance on which assessments may be 
done remotely and in 
what time frame.  
10. Section  9.3: updated 
visit windows for LFP 
screening and aDBS setup visits from 3 -45 
days to 1 -45 days  
11. Moved  blinding language 
earlier in Section  9.9 and 
clarified that unblinding 
at any time  during  aDBS 16. Updated per final published 
ISO14155:2020 ; [LOCATION_013] no longer 
participating  
17. Updated p er Medtronic procedure  
18. No longer following MEDDEV  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302841] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
setup  and adjustment  is 
a deviation  
12. Re-ordered Section  9.9.[ADDRESS_302842] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
Note 3 ; removed 
[LOCATION_013] SAE definition  
17. Section  11.4,  table [ADDRESS_302843] ion 11.7 removed 
MEDDEV definitions  
4.0 1. Glossary: Added 
definitions for 
directional stimulation, Primary Cohort and ring mode; updated SADE definition  
2. Section  5: defined 
primary cohort, ring mode and directional stimulation  
3. Section  7.1: Clarified 
that all investigators must be trained and experienced in DBS and management of PD  
4. Section  7.2: removed “as 
required” from CV  1. Clarification/correction  
2. More clearly defined the cohorts and which programming configurations fall within each 
3. Clarification  
4. Required per ISO14155  
5. Reminder per GDP  
6. More clearly defined the cohorts and which programming configurations fall within each 
7. Real- world experience shows 
non-cardiac artifact may vary 
over time and based upon patient state and LFP signal 
may be affected by [CONTACT_249029]  1-5, 7-28: None  
6: CRFs  
 

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302844] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
5. Section  8.2: added note 
that the date of IC 
signature [CONTACT_249041]’s medical records.  
6. Section  8.3: Updated 
general inclusion criterion #5 for both Primary and Directional Stimulation Cohort  
7. Section  9.4: removed 
prohibition for re -
screening due to signal artifact and inadequat e 
LFP signal  
8. Section  9.7.1: clarified 
signal artifact requirement and actions to be taken  
9. Section  9.9.1: Clarified 
re-testing procedure for 
LFP inclusion criterion  other than medication (e.g. 
movement)  
8. Clarification  
9. Clarification  
10. Clarification  
11. Clarification  
12. In current practice, clinicians can adjust therapy parameters as the subject’s disease state dictates. Investigators have always been allowed to make changes in programming 
outside of the study Enrollment 
to aDBS Evaluation Phase (allowed only when clinically necessary). This updat e clarifies 
that a change in aDBS mode is considered a change in programming. The investigator may only change modes if subject received both in the aDBS Evaluation Phase.  
13. Same as #[ADDRESS_302845] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
10. Section  9.9.1: Re -worded 
instructions for Dual and 
single threshold setup 
when only one hemi sphere has signal 
meeting the LFP screening inclusion criterion  
11. Section  9.9.1: re -ordered 
end of visit instruction  
12. Section  9.11: Added 
allowance that 
investigator may choose 
to switch aDBS modes as needed in the Long-term Follow -up phase.  
13. Section  9.12: cla rified 
that the subject will continue into the Extended Access Phase in aDBS, not necessarily the preferred mode.  
14. Section s 9.19 & 11.3: 
updated RTG to 14. Update in Medtronic business 
name  
15. Clarification  
16. Correction, this is not collected  
17. Correction. Data will continue to be retained in accordance with applicable local regulations.  
18. Clarification  
19. Correction: records will continue to be retained in line with applicable laws  
20. Reformatting and clarification  
21. Additional administrative information  
22. Administrative change  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302846] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
Neuromodulation and 
removed RTG from 
Glossary 
15. Section  11.4: Added 
clarification as to what 
“device” means  in th e 
context of AE definitions  
16. Sectio
n 11.5.1, Table 8: 
Removed “An underlying condition or disease” from relatedness classification  
17.  Section  15.2: removed 
“indefinitely” from data retention description  
18. Section  15.4: Clarified 
third party data access  
19. Section  15.7: Updated 
record retention information  
20. Section  15.9: moved to 
new Section  15.9.[ADDRESS_302847] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
21. New Section s 15.9.2 & 
15.9.3: added 
information regarding 
publication and authorship  
22. Moved content from Section  [IP_ADDRESS] to 
15.10.3  
5.0 1. Updated the CIP Template vE 
and v5.0.  
2. Added Competent Authority Number  
3. Updated Glossary of terms – Alpha – Beta, Globus Pallidus 
Internus, Multiple Imputations  
4. Definition updated Beta to Alpha - Beta throughout 
document  
5. Added sub -group analysis of 
selected mode  1.Upda ted template and version.  
2.Update only - Added Competent 
Authority number  
3. Updated and added missing terms  
 
 
4. Updating name [CONTACT_249042] 1-15: No impact  1 – 5: CIP  
6 (duration) – CIP, ICF  
7-11, 13 -20: CIP  
12 (addition of Impa rtial 
Witness) – CIP, 
ICF 
  

ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302848] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
6. Section 5.1 – updated study 
duration from 2.5 to 5 years  
7. Removed reference to A61 0 
Clinician Programmer 
Application v2.0 throughout documents  
8. Section  [IP_ADDRESS] Investigational 
DBS system – updated number of 
patient programmers from [ADDRESS_302849] Return –
aDBS feature should be disabled Standardize d terminology16,17. 
Frequency updated to [ADDRESS_302850] commonly used by [CONTACT_249030]. Revision 2017. Clin Neurophysiol Pr . 2017;2:170 -185. doi:10.1016/j.cnp.2017.07.002  
17 Kane N, Acharya J, Beni czky S, et al. Corrigendum to “A revised glossary of terms most commonly used by [CONTACT_249031]. Revision 2017” [Clin. Neurophysiol. Practice 2 (2017) 170 –185]. Clin Neurophy siol Pr . 
2019;4:133. doi:10.1016/j.cnp.2019.06.[ADDRESS_302851] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
prior to explant and is then no 
longer considered investigational  
10. Section  9.3 S cheduled f/u 
windows, Table 4, and Section  
9.12.1 Extended Access visits - 
follow -up windows clarified that 
Extended Access continues until commercialization, study exit and/or closure  
11. Section  9.5 Prior and 
Concomitant Medications – add 
clarification of no medication 
restrictions  
12. Section  9.[ADDRESS_302852] Consent – 
added impartial witness statement to CIP and ICF  
13. Section  9.13 unscheduled 
visits - Programming 
adjustments/optimizations are not reportable events  9.Clarification  
10.Clarification  
11. Template update  
12. Update – with the progression of 
PD addition of a witness to facilitate obtaining informed consent for subjects with visual difficulties  
 
     
 
 13. Clarification – pro
 gramming 
adjustments/optimizations not 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302853] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
14. Section  9.18  Deviation 
Handling - Changes after the 
aDBS Evaluation Phase would 
not be considered a deviation.  
15. Section  19.1 Study Exit and 
9.19.2 Study Completed  - Study 
Completion definition clarified 
16. Section  11.4 , Table 7, Table 8 
Definitions/Classifications – 
Table  7 - removed definition of 
underlying condition. Table 8  - 
removed redundant definition  
17. Section  13.4.4 – Clarified 
diary period analysis  
18. Section  13.5.3 – Endpoint 
Definition and Section  13.5.[ADDRESS_302854]  triggered by a change in clinical 
symptoms are not reportable events.  
14.Clarification – changes made after  
the aDBS Evaluation phase does not affect the analysis and therefore would not be consider ed a deviation.  
15.Clarification – subjects may exit at 
visit #6 or continue until commercialization.  
16. Update – redundant definitions. 
UADE/[LOCATION_003]DE already listed in table  
17. Clarification - In order to reasonably 
and accurately accommodate more actual diary data used in the analysis.  
This was allowed as the programmed parameters were still relevant to the analysis at the time of data collection.  
18. Clarification - In o
 rder to obtain an 
impedance for the TEED calculation and 
considering that impedance  would be 
generally stable over the trial period, 
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.[ADDRESS_302855] of 
the change on 
performance, 
effectiveness, or 
safety or other 
endpoints  Identification of 
the affected 
study 
documents  Author(s)/Title  
19. Section  15.3 – updated name 
[CONTACT_249043]  
20. Section 17 deleted  – 
duplicate section  impedance values were used from the 
aDBS Setup visit or the closest visit to 
that time.  
19. Updated – Name [INVESTIGATOR_41372]  
20 Duplicate section to Appendix A  
ADAPT -PD MDT19001 Clinical Investigation Plan  
  
 Version  5.0 Page 152 of 152  
 
Medtronic Business Restricted  
 
This document is electronically controlled                  CONFIDENTIAL      056-F275E Rev E Clinical Investigation Plan Template  
   
  Appendix A - aDBS Global Impression of Change Score (GIC ) 
This scale is used to help assess for acceptability of an aDBS mode vs. cDBS for an individual subject. A 
lower number is better  in terms of acceptability  (ie, greater efficacy with minimal side effects ).  
• “Acceptable”: A selection appearing in the white (unshaded) boxes means the mode has been 
deemed “acceptable” and is available for selection for that subject in the aDBS Evaluation 
Phase.  The subject may be programmed with this mode.   
• “Unacceptable”:  A selection appearing in the grey shading means the mode has been deemed 
“unacceptable” and is eliminated for selection in the aDBS Evaluation Phase.  The subject will not be programmed with that mode.   
To decide if a mode is acceptable to a subject, the fo llowing table will be used : 
 Side effects  
Efficacy  None  Does not 
significantly 
interfere with patient’s 
functioning  Significantly interferes with patient’s 
functioning  Side effects experienced outweigh 
efficacy  
Vast 
improvement  01 02 Fail:10  Fail:11  
Decided 
improvement  03 04 Fail:12  Fail:13  
Slight 
improvement  05 06 Fail:14  Fail:15  
Unchanged  07 08 Fail:16  Fail:17  
Worse  Fail:18  Fail:19  Fail:20  Fail:21  
 